Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, Suite B
New Haven, CT 06511
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, Suite BNew Haven, CT 06511
Alessandro Santin, MD
Obstetrics, Gynecology & Reproductive Sciences, Gynecologic Oncology
Telehealth is available
Patient type treated
Child, Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Obstetrics & Gynecology
Biography
Alessandro D. Santin, MD, is an oncologist who cares for patients with endometrial and other gynecologic cancers. He is experienced with intraperitoneal chemotherapy, which is given through the abdomen to treat ovarian cancer. Dr. Santin also treats patients from Connecticut and beyond who have been diagnosed with uterine serous carcinoma (USC), a highly aggressive and chemotherapy-resistant cancer.
Dr. Santin says his research, which explores cancers of the ovary, endometrium and cervix, as well as tumor immunology and immunotherapy, is driven by a desire to find better treatments for his patients.
“When you see a patient in the office, in the hospital after surgery or after they receive chemotherapy, you really understand that we need to do more,” Dr. Santin says.
Therefore, keeping an honest and open dialogue with patients is key, he says. “I let them know how serious the disease is,” he says. “But if we are upfront about their prognosis, we can also take advantage of cutting-edge treatments that we have available at Yale. Right now, genetics help us better understand the biology of the disease and allow for some patients to use new treatments that can make a difference.”
A professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine, Dr. Santin has been recognized as a "top doctor" in the state by a regional ranking service.
Titles
- Professor of Obstetrics, Gynecology, and Reproductive Sciences
- Co-Chief, Section of Gynecologic Oncology
- Clinical Research Team Leader, Gynecologic Oncology, Yale Cancer Center
Education & Training
- FellowUniversity of Arkansas for Medical Sciences (2000)
- FellowUniversity of California - Irvine Medical Center (1995)
- ResidentUniversity of Brescia School of Medicine (1993)
- MDUniversity of Brescia School of Medicine (1989)
Languages Spoken
- English
- Italiano (Italian)
Additional Information
Honors & Recognitions
- Genetics Institute Young Investigator Award.: American Association of Cancer Research (AACR) (1999)
Board Certifications
- Italian Board of Obstetrics & Gynecology, Obstetrics & Gynecology (1993)
Professional Service
- Society of Gynecologic Oncologists (2011 - Present): Scientific SGO Program Committee Member, 42nd Annual Meeting on Women's Cancer, March 6-9, 2011, Orlando, FL
- Board Member (2008 - Present): 2008-present, Member, Board of Permanent Officer, Yale University. 2009-present, Member, Protocol Review Committee, Smilow Yale Cancer Center. 2009-present, Director Elective/Subinternship in Gynecol/Oncol Yale University. 2010-present , Member of the Senior Appointments and Promotions Committee Yale University. 2012-present: Leader Disease Aligned Research Team in Gyn Oncology, Smilow Cancer Center.
Publications
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.
- McNamara B, Greenman M, Demirkiran C, Mutlu L, Hartwich T, Bellone S, Manavella D, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Santin A. Pre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer. Gynecologic Oncology 2024, 190: s36. DOI: 10.1016/j.ygyno.2024.07.058.
- Banerjee S, Van Nieuwenhuysen E, Santin A, Ring K, Colombo N, Thaker P, Prendergast E, Clamp A, Ray-Coquard I, Chon H, Moore K, Salinas E, Rose P, O'Malley D, Oaknin A, Monk B, Holloway R, Newman G, Moroney J, Van Gorp T, Kalbacher E, Gennigens C, Wojtynek N, Lustgarten S, Grisham R. Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Part A. Gynecologic Oncology 2024, 190: s55-s56. DOI: 10.1016/j.ygyno.2024.07.084.
- Mcnamara B, Greenman M, Bellone S, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. EV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma. 2024, a91.2-a91. DOI: 10.1136/ijgc-2024-igcs.135.
- Banerjee S, Aghajanian C, Nieuwenhuysen E, Santin A, Ring K, Colombo N, Thaker P, Prendergast E, Moore K, Chon H, Clamp A, O’malley D, Monk B, Cortés-Salgado A, Fabbro M, Kalbacher E, Gorp T, Lustgarten S, Youssoufian H, Grisham R. LB007/#1548 Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. 2024, a13-a13. DOI: 10.1136/ijgc-2024-igcs.13.
- Greenman M, Bellone S, Hartwich T, Buza N, Santin A. Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas. Gynecologic Oncology Reports 2024, 56: 101524. PMID: 39435258, PMCID: PMC11492078, DOI: 10.1016/j.gore.2024.101524.
- Greenman M, Chang Y, McNamara B, Mutlu L, Santin A. Unmet needs in cervical cancer – can biological therapies plug the gap? Expert Opinion On Biological Therapy 2024, 24: 995-1003. PMID: 39311611, DOI: 10.1080/14712598.2024.2408754.
- Hartwich T, Mansolf M, Demirkiran C, Greenman M, Bellone S, McNamara B, Nandi S, Alexandrov L, Yang‐Hartwich Y, Coma S, Pachter J, Santin A. Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer. Cancer Medicine 2024, 13: e70210. PMID: 39240189, PMCID: PMC11378359, DOI: 10.1002/cam4.70210.
- Danska-Bidzinska A, Makker V, Salutari V, Ayhan A, Romero I, Levy T, McCormack M, Baurain J, Mach P, Cadoo K, Mackay H, Friedlander M, Santin A, Slomovitz B, Miller D, McKenzie J, Yao L, Khemka V, Nogueira-Rodrigues A, Marth C. 737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study. Annals Of Oncology 2024, 35: s561. DOI: 10.1016/j.annonc.2024.08.799.
- Corr B, Dumbrava E, Spira A, Willmott L, Butrynski J, Tse K, Patel J, Mekan S, Mocci S, Wu T, Santin A. 733P Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03. Annals Of Oncology 2024, 35: s558. DOI: 10.1016/j.annonc.2024.08.795.
- Santin A, Corr B, Spira A, Willmott L, Butrynski J, Tse K, Patel J, Mekan S, Wu T, Lin K, Kuo P, Dumbrava E. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. Journal Of Clinical Oncology 2024, 42: 3421-3429. PMID: 39083724, PMCID: PMC11458108, DOI: 10.1200/jco.23.02767.
- Greenman M, Bellone S, Demirkiran C, Hartwich T, Santin A. Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer. Gynecologic Oncology Reports 2024, 54: 101459. PMID: 39108617, PMCID: PMC11300917, DOI: 10.1016/j.gore.2024.101459.
- McNamara B, Greenman M, Bellone S, Santin L, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecologic Oncology 2024, 189: 16-23. PMID: 38981151, DOI: 10.1016/j.ygyno.2024.07.002.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.
- Manrai P, McHenry A, Sun T, Santin A, Ratner E, Lin D, Elvin J, Hui P, Buza N. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations. International Journal Of Gynecological Pathology 2024 PMID: 38914011, DOI: 10.1097/pgp.0000000000001050.
- Danziger M, Noble H, Roque D, Xu F, Rao G, Santin A. Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy. Advances In Experimental Medicine And Biology 2024, 1452: 1-19. PMID: 38805122, DOI: 10.1007/978-3-031-58311-7_1.
- Erickson B, Enserro D, Lankes H, Dockery L, ghamande S, Oliver M, Gressel G, Castellano T, Ratner E, Deery A, Bishop E, Bradford L, Thomes Pepin J, Burton E, Blank S, Santin A, Havrilesky L, Aghajanian C, Nickles Fader A, Powell M. Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026). Journal Of Clinical Oncology 2024, 42: tps5641-tps5641. DOI: 10.1200/jco.2024.42.16_suppl.tps5641.
- Greenman M, McNamara B, Mutlu L, Santin A. Entering the golden age for antibody-drug conjugates in gynecologic cancer. Oncoscience 2024, 11: 51-52. PMID: 38770444, PMCID: PMC11104406, DOI: 10.18632/oncoscience.604.
- Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich T, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas. Gynecologic Oncology 2024, 187: 12-20. PMID: 38703673, DOI: 10.1016/j.ygyno.2024.04.010.
- Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.
- Garcia Y, Gorp T, Konecny G, Leary A, Santin A, Crusz S, Mantia-Smaldone G, Lorusso D, Colombo N, Thomes-Pepin J, Roszak A, Ottevanger P, Beiner M, Cibula D, Leath C, Li L, Method M, Moore K. 360 Health-related quality of life in patients with FRα positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator’s choice chemotherapy: analysis from the phase 3 MIRASOL trial. 2024, a34-a35. DOI: 10.1136/ijgc-2024-esgo.43.
- Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.
- Greenman M, McNamara B, Mutlu L, Santin A. Targeting cervical cancer with anti-PD-1 antibodies: what is new? Expert Opinion On Biological Therapy 2024, 24: 111-114. PMID: 38391293, DOI: 10.1080/14712598.2024.2323596.
- Bellone S, Siegel E, Scheim D, Santin A. Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID. Gynecologic Oncology Reports 2024, 51: 101324. PMID: 38273933, PMCID: PMC10809113, DOI: 10.1016/j.gore.2024.101324.
- Scheim D, Vottero P, Santin A, Hirsh A. Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19. International Journal Of Molecular Sciences 2023, 24: 17039. PMID: 38069362, PMCID: PMC10871123, DOI: 10.3390/ijms242317039.
- Grisham R, Aghajanian C, Nieuwenhuysen E, Rodrigues M, Ring K, Santin A, Colombo N, Prendergast E, Thaker P, Moore K, Salinas E, Ray-Coquard I, Chon H, Rose P, Oaknin A, Clamp A, Gandhi M, Monk B, Holloway R, Gorp T, Fabbro M, Gennigens C, Wojtynek N, Lustgarten S, Banerjee S. PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy. 2023, a3-a4. DOI: 10.1136/ijgc-2023-igcs.4.
- McNamara B, Greenman M, Pebley N, Mutlu L, Santin A. Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules 2023, 28: 7389. PMID: 37959808, PMCID: PMC10650896, DOI: 10.3390/molecules28217389.
- Bellone S, Siegel E, Santin A. Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID. Gynecologic Oncology Reports 2023, 50: 101301. PMID: 38029227, PMCID: PMC10654147, DOI: 10.1016/j.gore.2023.101301.
- AlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.
- Ledermann J, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Provencher D, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Kobie J, Nebozhyn M, Edmondson M, Sun Y, Cristescu R, Jelinic P, Keefe S, Matulonis U. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100. Gynecologic Oncology 2023, 178: 119-129. PMID: 37862791, DOI: 10.1016/j.ygyno.2023.09.012.
- Banerjee S, Ring K, Niewenhuysen E, Fabbro M, Aghajanian C, Oaknin A, Colombo N, Santin A, Clamp A, Moore K, Rose P, David M O, Chon H, Salinas E, Prendergast E, Lustgarten S, Rodrigues M, Gennigens C, Monk B, Grisham R. #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). 2023, a20-a21. DOI: 10.1136/ijgc-2023-esgo.29.
- Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.
- Characterization of tumor response with lenvatinib plus pembrolizumab in study 309/KEYNOTE-775 (177)Makker V, Lorusso D, Moore R, Miller D, Mackay H, Santin A, Ushijima K, Kim Y, Sanli U, Yonemori K, Xie R, Barresi G, McKenzie J, Colombo N. Characterization of tumor response with lenvatinib plus pembrolizumab in study 309/KEYNOTE-775 (177). Gynecologic Oncology 2023, 176: s68-s69. DOI: 10.1016/j.ygyno.2023.06.563.
- McNamara B, Mutlu L, Greenman M, Harold J, Santin A. HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma. Cancers 2023, 15: 4085. PMID: 37627113, PMCID: PMC10452357, DOI: 10.3390/cancers15164085.
- McNamara B, Chang Y, Goreshnik A, Santin A. Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals. International Journal Of Women's Health 2023, 15: 1353-1365. PMID: 37663226, PMCID: PMC10474218, DOI: 10.2147/ijwh.s400537.
- Vottero P, Tavernini S, Santin A, Scheim D, Tuszynski J, Aminpour M. Computational Prediction of the Interaction of Ivermectin with Fibrinogen. International Journal Of Molecular Sciences 2023, 24: 11449. PMID: 37511206, PMCID: PMC10380762, DOI: 10.3390/ijms241411449.
- Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.
- McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy. Gynecologic Oncology Reports 2023, 48: 101219. PMID: 37325293, PMCID: PMC10265462, DOI: 10.1016/j.gore.2023.101219.
- McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy. Gynecologic Oncology Reports 2023, 48: 101218. PMID: 37325296, PMCID: PMC10265468, DOI: 10.1016/j.gore.2023.101218.
- Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.
- Banerjee S, Ring K, Van Nieuwenhuysen E, Fabbro M, Aghajanian C, Oaknin A, Colombo N, Santin A, Clamp A, Moore K, Rose P, O'Malley D, Chon H, Salinas E, Prendergast E, Lustgarten S, Rodrigues M, Gennigens C, Monk B, Grisham R. Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). Journal Of Clinical Oncology 2023, 41: 5515-5515. DOI: 10.1200/jco.2023.41.16_suppl.5515.
- Santin A, Corr B, Spira A, Willmott L, Butrynski J, Tse K, Patel J, Mekan S, Wu T, Dumbrava E. TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC). Journal Of Clinical Oncology 2023, 41: 5610-5610. DOI: 10.1200/jco.2023.41.16_suppl.5610.
- Bellone S, McNamara B, Mutlu L, Demirkiran C, Hartwich T, Harold J, Yang-Hartwich Y, Siegel E, Santin A. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. International Journal Of Molecular Sciences 2023, 24: 8873. PMID: 37240216, PMCID: PMC10219151, DOI: 10.3390/ijms24108873.
- Makker V, Colombo N, Herráez A, Monk B, Mackay H, Santin A, Miller D, Moore R, Baron-Hay S, Ray-Coquard I, Ushijima K, Yonemori K, Kim Y, Alia E, Sanli U, Bird S, Orlowski R, McKenzie J, Okpara C, Barresi G, Lorusso D. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. Journal Of Clinical Oncology 2023, 41: 2904-2910. PMID: 37058687, PMCID: PMC10414727, DOI: 10.1200/jco.22.02152.
- Lorusso D, Colombo N, Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kim Y, McCormack M, Massaad R, Nguyen A, Zhao Q, McKenzie J, Prabhu V, Makker V. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice. European Journal Of Cancer 2023, 186: 172-184. PMID: 37086595, PMCID: PMC11003310, DOI: 10.1016/j.ejca.2023.03.015.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
- Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
- McNamara B, Chang Y, Mutlu L, Harold J, Santin A. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Expert Opinion On Biological Therapy 2023, 23: 227-233. PMID: 36800548, DOI: 10.1080/14712598.2023.2182679.
- Hill B, Graf R, Shah K, Danziger N, Lin D, Quintanilha J, Li G, Haberberger J, Ross J, Santin A, Slomovitz B, Elvin J, Eskander R. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. International Journal Of Gynecological Cancer 2023, 33: 504-513. PMID: 36750267, PMCID: PMC10086481, DOI: 10.1136/ijgc-2022-004026.
- Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
- Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
- Huang G, Tymon-Rosario J, Santin A. What role does adjuvant therapy play in the management of endometrial cancer? Expert Opinion On Pharmacotherapy 2023, 24: 7-10. PMID: 36594708, DOI: 10.1080/14656566.2022.2157207.
- Tymon-Rosario J, Chui M, Santin A. Chapter 3 Ovarian carcinosarcoma. 2023, 41-54. DOI: 10.1016/b978-0-323-82938-0.00003-3.
- Santin A, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland L, Monk B, Coleman R, Herzog T, Siegel J, Kasten L, Schlicker A, Schulz A, Köchert K, Walter A, Childs B, Elbi C, Bulat I. Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. International Journal Of Gynecological Cancer 2022, 33: ijgc-2022-003927. PMID: 36564099, PMCID: PMC10086500, DOI: 10.1136/ijgc-2022-003927.
- Manavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
- Tymon-Rosario J, Gorman M, Richardson D, Washington C, Santin A. Advances in antibody-drug conjugates for gynecologic malignancies. Current Opinion In Obstetrics & Gynecology 2022, 35: 6-14. PMID: 36484278, DOI: 10.1097/gco.0000000000000838.
- Mutlu L, Manavella D, Bellone S, Santin A. EP015/#546 In vitro and in vivo efficacy of trastuzumab deruxtecan (T-DXd) in epithelial ovarian cancer with HER2/NEU overexpression. 2022, a54.2-a54. DOI: 10.1136/ijgc-2022-igcs.106.
- Makker V, Colombo N, Herráez A, Monk B, Mackay H, Santin A, Miller D, Moore R, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Yonemori K, Kim Y, Alia E, Sanli U, Xie R, Zale M, Mckenzie J, Barresi G, Lorusso D. O018/#482 Updated safety of lenvatinib + pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775. 2022, a11-a11. DOI: 10.1136/ijgc-2022-igcs.20.
- Tymon-Rosario J, Gorman M, Santin A. Targeted Therapies in the Treatment of Uterine Serous Carcinoma. Current Treatment Options In Oncology 2022, 23: 1804-1817. PMID: 36447064, DOI: 10.1007/s11864-022-01030-7.
- Harold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
- Oaknin A, Kristeleit R, Mahdi H, Lim M, de Vivo R, Salinas E, Wilson M, Liontos M, Santin A, Provencher D, Demirkiran F, Willmott L, Chudecka-Głaz A, Herzog T, Beiner M, Copeland L, McNeish I, Lin K, Monk B. 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246). 2022, a472.1-a472. DOI: 10.1136/ijgc-2022-esgo.1018.
- Chow RD, Michaels T, Bellone S, Hartwich T, Bonazzoli E, Iwasaki A, Song E, Santin AD. Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma. Cancer Discovery 2022, 13: 312-331. PMID: 36301137, PMCID: PMC9905265, DOI: 10.1158/2159-8290.cd-22-0686.
- Doria D, Santin A, Tuszynski J, Scheim D, Aminpour M. Omicron SARS-CoV-2 Spike-1 Protein’s Decreased Binding Affinity to α7nAChr: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis. BioMedInformatics 2022, 2: 553-564. DOI: 10.3390/biomedinformatics2040035.
- Mutlu L, Manavella D, Gullo G, McNamara B, Santin A, Patrizio P. Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes. Cancers 2022, 14: 5187. PMID: 36358604, PMCID: PMC9656291, DOI: 10.3390/cancers14215187.
- Lorusso D, Makker V, Herraez A, Monk B, Mackay H, Santin A, Miller D, Moore R, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Yonemori K, Kim Y, Guerra Alia E, Sanli U, Huang J, McKenzie J, Barresi G, Colombo N. 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. 2022, a102.1-a102. DOI: 10.1136/ijgc-2022-esgo.223.
- Makker V, Colombo N, Herraez A, Monk B, Mackay H, Santin A, Miller D, Moore R, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Yonemori K, Kim Y, Alia E, Sanli U, Huang J, McKenzie J, Barresi G, Lorusso D. 525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775. Annals Of Oncology 2022, 33: s785-s786. DOI: 10.1016/j.annonc.2022.07.653.
- Makker V, Colombo N, Santin A, Miller D, Fujiwara K, Pignata S, Ray-Coquard I, Kim Y, Guerra E, Huang J, Barresi G, McKenzie J, Lorusso D. Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775. Journal Of Clinical Oncology 2022, 40: 5587-5587. DOI: 10.1200/jco.2022.40.16_suppl.5587.
- Santin A, Graf R, Shah K, Kelly A, Danziger N, Lin D, Oxnard G, Elvin J. Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study. Journal Of Clinical Oncology 2022, 40: 5596-5596. DOI: 10.1200/jco.2022.40.16_suppl.5596.
- Lorusso D, Colombo N, Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kim Y, McCormack M, Massaad R, Nguyen A, Zhao Q, McKenzie J, Prabhu V, Makker V. 20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC). Annals Of Oncology 2022, 33: s391-s392. DOI: 10.1016/j.annonc.2022.04.038.
- Yadav G, Roque DM, Bellone S, Manavella DD, Hartwich TMP, Zipponi M, Harold J, Tymon-Rosario J, Mutlu L, Altwerger G, Menderes G, Ratner E, Buza N, Hui P, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecologic Oncology 2022, 166: 351-357. PMID: 35641325, DOI: 10.1016/j.ygyno.2022.05.021.
- Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. Gynecologic Oncology 2022, 166: 117-125. PMID: 35599167, DOI: 10.1016/j.ygyno.2022.05.005.
- Makker V, Colombo N, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim Y, Guerra E, Sanli U, McCormack M, Smith A, Keefe S, Bird S, Dutta L, Orlowski R, Lorusso D. Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer. Obstetrical & Gynecological Survey 2022, 77: 275-276. DOI: 10.1097/ogx.0000000000001032.
- Aminpour M, Cannariato M, Preto J, Safaeeardebili M, Moracchiato A, Doria D, Donato F, Zizzi E, Deriu M, Scheim D, Santin A, Tuszynski J. In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds. Computation 2022, 10: 51. DOI: 10.3390/computation10040051.
- Mutlu L, Harold J, Tymon-Rosario J, Santin AD. Immune checkpoint inhibitors for recurrent endometrial cancer. Expert Review Of Anticancer Therapy 2022, 22: 249-258. PMID: 35176955, DOI: 10.1080/14737140.2022.2044311.
- Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.
- Reader JC, Fan C, Ory EC, Ju J, Lee R, Vitolo MI, Smith P, Wu S, Ching MMN, Asiedu EB, Jewell CM, Rao GG, Fulton A, Webb TJ, Yang P, Santin AD, Huang HC, Martin SS, Roque DM. Microtentacle Formation in Ovarian Carcinoma. Cancers 2022, 14: 800. PMID: 35159067, PMCID: PMC8834106, DOI: 10.3390/cancers14030800.
- Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.
- Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. New England Journal Of Medicine 2022, 386: 437-448. PMID: 35045221, DOI: 10.1056/nejmoa2108330.
- Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, Copeland LJ, Secord AA, Mutch DG, Santin A, Warshal DP, Spirtos NM, DiSilvestro PA, Ioffe OB, Miller DS. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. Journal Of Clinical Oncology 2022, 40: 968-977. PMID: 35007153, PMCID: PMC8937015, DOI: 10.1200/jco.21.02050.
- Tymon-Rosario J, Adjei NN, Roque DM, Santin AD. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment. Cancers 2021, 13: 6239. PMID: 34944858, PMCID: PMC8699494, DOI: 10.3390/cancers13246239.
- Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.
- Santin AD. VITT after ChAdOx1 nCoV-19 Vaccination. New England Journal Of Medicine 2021, 385: 2202-2205. PMID: 34731555, DOI: 10.1056/nejmc2111026.
- Makker V, Colombo N, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira R, Ushijima K, Sakata J, Yonemori K, Kim Y, Guerra E, Sanli U, Mccormack M, Huang J, Smith A. O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775. International Journal Of Gynecological Cancer 2021, 31: a4-a5. DOI: 10.1136/ijgc-2021-igcs.8.
- Makker V, Colombo N, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Banerjee S, Monk B, Ushijima K, Penson R, Kristeleit R, Fabbro M, Orlando M, Mackay H, Ren M, Orlowski R, Dutta L, Lorusso D. O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors. International Journal Of Gynecological Cancer 2021, 31: a1-a2. DOI: 10.1136/ijgc-2021-igcs.2.
- Zeybek B, Webster E, Pogosian N, Tymon-Rosario J, Balch A, Altwerger G, Clark M, Menderes G, Huang G, Azodi M, Ratner ES, Schwartz PE, Santin AD, Andikyan V. Financial toxicity in patients with gynecologic malignancies: a cross sectional study. Journal Of Gynecologic Oncology 2021, 32: e87. PMID: 34431257, PMCID: PMC8550931, DOI: 10.3802/jgo.2021.32.e87.
- Colombo N, Lorusso D, Santin A, Kim Y, Herráez A, Yonemori K, Fujiwara K, Colomba E, Miller D, Pignata S, Monk B, Guerra E, Kristeleit R, Orlando M, Sanli U, Dutta L, Orlowski R, Ren M, Makker V. 145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775). International Journal Of Gynecological Cancer 2021, 31: a78-a78. DOI: 10.1136/ijgc-2021-esgo.120.
- Liu F, Wu H, Peng B, Zhang S, Ma J, Deng G, Zou P, Liu J, Chen AT, Li D, Bellone S, Santin AD, Moliterno J, Zhou J. Vessel-Targeting Nanoclovers Enable Noninvasive Delivery of Magnetic Hyperthermia–Chemotherapy Combination for Brain Cancer Treatment. Nano Letters 2021, 21: 8111-8118. PMID: 34597054, DOI: 10.1021/acs.nanolett.1c02459.
- Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.
- Assem H, Rottmann D, Finkelstein A, Wang M, Ratner E, Santin AD, Buza N, Hui P. Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. Human Pathology 2021, 118: 1-8. PMID: 34508766, DOI: 10.1016/j.humpath.2021.09.001.
- Colombo N, Lorusso D, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Floquet A, Monk B, Banerjee S, Penson R, Kristeleit R, Fabbro M, Orlando M, Mackay H, Jensen E, Dutta L, Orlowski R, Makker V. 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775). Annals Of Oncology 2021, 32: s729-s730. DOI: 10.1016/j.annonc.2021.08.1169.
- Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.
- Tymon-Rosario J, Siegel ER, Bellone S, Harold J, Adjei N, Zeybek B, Mauricio D, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Azodi M, Schwartz PE, Fader AN, Santin AD. Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. Gynecologic Oncology 2021, 163: 93-99. PMID: 34372971, PMCID: PMC8721852, DOI: 10.1016/j.ygyno.2021.07.033.
- Santin A, Scheim D, McCullough P, Yagisawa M, Borody T. Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19. New Microbes And New Infections 2021, 43: 100924. PMID: 34466270, PMCID: PMC8383101, DOI: 10.1016/j.nmni.2021.100924.
- Makker V, Colombo N, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim Y, Guerra E, Sanli U, McCormack M, Huang J, Smith A, Keefe S, Dutta L, Orlowski R, Lorusso D. A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer. Gynecologic Oncology 2021, 162: s4. DOI: 10.1016/s0090-8258(21)00657-0.
- Levi G, Rocchetti C, Magri R, Uccelli S, Bottone D, Quadri F, Novali M, Santin AD, Bezzi M. Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. Monaldi Archives For Chest Disease 2021, 91 PMID: 34121379, DOI: 10.4081/monaldi.2021.1867.
- Roque D, Bellone S, Siegel E, Buza N, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Schwartz P, Ratner E, Alexandrov L, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin A. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Journal Of Clinical Oncology 2021, 39: 5523-5523. DOI: 10.1200/jco.2021.39.15_suppl.5523.
- Lorusso D, Colombo N, Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kim Y, McCormack M, Bird S, Prabhu V, Nguyen A, Zhao Q, Dutta L, Makker V. Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC). Journal Of Clinical Oncology 2021, 39: 5570-5570. DOI: 10.1200/jco.2021.39.15_suppl.5570.
- Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology 2021, 32: 1045-1046. PMID: 33932502, PMCID: PMC9465821, DOI: 10.1016/j.annonc.2021.04.013.
- Mauricio D, Zeybek B, Tymon-Rosario J, Harold J, Santin AD. Immunotherapy in Cervical Cancer. Current Oncology Reports 2021, 23: 61. PMID: 33852056, DOI: 10.1007/s11912-021-01052-8.
- Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2025182118. PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.
- McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, Leung S, Bellone S, Wong A, Brucker SY, Lee CH, Clarke BA, Huntsman DG, Bernardini MQ, Ngeow J, Santin AD, Goodfellow P, Levine DA, Köbel M, Kommoss S, Bosse T, Gilks CB, Talhouk A. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis. Cancer 2021, 127: 2409-2422. PMID: 33793971, DOI: 10.1002/cncr.33516.
- Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal Of The National Cancer Institute 2021, 113: 1369-1378. PMID: 33729494, PMCID: PMC8486331, DOI: 10.1093/jnci/djab034.
- Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Annals Of Oncology 2021, 32: 746-756. PMID: 33741442, DOI: 10.1016/j.annonc.2021.03.005.
- Mauricio D, Harold J, Tymon-Rosario JR, Zeybek B, Santin AD. Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer. Expert Opinion On Biological Therapy 2021, 21: 1087-1096. PMID: 33356644, DOI: 10.1080/14712598.2021.1869210.
- Santin A, Vergote I, Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland L, Monk B, Coleman R, Herzog T, Siegel J, Walter A, Childs B, Elbi C, Bulat I. 372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. International Journal Of Gynecological Cancer 2020, 30: a154-a154. DOI: 10.1136/ijgc-2020-igcs.322.
- Lee EK, Fader AN, Santin AD, Liu JF. Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies. Gynecologic Oncology 2020, 160: 322-332. PMID: 33160694, DOI: 10.1016/j.ygyno.2020.10.017.
- Webster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Arkfeld CK, Andikyan V, Menderes G, Huang G, Azodi M, Silasi DA, Santin AD, Schwartz PE, Ratner ES, Altwerger G. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports 2020, 34: 100667. PMID: 33204797, PMCID: PMC7653050, DOI: 10.1016/j.gore.2020.100667.
- Najjar O, Erickson B, Klein M, Dolan M, Shahi M, Grandelis A, Buza N, Tymon-Rosario J, Santin A, Ferriss J, Fader A. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort. Gynecologic Oncology 2020, 159: e13. DOI: 10.1016/j.ygyno.2020.07.048.
- Fader A, Roque D, Siegel E, Buza N, Hui P, Havrilesky L, Secord A, O'Malley D, Backes F, Nevadunsky N, Chambers S, Edraki B, Celano P, Bellone S, Azodi M, Ratner E, Litkouhi B, Silasi D, Schwartz P, Santin A. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis. Gynecologic Oncology 2020, 159: 7-8. DOI: 10.1016/j.ygyno.2020.06.014.
- Ledermann J, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Provencher D, Sehouli J, Colombo N, Martín A, Oaknin A, Saadatpour A, Kobie J, Jelinic P, Stein K, Matulonis U. Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100. Annals Of Oncology 2020, 31: s631-s632. DOI: 10.1016/j.annonc.2020.08.982.
- Romani C, Zizioli V, Silvestri M, Ardighieri L, Bugatti M, Corsini M, Todeschini P, Marchini S, D'Incalci M, Zanotti L, Ravaggi A, Facchetti F, Gambino A, Odicino F, Sartori E, Santin AD, Mitola S, Bignotti E, Calza S. Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients. Frontiers In Oncology 2020, 10: 1287. PMID: 32850397, PMCID: PMC7417514, DOI: 10.3389/fonc.2020.01287.
- Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research 2020, 26: 3928-3935. PMID: 32601075, PMCID: PMC8792803, DOI: 10.1158/1078-0432.ccr-20-0953.
- Oaknin A, Friedman CF, Roman LD, D’Souza A, Brana I, Bidard F, Goldman J, Alvarez EA, Boni V, ElNaggar AC, Passalacqua R, T.M. K, Santin AD, Keyvanjah K, Xu F, Eli LD, Lalani AS, Bryce RP, Hyman DM, Meric-Bernstam F, Solit DB, Monk BJ. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic Oncology 2020, 159: 150-156. PMID: 32723675, PMCID: PMC8336424, DOI: 10.1016/j.ygyno.2020.07.025.
- Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology 2020, 159: 17-22. PMID: 32709539, PMCID: PMC7541557, DOI: 10.1016/j.ygyno.2020.07.016.
- Li JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. Stage III uterine serous carcinoma: modern trends in multimodality treatment. Journal Of Gynecologic Oncology 2020, 31: e53. PMID: 32266802, PMCID: PMC7286763, DOI: 10.3802/jgo.2020.31.e53.
- Tymon-Rosario J, Zeybek B, Santin AD. Novel antibody-drug conjugates: current and future roles in gynecologic oncology. Current Opinion In Obstetrics & Gynecology 2020, 33: 26-33. PMID: 32618744, PMCID: PMC8253558, DOI: 10.1097/gco.0000000000000642.
- Bonazzoli E, Bellone S, Zammataro L, Gnutti B, Guglielmi A, Pelligra S, Nagarkatti N, Manara P, Tymon-Rosario J, Zeybek B, Altwerger G, Menderes G, Han C, Ratner E, Silasi DA, Huang GS, Andikyan V, Azodi M, Schwartz PE, Santin AD. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecologic Oncology 2020, 158: 769-775. PMID: 32600791, PMCID: PMC8253557, DOI: 10.1016/j.ygyno.2020.06.484.
- Webster EM, Zeybek B, Tymon-Rosario J, Santin AD. Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer. Oncoscience 2020, 7: 68-69. PMID: 33195736, PMCID: PMC7640901, DOI: 10.18632/oncoscience.514.
- Santin AD, Filiaci V, Bellone S, O'Cearbhaill R, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Birrer MJ. Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]. Gynecologic Oncology Reports 2020, 33: 100590. PMID: 32885014, PMCID: PMC7452617, DOI: 10.1016/j.gore.2020.100590.
- Matulonis U, Shapira R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Wu H, Keefe S, Stein K, Ledermann J. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. Journal Of Clinical Oncology 2020, 38: 6005-6005. DOI: 10.1200/jco.2020.38.15_suppl.6005.
- Santin A, Komiya T, Goldenberg D, Sharkey R, Hong Q, Wegener W, Goswami T, Bardia A. Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study. Journal Of Clinical Oncology 2020, 38: 6081-6081. DOI: 10.1200/jco.2020.38.15_suppl.6081.
- Erickson B, Najjar O, Klein M, Shahi M, Dolan M, Cimino-Mathews A, Grandelis A, Buza N, Delaney P, Tymon-Rosario J, Santin A, Ferriss J, Stone R, Nickles Fader A. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort. Journal Of Clinical Oncology 2020, 38: 6084-6084. DOI: 10.1200/jco.2020.38.15_suppl.6084.
- Saxena A, Michel L, Hong Q, Hilsinger K, Kanwal C, Pichardo C, Goswami T, Santin A. TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors. Journal Of Clinical Oncology 2020, 38: tps3648-tps3648. DOI: 10.1200/jco.2020.38.15_suppl.tps3648.
- Kim K, Hu W, Audenet F, Almassi N, Hanrahan AJ, Murray K, Bagrodia A, Wong N, Clinton TN, Dason S, Mohan V, Jebiwott S, Nagar K, Gao J, Penson A, Hughes C, Gordon B, Chen Z, Dong Y, Watson PA, Alvim R, Elzein A, Gao SP, Cocco E, Santin AD, Ostrovnaya I, Hsieh JJ, Sagi I, Pietzak EJ, Hakimi AA, Rosenberg JE, Iyer G, Vargas HA, Scaltriti M, Al-Ahmadie H, Solit DB, Coleman JA. Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications 2020, 11: 1975. PMID: 32332851, PMCID: PMC7181640, DOI: 10.1038/s41467-020-15885-7.
- Hassan R, Blumenschein GR, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, Seward SM, Thomas A, Kim SK, Rajagopalan P, Walter AO, Laurent D, Childs BH, Sarapa N, Elbi C, Bendell JC. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. Journal Of Clinical Oncology 2020, 38: 1824-1835. PMID: 32213105, PMCID: PMC7255978, DOI: 10.1200/jco.19.02085.
- Pelligra S, Buza N, Hui P, Bellone S, Zeybek B, Ratner E, Schwartz PE, Scambia G, Santin AD. Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. Gynecologic Oncology Reports 2020, 32: 100554. PMID: 32140533, PMCID: PMC7049633, DOI: 10.1016/j.gore.2020.100554.
- Perrone E, Lopez S, Zeybek B, Bellone S, Bonazzoli E, Pelligra S, Zammataro L, Manzano A, Manara P, Bianchi A, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Frontiers In Oncology 2020, 10: 118. PMID: 32117765, PMCID: PMC7028697, DOI: 10.3389/fonc.2020.00118.
- Lopez S, Perrone E, Bellone S, Bonazzoli E, Zeybek B, Han C, Tymon-Rosario J, Altwerger G, Menderes G, Bianchi A, Zammataro L, Manzano A, Manara P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Raspagliesi F, Angioli R, Buza N, Hui P, Bond HM, Santin AD. Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget 2020, 11: 560-570. PMID: 32082489, PMCID: PMC7007291, DOI: 10.18632/oncotarget.27342.
- Erickson BK, Zeybek B, Santin AD, Fader AN. Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. Current Opinion In Obstetrics & Gynecology 2020, 32: 57-64. PMID: 31833974, PMCID: PMC7307693, DOI: 10.1097/gco.0000000000000599.
- Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports 2020, 10: 973. PMID: 31969666, PMCID: PMC6976591, DOI: 10.1038/s41598-020-58009-3.
- Perrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon‐Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi D, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Molecular Oncology 2020, 14: 645-656. PMID: 31891442, PMCID: PMC7053235, DOI: 10.1002/1878-0261.12627.
- Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecologic Oncology 2020, 157: 161-166. PMID: 31924334, PMCID: PMC7127981, DOI: 10.1016/j.ygyno.2019.12.034.
- Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecologic Oncology Reports 2020, 31: 100532. PMID: 31934607, PMCID: PMC6951478, DOI: 10.1016/j.gore.2019.100532.
- Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, Bianchi A, Zammataro L, Manzano A, Bonazzoli E, Manara P, Buza N, Hui P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Lopez S, Santin AD. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecologic Oncology 2019, 156: 430-438. PMID: 31839338, DOI: 10.1016/j.ygyno.2019.11.018.
- Tymon-Rosario J, Zeybek B, Han C, Santin AD. Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. Annals Of Translational Medicine 2019, 0: s308. PMID: 32016027, PMCID: PMC6976388, DOI: 10.21037/atm.2019.10.28.
- Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22730-22736. PMID: 31624127, PMCID: PMC6842590, DOI: 10.1073/pnas.1911385116.
- Lopez S, Perrone E, Zeybek B, Bellone S, Manzano A, Zammataro L, Han C, Altwerger G, Angioli R, Santin A. 93 Sacituzumab govitecan in uterine and ovarian carcinosarcomas. International Journal Of Gynecological Cancer 2019, 29: a48. DOI: 10.1136/ijgc-2019-igcs.93.
- Perrone E, Lopez S, Zeibek B, Bellone S, Zammataro L, Manzano A, Bonazzoli E, Manara P, Scambia G, Santin A. 51 In vitro and in vivo activity of sacituzumab govitecan, in ovarian cancer. International Journal Of Gynecological Cancer 2019, 29: a29. DOI: 10.1136/ijgc-2019-igcs.51.
- Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Modern Pathology 2019, 33: 118-127. PMID: 31477811, DOI: 10.1038/s41379-019-0358-x.
- Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology 2019, 155: 144-150. PMID: 31434613, PMCID: PMC6788971, DOI: 10.1016/j.ygyno.2019.08.010.
- Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Annals Of Oncology 2019, 30: 1080-1087. PMID: 31046082, DOI: 10.1093/annonc/mdz135.
- Gay L, Schink J, Wright J, Lele S, Mayor P, Odunsi K, Hemmerich A, Ngo N, Secord A, Hou J, Konecny G, Santin A, Elvin J. Targeting ERBB family genomic alterations in gynecological malignancies. Gynecologic Oncology 2019, 154: 89. DOI: 10.1016/j.ygyno.2019.04.210.
- Yadav G, Lopez S, Han C, Altwerger G, Menderes G, Bellone S, Bianchi A, Ratner E, Schwartz P, Santin A. The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in uterine serous carcinoma overexpressing HER2. Gynecologic Oncology 2019, 154: 34. DOI: 10.1016/j.ygyno.2019.04.082.
- Lopez S, Han C, Altwerger G, Menderes G, Zammataro L, Bellone S, Bianchi A, Zeybek B, Ratner E, Schwartz P, Santin A. Whole exome sequencing (WES) reveals novel therapeutic targets in cervical cancer. Gynecologic Oncology 2019, 154: 61-62. DOI: 10.1016/j.ygyno.2019.04.146.
- Zeybek B, Bonazzoli E, Lopez S, Han C, Altwerger G, Menderes G, Bellone S, Bianchi A, Ratner E, Schwartz P, Santin A. Whole exome sequencing (WES) of primary, metastatic and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Gynecologic Oncology 2019, 154: 62-63. DOI: 10.1016/j.ygyno.2019.04.148.
- Powell M, Filiaci V, Hensley M, Huang H, Moore K, Tewari K, Copeland L, Secord A, Mutch D, Santin A, Richards W, Warshal D, Spirtos N, Disilverstro P, Ioffe O, Miller D. A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial. Journal Of Clinical Oncology 2019, 37: 5500-5500. DOI: 10.1200/jco.2019.37.15_suppl.5500.
- Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Buza N, Lopez S, Perrone E, Manara P, Bellone S, Zammataro L, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Journal Of Clinical Oncology 2019, 37: e17028-e17028. DOI: 10.1200/jco.2019.37.15_suppl.e17028.
- Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.
- Cocco E, Lopez S, Santin AD, Scaltriti M. Prevalence and role of HER2 mutations in cancer. Pharmacology & Therapeutics 2019, 199: 188-196. PMID: 30951733, PMCID: PMC6571037, DOI: 10.1016/j.pharmthera.2019.03.010.
- Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology 2019, 153: 335-342. PMID: 30827726, PMCID: PMC6486855, DOI: 10.1016/j.ygyno.2019.02.028.
- Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal Of Medicine 2019, 380: 741-751. PMID: 30786188, DOI: 10.1056/nejmoa1814213.
- Boettcher AN, Kiupel M, Adur MK, Cocco E, Santin AD, Bellone S, Charley SE, Blanco-Fernandez B, Risinger JI, Ross JW, Tuggle CK, Shapiro EM. Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs. Frontiers In Oncology 2019, 9: 9. PMID: 30723704, PMCID: PMC6349777, DOI: 10.3389/fonc.2019.00009.
- Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Gynecologic Oncology 2019, 153: 158-164. PMID: 30630630, PMCID: PMC6430698, DOI: 10.1016/j.ygyno.2019.01.002.
- Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.
- Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 116: 619-624. PMID: 30584090, PMCID: PMC6329978, DOI: 10.1073/pnas.1814027116.
- Lopez S, Zeybek B, Santin AD. Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management. Oncotarget 2018, 9: 36652-36653. PMID: 30613348, PMCID: PMC6291176, DOI: 10.18632/oncotarget.26413.
- Tewari K, Vergote I, Oaknin A, Alvarez E, Gaillard S, Lheureux S, Rischin D, Santin A, Feng M, Mathias M, Fury M, Lowy I, Monk B. 280TiP GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. Annals Of Oncology 2018, 29: ix86. DOI: 10.1093/annonc/mdy436.027.
- Blakaj A, Jairam V, Buza N, Schwartz P, Santin A, Damast S. HER2/neu Overexpression and Recurrence Risk in Early Stage Uterine Serous Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s218-s219. DOI: 10.1016/j.ijrobp.2018.07.139.
- Zeybek B, Lopez S, Santin AD. BET inhibitors: Betting on improved outcomes in uterine serous carcinoma. Oncotarget 2018, 9: 35470-35471. PMID: 30464799, PMCID: PMC6231456, DOI: 10.18632/oncotarget.26245.
- Ledermann J, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Provencher D, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Cristescu R, Kobie J, Ruman J, Matulonis U. LBA36 Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. Annals Of Oncology 2018, 29: viii728. DOI: 10.1093/annonc/mdy424.043.
- Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research 2018, 24: 4845-4853. PMID: 29941483, PMCID: PMC6168417, DOI: 10.1158/1078-0432.ccr-18-0864.
- Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerAltwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2449-2456. PMID: 30255380, DOI: 10.1007/s00432-018-2753-y.
- Menderes G, Lopez S, Han C, Altwerger G, Gysler S, Varughese J, Schwartz PE, Santin AD. Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it. Discovery Medicine 2018, 26: 39-50. PMID: 30265854.
- Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, Rimm DL, Liu Y, Ratner E, Schwartz PE, Santin AD. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clinical Cancer Research 2018, 24: 3282-3291. PMID: 29351920, PMCID: PMC6050068, DOI: 10.1158/1078-0432.ccr-17-1805.
- Feinberg J, Elvin J, Bellone S, Santin A. Identification of ovarian cancer patients for immunotherapy by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA). Gynecologic Oncology 2018, 149: 36. DOI: 10.1016/j.ygyno.2018.04.081.
- Santin A, Fader A. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002). Gynecologic Oncology 2018, 149: 12. DOI: 10.1016/j.ygyno.2018.04.033.
- Han C, Altwerger G, Menderes G, Haines K, Feinberg J, Lopez S, Manzano A, Varughese J, Santin AD. Novel targeted therapies in ovarian and uterine carcinosarcomas. Discovery Medicine 2018, 25: 309-319. PMID: 30021104.
- Han C, Bellone S, Zammataro L, Schwartz PE, Santin AD. Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment. Gynecologic Oncology Reports 2018, 25: 41-44. PMID: 29946554, PMCID: PMC6014583, DOI: 10.1016/j.gore.2018.05.011.
- Han C, Bellone S, Schwartz PE, Govindan SV, Sharkey RM, Goldenberg DM, Santin AD. Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. Gynecologic Oncology Reports 2018, 25: 37-40. PMID: 29977989, PMCID: PMC6030029, DOI: 10.1016/j.gore.2018.05.009.
- Matulonis U, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Provencher D, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Katchar K, Wang Z, Ruman J, Ledermann J. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. Journal Of Clinical Oncology 2018, 36: 5511-5511. DOI: 10.1200/jco.2018.36.15_suppl.5511.
- Bulat I, Moore K, Haceatrean A, Chung J, Rajagopalan P, Xia C, Laurent D, Childs B, Santin A. Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Journal Of Clinical Oncology 2018, 36: 5571-5571. DOI: 10.1200/jco.2018.36.15_suppl.5571.
- Tewari K, Vergote I, Oaknin A, Alvarez E, Chase D, Gaillard S, Lheureux S, Rischin D, Santin A, Feng M, Mathias M, Fury M, Lowy I, Monk B. GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer. Journal Of Clinical Oncology 2018, 36: tps5600-tps5600. DOI: 10.1200/jco.2018.36.15_suppl.tps5600.
- Santin A, Deng W, Frumovitz M, Huh W, Khleif S, Lankes H, Ratner E, O'Cearbhaill R, Jazaeri A, Birrer M. A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer. Journal Of Clinical Oncology 2018, 36: 5536-5536. DOI: 10.1200/jco.2018.36.15_suppl.5536.
- Grechukhina O, Gressel GM, Munday W, Wong S, Santin A, Vash-Margita A. Endometrial Carcinoma in a 26‐Year‐Old Patient with Bardet‐Biedl Syndrome. Case Reports In Obstetrics And Gynecology 2018, 2018: 1952351. PMID: 29854508, PMCID: PMC5960523, DOI: 10.1155/2018/1952351.
- Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.
- Corsini M, Ravaggi A, Odicino F, Santin AD, Ravelli C, Presta M, Romani C, Mitola S. Claudin3 is localized outside the tight junctions in human carcinomas. Oncotarget 2018, 9: 18446-18453. PMID: 29719617, PMCID: PMC5915084, DOI: 10.18632/oncotarget.24858.
- Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal Of Clinical Oncology 2018, 36: 2044-2051. PMID: 29584549, DOI: 10.1200/jco.2017.76.5966.
- Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.
- Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human Pathology 2018, 76: 133-140. PMID: 29518404, DOI: 10.1016/j.humpath.2018.02.019.
- Albright BB, Black JD, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Buza N, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. Gynecologic Oncology Reports 2018, 23: 28-33. PMID: 29387776, PMCID: PMC5771964, DOI: 10.1016/j.gore.2018.01.003.
- Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clinical Cancer Research 2017, 23: 5836-5845. PMID: 28679774, PMCID: PMC5626613, DOI: 10.1158/1078-0432.ccr-16-2862.
- MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget 2017, 5: 84579-84594. PMID: 29137450, PMCID: PMC5663622, DOI: 10.18632/oncotarget.19961.
- Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology 2017, 147: 145-152. PMID: 28705408, PMCID: PMC5605415, DOI: 10.1016/j.ygyno.2017.07.009.
- Menderes G, Bonazzoli E, Bellone S, Black J, Pettinella F, Masserdotti A, Zammataro L, Lopez S, Litkouhi B, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A. Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2017, 145: 112. DOI: 10.1016/j.ygyno.2017.03.263.
- Altwerger G, Gressel G, Menderes G, Black J, Nelson W, Litkouhi B, Santin A, Schwartz P, Ratner E. Carboplatin hypersensitivity correlates with mutations in the DNA repair enzyme BRCA. Gynecologic Oncology 2017, 145: 113. DOI: 10.1016/j.ygyno.2017.03.265.
- Altwerger G, Gressel G, English D, Nelson W, Menderes G, Black J, Santin A, Schwartz P, Ratner E. A single institution’s experience with a fast, effective carboplatin desensitization protocol and identification of risk factors for high-grade hypersensitivity reactions. Gynecologic Oncology 2017, 145: 123. DOI: 10.1016/j.ygyno.2017.03.288.
- Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Pettinella F, Masserdotti A, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression. Journal Of Clinical Oncology 2017, 35: e14009-e14009. DOI: 10.1200/jco.2017.35.15_suppl.e14009.
- Huang GS, Santin AD. Genetic landscape of clear cell endometrial cancer and the era of precision medicine. Cancer 2017, 123: 3216-3218. PMID: 28485840, PMCID: PMC5907932, DOI: 10.1002/cncr.30743.
- Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D’Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Journal Of Experimental & Clinical Cancer Research 2017, 36: 63. PMID: 28482906, PMCID: PMC5422964, DOI: 10.1186/s13046-017-0536-y.
- Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology 2017, 146: 179-186. PMID: 28473206, PMCID: PMC5533304, DOI: 10.1016/j.ygyno.2017.04.023.
- Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Medical Oncology 2017, 34: 91. PMID: 28397106, PMCID: PMC5896014, DOI: 10.1007/s12032-017-0956-8.
- Carvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Gynecologic Oncology 2017, 145: 154-158. PMID: 28196634, PMCID: PMC5941302, DOI: 10.1016/j.ygyno.2017.02.002.
- Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics 2017, 16: 323-333. PMID: 27956521, PMCID: PMC5292071, DOI: 10.1158/1535-7163.mct-16-0501.
- Santin AD, Bellone S, Buza N, Schwartz PE. Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1). Gynecologic Oncology Reports 2016, 19: 10-12. PMID: 28018954, PMCID: PMC5175991, DOI: 10.1016/j.gore.2016.12.003.
- Roque DM, Santin AD. Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade. Expert Review Of Clinical Immunology 2016, 13: 175-180. PMID: 27905822, PMCID: PMC5537620, DOI: 10.1080/1744666x.2017.1266938.
- Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, Lifton RP. Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clinical Cancer Research 2016, 22: 5682-5687. PMID: 27486176, PMCID: PMC5135588, DOI: 10.1158/1078-0432.ccr-16-1031.
- Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.
- Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecologic Oncology 2016, 144: 77-82. PMID: 27789084, DOI: 10.1016/j.ygyno.2016.09.027.
- Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. Journal Of Clinical Investigation 2016, 126: 4157-4173. PMID: 27721235, PMCID: PMC5096908, DOI: 10.1172/jci87252.
- Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 12238-12243. PMID: 27791010, PMCID: PMC5087050, DOI: 10.1073/pnas.1614120113.
- Gunderson C, Santin A, delPriore G, Elvin J, Ramkissoon S, Ali S, McMahon C, Fabrizio D, Chalmers Z, Frampton G, Chmielecki J, Vergilio J, Suhn J, Gay L, Miller V, Stephens P, Ross J, Moore K. Comprehensive Genomic Profiling of Uterine Leiomyosarcomas Identifies Frequent Clinically Relevant Genomic Alterations and Opportunities for Personalized Therapies. Gynecologic Oncology 2016, 143: 208-209. DOI: 10.1016/j.ygyno.2016.08.276.
- Deng Y, Yang F, Cocco E, Song E, Zhang J, Cui J, Mohideen M, Bellone S, Santin AD, Saltzman WM. Improved i.p. drug delivery with bioadhesive nanoparticles. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 11453-11458. PMID: 27663731, PMCID: PMC5068292, DOI: 10.1073/pnas.1523141113.
- Hoque SM, Huang Y, Cocco E, Maritim S, Santin AD, Shapiro EM, Coman D, Hyder F. Improved specific loss power on cancer cells by hyperthermia and MRI contrast of hydrophilic FexCo1‐xFe2O4 nanoensembles. Contrast Media & Molecular Imaging 2016, 11: 514-526. PMID: 27659164, DOI: 10.1002/cmmi.1713.
- Bandiera E, Todeschini P, Romani C, Zanotti L, Erba E, Colmegna B, Bignotti E, Santin AD, Sartori E, Odicino FE, Pecorelli S, Tassi RA, Ravaggi A. The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines. Oncology Letters 2016, 12: 2493-2500. PMID: 27698818, PMCID: PMC5038480, DOI: 10.3892/ol.2016.5008.
- Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Molecular Cancer Therapeutics 2016, 15: 1900-1909. PMID: 27256376, DOI: 10.1158/1535-7163.mct-16-0163.
- Muralikrishnan S, Hatzis C, Katz A, Santin A, Schwartz PE, Abu-Khalaf MM. Chemotherapy for Elderly Ovarian Cancer Patients. Gynecology & Obstetrics 2016, 69: 1-5. PMID: 27695647, PMCID: PMC5042145, DOI: 10.4172/2161-0932.1000397.
- Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal Of Cancer 2016, 115: 303-311. PMID: 27351214, PMCID: PMC4973158, DOI: 10.1038/bjc.2016.198.
- English DP, Menderes G, Black J, Schwab CL, Santin AD. Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer. Expert Review Of Molecular Diagnostics 2016, 16: 769-782. PMID: 27169329, DOI: 10.1080/14737159.2016.1188692.
- Blumenschein G, Hassan R, Moore K, Santin A, Kindler H, Nemunaitis J, Seward S, Rajagopalan P, Walter A, Sarapa N, Bendell J. Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). Journal Of Clinical Oncology 2016, 34: 2509-2509. DOI: 10.1200/jco.2016.34.15_suppl.2509.
- Santin A, Moore K, Gunderson C, Gowen K, Fabrizio D, Frampton G, Vergilio J, Suh J, Gay L, Ramkissoon S, Ali S, Miller V, Stephens P, Ross J, Sun J, Elvin J. Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA). Journal Of Clinical Oncology 2016, 34: 5591-5591. DOI: 10.1200/jco.2016.34.15_suppl.5591.
- Menderes G, Zhao S, Schwab C, Lopez S, Black J, Bellone S, Silasi D, Ratner E, Azodi M, Litkouhi B, Schwartz P, Schlessinger J, Lifton R, Santin A. Mutational landscape of uterine and ovarian carcinosarcomas. Journal Of Clinical Oncology 2016, 34: 5589-5589. DOI: 10.1200/jco.2016.34.15_suppl.5589.
- Roque DM, Santin AD. Oncofertility in gynecologic oncology: an oxymoron? Future Oncology 2016, 12: 1683-1686. PMID: 27173792, DOI: 10.2217/fon-2016-0167.
- Menderes G, Hicks C, Black JD, Schwab CL, Santin AD. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. Expert Opinion On Biological Therapy 2016, 16: 989-1004. PMID: 27070175, DOI: 10.1080/14712598.2016.1177018.
- Menderes G, Clark M, Santin AD. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discovery Medicine 2016, 21: 293-303. PMID: 27232515.
- Dioguardi C, Uslu B, Haynes M, Kurus M, Gul M, Miao DQ, De Santis L, Ferrari M, Bellone S, Santin A, Giulivi C, Hoffman G, Usdin K, Johnson J. Granulosa cell and oocyte mitochondrial abnormalities in a mouse model of fragile X primary ovarian insufficiency. Molecular Human Reproduction 2016, 22: 384-396. PMID: 26965313, PMCID: PMC4884918, DOI: 10.1093/molehr/gaw023.
- Menderes G, Schwab CL, Black J, Santin AD. The Role of the Immune System in Ovarian Cancer and Implications on Therapy. Expert Review Of Clinical Immunology 2016, 12: 681-695. PMID: 26821930, DOI: 10.1586/1744666x.2016.1147957.
- Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. European Journal Of Gynaecological Oncology 2016, 37: 199-203. PMID: 27172745.
- de Haydu C, Black JD, Schwab CL, English DP, Santin AD. An update on the current pharmacotherapy for endometrial cancer. Expert Opinion On Pharmacotherapy 2015, 17: 489-499. PMID: 26629895, DOI: 10.1517/14656566.2016.1127351.
- Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Review Of Anticancer Therapy 2015, 16: 83-98. PMID: 26568261, DOI: 10.1586/14737140.2016.1121108.
- Black J, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab C, English D, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. Gynecologic Oncology 2015, 139: 596. DOI: 10.1016/j.ygyno.2015.09.058.
- Schwab C, English D, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology 2015, 139: 597. DOI: 10.1016/j.ygyno.2015.09.061.
- Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Erratum: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. British Journal Of Cancer 2015, 113: 1641-1641. PMID: 26625219, PMCID: PMC4705897, DOI: 10.1038/bjc.2015.388.
- Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. Molecular Cancer Therapeutics 2015, 14: 2519-2526. PMID: 26333383, PMCID: PMC4636465, DOI: 10.1158/1535-7163.mct-15-0383.
- Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Menderes G, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal Of Experimental & Clinical Cancer Research 2015, 34: 123. PMID: 26474755, PMCID: PMC4609066, DOI: 10.1186/s13046-015-0241-7.
- Romani C, Cocco E, Bignotti E, Moratto D, Bugatti A, Todeschini P, Bandiera E, Tassi R, Zanotti L, Pecorelli S, Sartori E, Odicino FE, de Marco A, Santin AD, Ravaggi A, Mitola S. Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery. Oncotarget 2015, 6: 34617-34628. PMID: 26416446, PMCID: PMC4741477, DOI: 10.18632/oncotarget.5315.
- Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. British Journal Of Cancer 2015, 113: 1020-1026. PMID: 26325104, PMCID: PMC4651122, DOI: 10.1038/bjc.2015.306.
- Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer. International Journal Of Cancer 2015, 137: 2618-2629. PMID: 26060989, PMCID: PMC4573336, DOI: 10.1002/ijc.29632.
- Santin AD, Roque DM. Reply. American Journal Of Obstetrics And Gynecology 2015, 213: 881. PMID: 26292047, DOI: 10.1016/j.ajog.2015.08.029.
- Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. American Journal Of Obstetrics And Gynecology 2015, 214: 99.e1-99.e8. PMID: 26272866, PMCID: PMC4698047, DOI: 10.1016/j.ajog.2015.08.011.
- Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology 2015, 139: 112-117. PMID: 26260909, PMCID: PMC4587290, DOI: 10.1016/j.ygyno.2015.08.002.
- Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics. Gynecologic And Obstetric Investigation 2015, 81: 169-173. PMID: 26067608, DOI: 10.1159/000431219.
- Black J, Lopez S, Cocco E, Bellone S, Bonazzoli E, Schwab C, English D, Goedings P, Beusker P, van der Lee M, Timmers M, Dokter W, Schwartz P, Santin A. SYD985, a novel HER2-targeting antibody-drug conjugate in preclinical models for USC, both in vitro and in vivo. Journal Of Clinical Oncology 2015, 33: e16527-e16527. DOI: 10.1200/jco.2015.33.15_suppl.e16527.
- Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, Silasi DA, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecologic Oncology 2015, 138: 11-17. PMID: 25931171, PMCID: PMC4469551, DOI: 10.1016/j.ygyno.2015.04.027.
- Black JD, Lopez S, Cocco E, Schwab CL, English DP, Santin AD. Clostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (c-CPE) for the Detection and Treatment of Gynecologic Cancers. Toxins 2015, 7: 1116-1125. PMID: 25835384, PMCID: PMC4417958, DOI: 10.3390/toxins7041116.
- Schwab C, English D, Black J, Lopez S, Bellone S, Roque D, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology 2015, 137: 61. DOI: 10.1016/j.ygyno.2015.01.142.
- Black J, Lopez S, Bellone S, Schwab C, English D, Roque D, Silasi D, Ratner E, Azodi M, Rutherford T, Schwartz P, Santin A. Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma. Gynecologic Oncology 2015, 137: 161-162. DOI: 10.1016/j.ygyno.2015.01.404.
- Roque D, Schwab C, Goloubeva O, English D, Black J, Silasi D, Azodi M, Rutherford T, Santin A, Schwartz P, Ratner E. Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and interval debulking. Gynecologic Oncology 2015, 137: 106-107. DOI: 10.1016/j.ygyno.2015.01.265.
- Pasternak M, Jorgensen E, Azodi M, Ratner E, Rutherford T, Santin A, Schwartz P, Silasi D. Cervical adenocarcinoma in situ: An institutional retrospective review of surgical management and outcome. Gynecologic Oncology 2015, 137: 76. DOI: 10.1016/j.ygyno.2015.01.184.
- Lopez S, Bellone S, Black J, Schwab C, English D, Terranova C, Schwartz P, Rutherford T, Angioli R, Santin A. Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations. Gynecologic Oncology 2015, 137: 144. DOI: 10.1016/j.ygyno.2015.01.359.
- Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecologic Oncology 2015, 137: 392-400. PMID: 25792179, DOI: 10.1016/j.ygyno.2015.03.008.
- Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. Tumor Biology 2015, 36: 5505-5513. PMID: 25669172, PMCID: PMC5573583, DOI: 10.1007/s13277-015-3218-4.
- English D, Bellone S, Schwab C, Roque D, Chatterjee S, Ratner E, Schwartz P, Rutherford T, Santin A. Solitomab, an EpCAM/CD3 bispecific antibody (BITE), is highly active against primary chemotherapy resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Gynecologic Oncology 2015, 136: 401. DOI: 10.1016/j.ygyno.2014.11.041.
- Schwab C, Roque D, English D, Bellone S, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi D, Azodi M, Schwartz P, Rutherford T, Santin A. Afatinib, an irreversible ErbB family blocker, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro and in vivo. Gynecologic Oncology 2015, 136: 397-398. DOI: 10.1016/j.ygyno.2014.11.032.
- Damast S, Higgins SA, Ratner E, De Leon MC, Mani S, Silasi DA, Azodi M, Santin A, Rutherford T, Schwartz PE. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal Of Contemporary Brachytherapy 2015, 7: 35-40. PMID: 25829935, PMCID: PMC4371058, DOI: 10.5114/jcb.2015.48539.
- Santin AD, Bellone S, Centritto F, Schlessinger J, Lifton R. Improved survival of patients with hypermutation in uterine serous carcinoma. Gynecologic Oncology Reports 2015, 12: 3-4. PMID: 26076146, PMCID: PMC4442647, DOI: 10.1016/j.gore.2015.01.005.
- Schwab CL, Santin AD. Targeted therapy in the treatment of uterine serous carcinoma. Pharmacogenomics 2015, 16: 97-99. PMID: 25616096, DOI: 10.2217/pgs.14.176.
- Miller DT, Roque DM, Santin AD. Use of Monsel solution to treat obstetrical hemorrhage: a review and comparison to other topical hemostatic agents. American Journal Of Obstetrics And Gynecology 2015, 212: 725-735. PMID: 25577672, PMCID: PMC4457701, DOI: 10.1016/j.ajog.2014.12.029.
- English D, Roque D, Buza N, Santin A. HER2 as Biomarker for Endometrial Cancer. Biomarkers In Disease: Methods, Discoveries And Applications 2015, 507-526. DOI: 10.1007/978-94-007-7681-4_26.
- Black J, Roque D, Gold L, Santin A. Future Directions and New Targets in Endometrial Cancer. Current Clinical Oncology 2015, 259-271. DOI: 10.1007/7631_2015_1.
- Schwab CL, English DP, Roque DM, Pasternak M, Santin AD. Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy 2014, 6: 1279-1293. PMID: 25524384, PMCID: PMC4312614, DOI: 10.2217/imt.14.90.
- Romani C, Calza S, Todeschini P, Tassi RA, Zanotti L, Bandiera E, Sartori E, Pecorelli S, Ravaggi A, Santin AD, Bignotti E. Identification of Optimal Reference Genes for Gene Expression Normalization in a Wide Cohort of Endometrioid Endometrial Carcinoma Tissues. PLOS ONE 2014, 9: e113781. PMID: 25473950, PMCID: PMC4256201, DOI: 10.1371/journal.pone.0113781.
- Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical & Experimental Metastasis 2014, 32: 29-38. PMID: 25398397, PMCID: PMC4310789, DOI: 10.1007/s10585-014-9688-8.
- English D, Santin A. FIGO 2008 staging for endometrial cancer. 2014, 82-96. DOI: 10.2217/fmeb2013.13.115.
- Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. British Journal Of Cancer 2014, 111: 1750-1756. PMID: 25268372, PMCID: PMC4453741, DOI: 10.1038/bjc.2014.519.
- English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer 2014, 121: 403-412. PMID: 25251053, PMCID: PMC4304922, DOI: 10.1002/cncr.29062.
- Lopez S, Schwab CL, Cocco E, Bellone S, Bonazzoli E, English DP, Schwartz PE, Rutherford T, Angioli R, Santin AD. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecologic Oncology 2014, 135: 312-317. PMID: 25172762, PMCID: PMC4270135, DOI: 10.1016/j.ygyno.2014.08.024.
- Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecologic Oncology 2014, 135: 142-148. PMID: 25124161, DOI: 10.1016/j.ygyno.2014.08.006.
- Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, Yang Y, Liu N, Zhao X, Santin AD, Taylor H, Huang Y. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene 2014, 34: 3076-3084. PMID: 25088204, DOI: 10.1038/onc.2014.236.
- Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA. Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging. International Journal Of Gynecological Cancer 2014, 24: 1118-1125. PMID: 24927247, DOI: 10.1097/igc.0000000000000156.
- English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Medicine 2014, 3: 1256-1265. PMID: 24890382, PMCID: PMC4302675, DOI: 10.1002/cam4.274.
- Roque D, Schwab C, English D, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: An institutional experience. Gynecologic Oncology 2014, 133: 69. DOI: 10.1016/j.ygyno.2014.03.187.
- Schwab CL, English DP, Roque DM, Santin AD. Taxanes. Anti-Cancer Drugs 2014, 25: 522-535. PMID: 24300913, PMCID: PMC3980024, DOI: 10.1097/cad.0000000000000057.
- English D, Schwab C, Roque D, Bellone S, Ratner E, Silasi D, Azodi M, Schwartz P, Rutherford T, Santin A. Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Gynecologic Oncology 2014, 133: 98. DOI: 10.1016/j.ygyno.2014.03.261.
- English D, Pasternak M, Warmington J, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A, Rutherford T. Evaluation of the diagnostic accuracy of cervical biopsy and determination of associated risk factors for positive margin status in recurrent cervical dysplasia after leep or conization. Journal Of Clinical Oncology 2014, 32: 5609-5609. DOI: 10.1200/jco.2014.32.15_suppl.5609.
- Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM. Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer. International Journal Of Gynecological Cancer 2014, 24: 528-533. PMID: 24557436, DOI: 10.1097/igc.0000000000000085.
- Buza N, Roque DM, Santin AD. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Archives Of Pathology & Laboratory Medicine 2014, 138: 343-50. PMID: 24576030, DOI: 10.5858/arpa.2012-0416-ra.
- Black JD, English DP, Roque DM, Santin AD. Targeted Therapy in Uterine Serous Carcinoma: An Aggressive Variant of Endometrial Cancer. Women's Health 2014, 10: 45-57. PMID: 24328598, PMCID: PMC3984476, DOI: 10.2217/whe.13.72.
- English D, Roque D, Buza N, Santin A. HER2 as Biomarker for Endometrial Cancer. 2014, 1-16. DOI: 10.1007/978-94-007-7744-6_26-1.
- Damast S, Higgins S, Ratner E, de Leon M, Mani S, Silasi D, Azodi M, Santin A, Rutherford T, Schwartz P. 7 Gy x 2 – An Effective Brachytherapy Regimen for Stage I-II Uterine Papillary Serous Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s420-s421. DOI: 10.1016/j.ijrobp.2013.06.1106.
- Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clinical & Experimental Metastasis 2013, 31: 101-110. PMID: 24005572, PMCID: PMC3947146, DOI: 10.1007/s10585-013-9614-5.
- English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecologic Oncology 2013, 131: 753-758. PMID: 24012800, DOI: 10.1016/j.ygyno.2013.08.033.
- English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). American Journal Of Obstetrics And Gynecology 2013, 209: 465.e1-465.e9. PMID: 23891627, DOI: 10.1016/j.ajog.2013.07.020.
- Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, Roque DM, Santin AD. Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. Journal Of Translational Medicine 2013, 11: 162. PMID: 23819652, PMCID: PMC3706350, DOI: 10.1186/1479-5876-11-162.
- Ahmad A, Varughese J, Hui P, Santin A, Azodi M, Silasi D, Schwartz P, Rutherford T, Ratner E. Institutional review of primary lymphoma of the female genital tract: A 32-year experience. Gynecologic Oncology 2013, 130: e152-e153. DOI: 10.1016/j.ygyno.2013.04.428.
- Ahmad A, Ahmad S, Weidhaas J, Hui P, Santin A, Azodi M, Silasi D, Schwartz P, Rutherford T, Ratner E. Ovarian versus uterine serous carcinomas: Clinicopathologic and miRNA analysis. Gynecologic Oncology 2013, 130: e92. DOI: 10.1016/j.ygyno.2013.04.274.
- Roque D, Buza N, Glasgow M, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Gynecologic Oncology 2013, 130: e124-e125. DOI: 10.1016/j.ygyno.2013.04.358.
- Joo W, Silasi D, Ratner E, Santin A, Azodi M, Rutherford T, Schwartz P. Risk factors for omental metastasis in clinical stage I endometrial cancer: A meta-analysis. Gynecologic Oncology 2013, 130: e67. DOI: 10.1016/j.ygyno.2013.04.220.
- Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighieri L, Falchetti M, Donzelli C, Siegel ER, Azodi M, Silasi DA, Ratner E, Schwartz PE, Rutherford TJ, Santin AD. Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. British Journal Of Cancer 2013, 109: 462-471. PMID: 23807163, PMCID: PMC3721400, DOI: 10.1038/bjc.2013.315.
- Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology 2013, 26: 1605-1612. PMID: 23765245, DOI: 10.1038/modpathol.2013.113.
- English DP, Santin AD. Claudins Overexpression in Ovarian Cancer: Potential Targets for Clostridium Perfringens Enterotoxin (CPE) Based Diagnosis and Therapy. International Journal Of Molecular Sciences 2013, 14: 10412-10437. PMID: 23685873, PMCID: PMC3676847, DOI: 10.3390/ijms140510412.
- Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi D, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013, 119: 2582-2592. PMID: 23585021, PMCID: PMC3700638, DOI: 10.1002/cncr.28017.
- Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. American Journal Of Obstetrics And Gynecology 2013, 209: 62.e1-62.e9. PMID: 23583215, DOI: 10.1016/j.ajog.2013.04.017.
- English DP, Roque DM, Santin AD. HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies. Molecular Diagnosis & Therapy 2013, 17: 85-99. PMID: 23529353, PMCID: PMC3660991, DOI: 10.1007/s40291-013-0024-9.
- Roque DM, Santin AD. Updates in therapy for uterine serous carcinoma. Current Opinion In Obstetrics & Gynecology 2013, 25: 29-37. PMID: 23138439, DOI: 10.1097/gco.0b013e32835af98d.
- Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 2916-2921. PMID: 23359684, PMCID: PMC3581983, DOI: 10.1073/pnas.1222577110.
- Fader AN, Santin AD, Gehrig PA. Early stage uterine serous carcinoma: Management updates and genomic advances. Gynecologic Oncology 2013, 129: 244-250. PMID: 23321062, DOI: 10.1016/j.ygyno.2013.01.004.
- English DP, Roque DM, Santin AD. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? Expert Review Of Anticancer Therapy 2013, 13: 63-74. PMID: 23259428, DOI: 10.1586/era.12.158.
- Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, Romani C, Todeschini P, Bandiera E, Tassi RA, Facchetti F, Sartori E, Pecorelli S, Roque DM, Santin AD. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clinical Pathology 2012, 12: 22. PMID: 23151048, PMCID: PMC3534488, DOI: 10.1186/1472-6890-12-22.
- Lal-Nag M, Battis M, Santin AD, Morin PJ. Claudin-6: a novel receptor for CPE-mediated cytotoxicity in ovarian cancer. Oncogenesis 2012, 1: e33-e33. PMID: 23552466, PMCID: PMC3511677, DOI: 10.1038/oncsis.2012.32.
- Roque D, Schwartz P, Santin A. Targeted therapy for high-risk endometrial carcinoma. Journal Of Clinical Practice 2012, 9: 539-554. DOI: 10.2217/cpr.12.44.
- Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A. Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer. International Scholarly Research Notices 2012, 2012: 245756. PMID: 22792477, PMCID: PMC3390037, DOI: 10.5402/2012/245756.
- ElSahwi K, Barber E, Illuzzi J, Buza N, Ratner E, Silasi D, Santin A, Azodi M, Schwartz P, Hui P, Rutherford T. Corrigendum to “The Significance of Perineural Invasion in Early-stage Cervical Cancer” [Gynecologic Oncology 123 (2011) 561–564]. Gynecologic Oncology 2012, 125: 770. DOI: 10.1016/j.ygyno.2012.02.026.
- Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi D, Santin AD, Schwartz PE. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal Of Surgical Oncology 2012, 107: 195-200. PMID: 22648987, DOI: 10.1002/jso.23171.
- Santin A, Varughese J, Chan J, McClure C, Lea J. In vitro chemosensitivity assay for patients with gynecologic sarcoma. Journal Of Clinical Oncology 2012, 30: e13078-e13078. DOI: 10.1200/jco.2012.30.15_suppl.e13078.
- deLeon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC). Journal Of Clinical Oncology 2012, 30: 5099-5099. DOI: 10.1200/jco.2012.30.15_suppl.5099.
- de Leon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Demographics of uterine serous cancer (USC) patients: A single institutional experience. Journal Of Clinical Oncology 2012, 30: e15581-e15581. DOI: 10.1200/jco.2012.30.15_suppl.e15581.
- Roque D, Ratner E, Silasi D, Azodi M, Schwartz P, Rutherford T, Santin A. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer. Journal Of Clinical Oncology 2012, 30: e15526-e15526. DOI: 10.1200/jco.2012.30.15_suppl.e15526.
- Guzzo F, Bellone S, Buza N, Hui P, Carrara L, Varughese J, Cocco E, Betti M, Todeschini P, Gasparrini S, Schwartz PE, Rutherford TJ, Angioli R, Pecorelli S, Santin AD. HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas. International Journal Of Gynecological Pathology 2012, 31: 211-221. PMID: 22498937, PMCID: PMC3366047, DOI: 10.1097/pgp.0b013e31823bb24d.
- Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. British Journal Of Cancer 2012, 106: 1543-1550. PMID: 22531721, PMCID: PMC3341945, DOI: 10.1038/bjc.2012.132.
- Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ. EGFR/HER-targeted therapeutics in ovarian cancer. Future Medicinal Chemistry 2012, 4: 447-469. PMID: 22416774, PMCID: PMC4620931, DOI: 10.4155/fmc.12.11.
- Roque D, Santin A. Antigen-specific immunotherapy for ovarian cancer. 2012, 136-154. DOI: 10.2217/ebo.11.180.
- Roque D, Carrara L, Cocco E, Guzzo F, Sartori E, Bellone S, Pecorelli S, Schwartz P, Rutherford T, Santin A. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcomas cell lines is linked to tubulin-beta-III expression. Gynecologic Oncology 2012, 125: s81. DOI: 10.1016/j.ygyno.2011.12.195.
- Roque D, Bellone S, Betti M, Silasi D, Ratner E, Azodi M, Schwartz P, Rutherford T, Pecorelli S, Santin A. Mammaglobin B (SCGB2A1)-specific CD8+ cytotoxic T lymphocytes (CTL) are highly effective in killing autologous chemotherapy resistant ovarian cancer cells: Implications for SCGB2A1 dendritic cell-based therapeutic vaccines. Gynecologic Oncology 2012, 125: s34. DOI: 10.1016/j.ygyno.2011.12.078.
- El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Review Of Anticancer Therapy 2012, 12: 41-49. PMID: 22149431, PMCID: PMC3287395, DOI: 10.1586/era.11.192.
- Carrara L, Guzzo F, Roque DM, Bellone S, Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Gynecologic Oncology 2011, 125: 231-236. PMID: 22209775, PMCID: PMC3303974, DOI: 10.1016/j.ygyno.2011.12.446.
- Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31: 4559-4566. PMID: 22139083, PMCID: PMC3342446, DOI: 10.1038/onc.2011.539.
- Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A. Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 2496-2506. PMID: 22028406, PMCID: PMC3237732, DOI: 10.1158/1055-9965.epi-11-0635.
- Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi DA, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. Journal Of Experimental & Clinical Cancer Research 2011, 30: 106. PMID: 22075385, PMCID: PMC3224774, DOI: 10.1186/1756-9966-30-106.
- Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD, DiMaio D. Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology 2011, 422: 114-124. PMID: 22056390, PMCID: PMC3229657, DOI: 10.1016/j.virol.2011.10.012.
- Bignotti E, Ravaggi A, Romani C, Falchetti M, Lonardi S, Facchetti F, Pecorelli S, Varughese J, Cocco E, Bellone S, Schwartz PE, Rutherford TJ, Santin AD. Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma. International Journal Of Gynecological Cancer 2011, 21: 1613-1621. PMID: 21892093, PMCID: PMC3233648, DOI: 10.1097/igc.0b013e318228f6da.
- ElSahwi KS, Hooper C, De Leon MC, Gallo TN, Ratner E, Silasi DA, Santin AD, Schwartz PE, Rutherford TJ, Azodi M. Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecologic Oncology 2011, 124: 260-264. PMID: 22036203, DOI: 10.1016/j.ygyno.2011.09.038.
- El-Sahwi KS, Illuzzi J, Varughese J, Carusillo N, Ratner ES, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study. Gynecologic Oncology 2011, 124: 471-473. PMID: 22014628, DOI: 10.1016/j.ygyno.2011.09.029.
- ElSahwi KS, Barber E, Illuzzi J, Buza N, Ratner E, Silasi DA, Santin AD, Azodi M, Schwartz PE, Rutherford TJ. The significance of perineural invasion in early-stage cervical cancer. Gynecologic Oncology 2011, 123: 561-564. PMID: 21968340, DOI: 10.1016/j.ygyno.2011.08.028.
- Todeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. British Journal Of Cancer 2011, 105: 1176-1182. PMID: 21915118, PMCID: PMC3208497, DOI: 10.1038/bjc.2011.369.
- Santin AD, Sill MW, McMeekin DS, Leitao MM, Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecologic Oncology 2011, 122: 495-500. PMID: 21684583, PMCID: PMC3152667, DOI: 10.1016/j.ygyno.2011.05.040.
- Richter C, Buza N, Hui P, Silasi D, Azodi M, Santin A, Rutherford T, Schwartz P. Urinary hCG Screening in the Gynecologic Oncology Population. Journal Of Gynecologic Surgery 2011, 27: 143-146. DOI: 10.1089/gyn.2010.0048.
- ElSahwi KS, Santin AD. erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. Obstetrics And Gynecology International 2011, 2011: 128295. PMID: 21876697, PMCID: PMC3159302, DOI: 10.1155/2011/128295.
- Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. American Journal Of Obstetrics And Gynecology 2011, 205: 567.e1-567.e7. PMID: 21889762, PMCID: PMC3224189, DOI: 10.1016/j.ajog.2011.06.093.
- Cocco E, Varughese J, Buza N, Bellone S, Lin KY, Bellone M, Todeschini P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Carrara L, Tassi R, Pecorelli S, Lockwood CJ, Santin AD. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. Clinical & Experimental Metastasis 2011, 28: 689-700. PMID: 21725665, PMCID: PMC3697933, DOI: 10.1007/s10585-011-9401-0.
- Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. Retraction to “A 3′ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer” [Gynecol. Oncol. 120 (2011) S3]. Gynecologic Oncology 2011, 122: 205. PMID: 21770066, DOI: 10.1016/j.ygyno.2011.03.028.
- Cocco E, Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, Todeschini P, Carrara L, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Lockwood CJ, Santin AD. Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor. BMC Cancer 2011, 11: 263. PMID: 21693061, PMCID: PMC3141777, DOI: 10.1186/1471-2407-11-263.
- Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin‐Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin. Cancer 2011, 117: 5519-5528. PMID: 21692061, PMCID: PMC3701957, DOI: 10.1002/cncr.26215.
- Santin A, Varughese J, Lea J. In vitro chemosensitivity assay for patients with gynecologic sarcoma. Journal Of Clinical Oncology 2011, 29: e20513-e20513. DOI: 10.1200/jco.2011.29.15_suppl.e20513.
- Varughese J, Casagrande F, Cocco E, Bellone S, Richter C, Bellone M, Todeschini P, Carrara L, Guzzo F, Siegel E, Silasi D, Azodi M, Rutherford T, Pecorelli S, Schwartz P, Santin A. The effect of intraperitoneal administration of clostridium perfringens enterotoxin on chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice. Journal Of Clinical Oncology 2011, 29: e13077-e13077. DOI: 10.1200/jco.2011.29.15_suppl.e13077.
- Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecologic Oncology 2011, 122: 171-177. PMID: 21453957, PMCID: PMC3104081, DOI: 10.1016/j.ygyno.2011.03.002.
- Bellone M, Cocco E, Varughese J, Bellone S, Todeschini P, El-Sahwi K, Carrara L, Guzzo F, Schwartz PE, Rutherford TJ, Pecorelli S, Marshall DJ, Santin AD. Expression of αV-Integrins in Uterine Serous Papillary Carcinomas; Implications for Targeted Therapy With Intetumumab (CNTO 95), a Fully Human Antagonist Anti-αV-Integrin Antibody. International Journal Of Gynecological Cancer 2011, 21: 1084. PMID: 21633302, PMCID: PMC3690508, DOI: 10.1097/igc.0b013e3182187324.
- Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. RETRACTED: A 3’ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer. Gynecologic Oncology 2011, 120: s3. DOI: 10.1016/j.ygyno.2010.12.010.
- Santin A, Bellone S, Varughese J, Cocco E, Ratner E, Silasi D, Rutherford T, Schwartz P, Azodi M, Pecorelli S. Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Gynecologic Oncology 2011, 120: s6-s7. DOI: 10.1016/j.ygyno.2010.12.018.
- Abu-Khalaf M, Santin A, Ratner E, Silasi D, ElSahwi K, Baker L, Luther M, Azodi M, Rutherford T, Schwartz P. A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer. Gynecologic Oncology 2011, 120: s97-s98. DOI: 10.1016/j.ygyno.2010.12.232.
- Santin A, Patricia G, Sill M, McMeekin D, Leitao M, Brown J, Sutton G, Van Le L, Boardman C. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecologic Oncology 2011, 120: s18. DOI: 10.1016/j.ygyno.2010.12.047.
- Varughese J, Cocco E, Bellone S, de Leon M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Uterine serous papillary carcinomas overexpress human trophoblast‐cell‐surface marker (trop‐2) and are highly sensitive to immunotherapy with hRS7, a humanized anti‐trop‐2 monoclonal antibody. Cancer 2011, 117: 3163-3172. PMID: 21246534, PMCID: PMC3128671, DOI: 10.1002/cncr.25891.
- Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Primary Cervical Carcinoma Cell Lines Overexpress Epithelial Cell Adhesion Molecule (EpCAM) and Are Highly Sensitive to Immunotherapy With MT201, a Fully Human Monoclonal Anti-EpCAM Antibody. International Journal Of Gynecological Cancer 2010, 20: 1440-1447. PMID: 21370592, PMCID: PMC3701951, DOI: 10.1111/igc.0b013e3181fb18a1.
- Elsahwi K, Hooper C, Rutherford T, Silasi D, Santin A, Schwartz P, Azodi M. Comparison between 150 Cases of Robotic vs. 150 Cases of Open Surgical Staging for Endometrial Cancer. Journal Of Minimally Invasive Gynecology 2010, 17: s45. DOI: 10.1016/j.jmig.2010.08.234.
- Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. American Journal Of Obstetrics And Gynecology 2010, 203: 582.e1-582.e7. PMID: 20870202, PMCID: PMC2993821, DOI: 10.1016/j.ajog.2010.07.041.
- Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.
- Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. British Journal Of Cancer 2010, 103: 812-819. PMID: 20700124, PMCID: PMC2966612, DOI: 10.1038/sj.bjc.6605760.
- Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, Siegel EE, Richter CE, Schwartz PE, Rutherford TJ, Santin AD. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecologic Oncology 2010, 119: 140-145. PMID: 20673976, PMCID: PMC2939197, DOI: 10.1016/j.ygyno.2010.06.024.
- Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer 2010, 10: 349. PMID: 20598131, PMCID: PMC2908101, DOI: 10.1186/1471-2407-10-349.
- Wang H, Lin K, Merl M, Higgins S, Silasi D, Santin A, Azodi M, Rutherford T, Schwartz P, Abu-Khalaf M. Cisplastin (C) and ifosfamide (I) chemotherapy with vaginal cuff brachytherapy (VCBT) for treatment of uterine carcinosarcoma. Journal Of Clinical Oncology 2010, 28: 5123-5123. DOI: 10.1200/jco.2010.28.15_suppl.5123.
- Schwartz P, Glasgow M, Yu H, Rutherford T, Azodi M, Silasi D, Santin A. Neoadjuvant carboplatin and paclitaxel (CP) chemotherapy (NACT) in patients (pts) with advancedstage (AS) epithelial ovarian cancer (EOC) compared with upfront surgical cytoreduction (USC) followed by CP. Journal Of Clinical Oncology 2010, 28: e15511-e15511. DOI: 10.1200/jco.2010.28.15_suppl.e15511.
- Richter C, Cocco E, Bellone S, Casagrande F, Bellone M, Silasi D, Azodi M, Schwartz P, Rutherford T, Santin A. EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201) in chemotherapy-resistant ovarian cancer cell lines. Journal Of Clinical Oncology 2010, 28: e15524-e15524. DOI: 10.1200/jco.2010.28.15_suppl.e15524.
- Katz A, Yu H, Elsahwi K, Ratner E, Silasi D, Santin A, Azodi M, Rutherford T, Schwartz P, Abu-Khalaf M. Retrospective analysis of elderly patients (pts) with primary epithelial ovarian cancer (EOC) age 70 or older. Journal Of Clinical Oncology 2010, 28: e15518-e15518. DOI: 10.1200/jco.2010.28.15_suppl.e15518.
- Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, Siegel ER, Schwartz PE, Rutherford TJ, Santin AD. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. American Journal Of Obstetrics And Gynecology 2010, 203: 162.e1-162.e8. PMID: 20417484, PMCID: PMC2918912, DOI: 10.1016/j.ajog.2010.02.056.
- Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal Of Clinical Pathology 2010, 63: 544. PMID: 20418225, DOI: 10.1136/jcp.2010.077446.
- Santin AD. Letter to the Editor referring to the manuscript entitled: “Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study” recently reported by Fleming et al., (Gynecol Oncol., 116;15–20;2010). Gynecologic Oncology 2010, 118: 95-96. PMID: 20172595, DOI: 10.1016/j.ygyno.2010.01.043.
- Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. European Journal Of Cancer 2010, 46: 944-953. PMID: 20060709, DOI: 10.1016/j.ejca.2009.12.019.
- El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201). Molecular Cancer Therapeutics 2010, 9: 57-66. PMID: 20053761, PMCID: PMC2806489, DOI: 10.1158/1535-7163.mct-09-0675.
- Cocco E, Bellone S, El‐Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A. Cancer 2009, 116: 843-851. PMID: 20041483, PMCID: PMC2819580, DOI: 10.1002/cncr.24838.
- Xu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P. HER‐2/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology 2009, 56: 269-273. PMID: 20102407, DOI: 10.1111/j.1365-2559.2009.03464.x.
- El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. British Journal Of Cancer 2009, 102: 134-143. PMID: 19920829, PMCID: PMC2813756, DOI: 10.1038/sj.bjc.6605448.
- Tassi R, Siegel E, Bignotti E, Ravaggi A, Todeschini P, Zanotti L, Bandiera E, Romani C, Santin A, Pecorelli S. 8016 Gene expression profile as a diagnostic tool for synchronous ovarian/endometrial cancer. European Journal Of Cancer Supplements 2009, 7: 454. DOI: 10.1016/s1359-6349(09)71538-1.
- Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, Romani C, Bandiera E, Zanotti L, Pecorelli S, Santin AD. Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer 2009, 9: 253. PMID: 19635143, PMCID: PMC2724548, DOI: 10.1186/1471-2407-9-253.
- Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, Tognon G, Ragnoli M, Santin AD, Gion M, Pecorelli S, Ravaggi A. Human Kallikrein 5. International Journal Of Gynecological Cancer 2009, 19: 1015-1021. PMID: 19820362, DOI: 10.1111/igc.0b013e3181ab597f.
- Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy. International Journal Of Gynecological Cancer 2009, 19: 860-866. PMID: 19574774, DOI: 10.1111/igc.0b013e3181a8331f.
- Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. British Journal Of Cancer 2009, 101: 335-341. PMID: 19536090, PMCID: PMC2720219, DOI: 10.1038/sj.bjc.6605129.
- Santin A, Bellone S, El-Sahwi K, Buza N, Tavassoli F, Silasi D, Azodi M, Schwartz P, Rutherford T, Pecorelli S. Potential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma. Journal Of Clinical Oncology 2009, 27: e16502-e16502. DOI: 10.1200/jco.2009.27.15_suppl.e16502.
- Romani C, Comper F, Bandiera E, Ravaggi A, Bignotti E, Tassi RA, Pecorelli S, Santin AD. Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. American Journal Of Obstetrics And Gynecology 2009, 201: 70.e1-70.e9. PMID: 19426958, PMCID: PMC3701950, DOI: 10.1016/j.ajog.2009.02.010.
- Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines. Journal Of Virology 2009, 83: 6779-6789. PMID: 19386711, PMCID: PMC2698533, DOI: 10.1128/jvi.02443-08.
- Santin A. Prospective identification and characterization of ovarian cancer stem cells: Implications for the treatment of chemotherapy resistant/recurrent ovarian disease. Cell Cycle 2009, 8: 3-5. DOI: 10.4161/cc.8.1.7670.
- Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Induction of human tumor‐associated differentially expressed gene‐12 (TADG‐12/TMPRSS3)‐specific cytotoxic T lymphocytes in human lymphocyte antigen‐A2.1–positive healthy donors and patients with advanced ovarian cancer. Cancer 2008, 115: 800-811. PMID: 19117353, DOI: 10.1002/cncr.24048.
- Ravindranath M, Muthugounder S, Presser N, Selvan S, Santin A, Bellone S, Saravanan T, Morton D. Corrigendum to “Immunogenic gangliosides in human ovarian carcinoma” [Biochem. Biophys. Res. Commun. 353 (2007) 251–258]. Biochemical And Biophysical Research Communications 2008, 377: 1331. DOI: 10.1016/j.bbrc.2008.09.103.
- Wang X, Santin A, Bellone S, Gupta S, Nakagawa M. A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. Cancer Immunology, Immunotherapy 2008, 58: 309-309. PMCID: PMC11030283, DOI: 10.1007/s00262-008-0617-z.
- Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. American Journal Of Obstetrics And Gynecology 2008, 200: 75.e1-75.e10. PMID: 18976739, DOI: 10.1016/j.ajog.2008.08.014.
- TASSI RA, BIGNOTTI E, FALCHETTI M, RAVANINI M, CALZA S, RAVAGGI A, BANDIERA E, FACCHETTI F, PECORELLI S, SANTIN AD. Claudin‐7 expression in human epithelial ovarian cancer. International Journal Of Gynecological Cancer 2008, 18: 1262-1271. PMID: 18298564, DOI: 10.1111/j.1525-1438.2008.01194.x.
- Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, Romani C, Bandiera E, Odicino FE, Pecorelli S, Santin AD. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. British Journal Of Cancer 2008, 99: 768-773. PMID: 18682706, PMCID: PMC2528153, DOI: 10.1038/sj.bjc.6604546.
- TASSI RA, BIGNOTTI E, FALCHETTI M, CALZA S, RAVAGGI A, ROSSI E, MARTINELLI F, BANDIERA E, PECORELLI S, SANTIN AD. Mammaglobin B expression in human endometrial cancer. International Journal Of Gynecological Cancer 2008, 18: 1090-1096. PMID: 18021217, DOI: 10.1111/j.1525-1438.2007.01137.x.
- Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. International Journal Of Gynecology & Obstetrics 2008, 102: 128-131. PMID: 18555254, DOI: 10.1016/j.ijgo.2008.04.008.
- Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. American Journal Of Obstetrics And Gynecology 2008, 199: e7-e10. PMID: 18550023, DOI: 10.1016/j.ajog.2008.04.012.
- Wang X, Santin AD, Bellone S, Gupta S, Nakagawa M. A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. Cancer Immunology, Immunotherapy 2008, 58: 301-308. PMID: 18446336, PMCID: PMC2782377, DOI: 10.1007/s00262-008-0525-2.
- Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ. Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial. Journal Of Virology 2007, 82: 1968-1979. PMID: 18057249, PMCID: PMC2258728, DOI: 10.1128/jvi.02343-07.
- Santin A. Reply. American Journal Of Obstetrics And Gynecology 2007, 197: 555-556. DOI: 10.1016/j.ajog.2007.08.029.
- Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic cell-based therapeutic vaccines for cervical cancer. Expert Review Of Anticancer Therapy 2007, 7: 1473-1486. PMID: 17944571, DOI: 10.1586/14737140.7.10.1473.
- Boerma M, Wang J, Burnett AF, Santin AD, Roman JJ, Hauer-Jensen M. Local Administration of Interleukin-11 Ameliorates Intestinal Radiation Injury in Rats. Cancer Research 2007, 67: 9501-9506. PMID: 17909060, DOI: 10.1158/0008-5472.can-07-0810.
- Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor. Obstetrics And Gynecology 2007, 110: 518-520. PMID: 17666649, DOI: 10.1097/01.aog.0000267533.56546.c2.
- Facchetti F, Lonardi S, Gentili F, Bercich L, Falchetti M, Tardanico R, Baronchelli C, Lucini L, Santin A, Murer B. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Archiv 2007, 451: 669-680. PMID: 17609977, DOI: 10.1007/s00428-007-0448-x.
- Santin AD, Bellone S, Siegel ER, McKenney JK, Thomas M, Roman JJ, Burnett A, Tognon G, Bandiera E, Pecorelli S. Overexpression of Clostridium perfringens Enterotoxin Receptors Claudin-3 and Claudin-4 in Uterine Carcinosarcomas. Clinical Cancer Research 2007, 13: 3339-3346. PMID: 17545541, DOI: 10.1158/1078-0432.ccr-06-3037.
- Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S, Santin AD. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecologic Oncology 2007, 106: 513-520. PMID: 17540437, DOI: 10.1016/j.ygyno.2007.04.028.
- Winfield HL, De Las Casas LE, Greenfield WW, Santin AD, McKenney JK. Low-grade Fibromyxoid Sarcoma Presenting Clinically as a Primary Ovarian Neoplasm. International Journal Of Gynecological Pathology 2007, 26: 173-176. PMID: 17413985, DOI: 10.1097/01.pgp.0000228145.36807.43.
- Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD. Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecologic Oncology 2007, 105: 578-585. PMID: 17343903, DOI: 10.1016/j.ygyno.2007.01.043.
- Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, Santin AD. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. American Journal Of Obstetrics And Gynecology 2007, 196: 245.e1-245.e11. PMID: 17346539, DOI: 10.1016/j.ajog.2006.10.874.
- Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S. Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma. Cancer 2007, 109: 1312-1322. PMID: 17326053, DOI: 10.1002/cncr.22536.
- Ravindranath MH, Muthugounder S, Presser N, Selvan SR, Santin AD, Bellone S, Saravanan TS, Morton DL. Immunogenic gangliosides in human ovarian carcinoma. Biochemical And Biophysical Research Communications 2006, 353: 251-258. PMID: 17188646, DOI: 10.1016/j.bbrc.2006.12.001.
- Santin A, Bandiera E, Comper F, Bellone M, Marizzoni S, Zanolini A, Palmieri M, Siegel E, Mckinney J, Thomas M, Hennings L, Roman J, Burnett A, Cannon M, Pecorelli S. 0047: Claudin-3 and Claudin-4 Receptor Overexpression: Novel Targets for a Type Specific Therapy Against Uterine Serous Papillary Carcinomas Using Clostridium Perfringens Enterotoxin. International Journal Of Gynecological Cancer 2006, 16: 612.2-612. DOI: 10.1136/ijgc-00009577-200610001-00047.
- Santin A, Bellone S, Palmieri M, Ravaggi A, Zanolini A, Roman J, Burnett A, Cannon M, Pecorelli S. 0348: Phase I Dose Escalation Trial of Hpv16/18 E7-Pulsed Dendritic Cell Vaccination in Stage Ib-Iia Cervical Cancer Patients. International Journal Of Gynecological Cancer 2006, 16: 699.3-699. DOI: 10.1136/ijgc-00009577-200610001-00348.
- Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immunology Research 2006, 6: 9. PMID: 16808432.
- Ravaggi A, Romani C, Pasinetti B, Tassi RA, Bignotti E, Bandiera E, Odicino FE, Ragnoli M, Donzelli C, Falchetti M, Calza S, Santin AD, Pecorelli S. Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. Archives Of Virology 2006, 151: 1899-1916. PMID: 16732494, DOI: 10.1007/s00705-006-0787-y.
- Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecologic Oncology 2006, 103: 405-416. PMID: 16725184, DOI: 10.1016/j.ygyno.2006.03.056.
- Santin AD, Diamandis EP, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A, Pecorelli S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. American Journal Of Obstetrics And Gynecology 2006, 194: 1296-1302. PMID: 16647913, DOI: 10.1016/j.ajog.2005.10.794.
- Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecologic Oncology 2005, 100: 469-478. PMID: 16249018, DOI: 10.1016/j.ygyno.2005.09.040.
- Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S. Amplification of c‐erbB2 oncogene. Cancer 2005, 104: 1391-1397. PMID: 16116605, DOI: 10.1002/cncr.21308.
- Bignotti E, Tassi R, Calza S, Ravaggi A, Romani C, Rossi E, Donzelli C, Falchetti M, Pasinetti B, Odicino F, Pecorelli S, Santin A. 00086 ANALYSIS OF GENE EXPRESSION PATTERNS THAT DEFINES SEROUS PAPILLARY OVARIAN CARCINOMAS. International Journal Of Gynecological Cancer 2005, 15: 75.2-75. DOI: 10.1136/ijgc-00009577-200509001-00086.
- Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecologic Oncology 2005, 98: 92-98. PMID: 15904949, DOI: 10.1016/j.ygyno.2005.03.016.
- Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecologic Oncology 2005, 98: 24-30. PMID: 15894362, DOI: 10.1016/j.ygyno.2005.03.041.
- Santin AD, Cané S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin. Cancer Research 2005, 65: 4334-4342. PMID: 15899825, DOI: 10.1158/0008-5472.can-04-3472.
- Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ. Definition of an Immunogenic Region Within the Ovarian Tumor Antigen Stratum Corneum Chymotryptic Enzyme. Clinical Cancer Research 2005, 11: 3446-3454. PMID: 15867247, DOI: 10.1158/1078-0432.ccr-04-2043.
- Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S. Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer. Clinical Cancer Research 2005, 11: 3320-3325. PMID: 15867230, DOI: 10.1158/1078-0432.ccr-04-2528.
- Santin AD, Zhan F, Cane' S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal Of Cancer 2005, 92: 1561-1573. PMID: 15785748, PMCID: PMC2362016, DOI: 10.1038/sj.bjc.6602480.
- Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer. American Journal Of Obstetrics And Gynecology 2005, 192: 813-818. PMID: 15746676, DOI: 10.1016/j.ajog.2004.10.605.
- Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Current Pharmaceutical Design 2005, 11: 3485-500. PMID: 16248803, DOI: 10.2174/138161205774414565.
- Santin AD, Zhan F, Bignotti E, Siegel ER, Cané S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005, 331: 269-291. PMID: 15629771, DOI: 10.1016/j.virol.2004.09.045.
- Santin A. 3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer. Handbook Of Immunohistochemistry And In Situ Hybridization Of Human Carcinomas 2005, 4: 333-338. DOI: 10.1016/s1874-5784(05)80089-3.
- Santin A, Bellone S, Cane' S, Palmieri M, Bignotti E, Anfossi S, Thomas M, Roman J, Kay H, Burnett A, O'Brien T, Cannon M, John S, Zhan F, Tian E, Pecorelli S. GENE EXPRESSION FINGERPRINT OF UTERINE SEROUS PAPILLARY CARCINOMA: IDENTIFICATION OF NOVEL MOLECULAR MARKERS FOR UTERINE SEROUS CANCER DIAGNOSIS AND THERAPY. International Journal Of Gynecological Cancer 2004, 14: 2.3-2. DOI: 10.1136/ijgc-00009577-200409001-00006.
- Santin AD, Cane' S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Roman JJ, Anfossi S, O'Brien T, Pecorelli S. The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. Gynecologic Oncology 2004, 94: 283-288. PMID: 15297163, DOI: 10.1016/j.ygyno.2004.05.023.
- Santin AD, Bellone S, O’Brien T, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Review Of Anticancer Therapy 2004, 4: 679-689. PMID: 15270671, DOI: 10.1586/14737140.4.4.679.
- Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. International Journal Of Cancer 2004, 112: 14-25. PMID: 15305371, DOI: 10.1002/ijc.20408.
- Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. British Journal Of Cancer 2004, 90: 1814-1824. PMID: 15208622, PMCID: PMC2409747, DOI: 10.1038/sj.bjc.6601791.
- Santin AD, Ravindranath MH, Bellone S, Muthugounder S, Palmieri M, O'Brien TJ, Roman J, Cannon MJ, Pecorelli S. Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG An International Journal Of Obstetrics & Gynaecology 2004, 111: 613-618. PMID: 15198791, DOI: 10.1111/j.1471-0528.2004.00142.x.
- Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Current Opinion In Obstetrics & Gynecology 2004, 16: 87-92. PMID: 15128013, DOI: 10.1097/00001703-200402000-00015.
- Cane' S, Bignotti E, Bellone S, Palmieri M, De Las Casas L, Roman JJ, Pecorelli S, Cannon MJ, O'Brien T, Santin AD. The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer. American Journal Of Obstetrics And Gynecology 2004, 190: 60-66. PMID: 14749636, DOI: 10.1016/j.ajog.2003.07.020.
- Santin A, Bellone S, Palmieri M, Bossini B, Cane' S, Bignotti E, Roman J, Cannon M, Pecorelli S. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. International Journal Of Gynecological Cancer 2004, 14: 64-75. DOI: 10.1136/ijgc-00009577-200401000-00008.
- Santin A. Response to letter to the editor by Lu et al. Gynecologic Oncology 2004, 92: 387. DOI: 10.1016/j.ygyno.2003.10.014.
- Santin AD, Bellone S, Palmieri M, Bossini B, Cane' S, Bignotti E, Roman JJ, Cannon MJ, Pecorelli S. Restoration of tumor specific human leukocyte antigens class I‐restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. International Journal Of Gynecological Cancer 2004, 14: 64-75. PMID: 14764031, DOI: 10.1111/j.1048-891x.2004.014175.x.
- Santin AD, Cane' S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Anfossi S, Roman JJ, O'Brien T, Pecorelli S. The novel serine protease tumor‐associated differentially expressed gene–15 (matriptase/MT‐SP1) is highly overexpressed in cervical carcinoma. Cancer 2003, 98: 1898-1904. PMID: 14584072, DOI: 10.1002/cncr.11753.
- Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecologic Oncology 2003, 91: 231-240. PMID: 14529687, DOI: 10.1016/s0090-8258(03)00460-8.
- Santin AD, Bellone S, Parrish RS, Coke C, Dunn D, Roman J, Theus JW, Cannon MJ, Parham GP, Pecorelli S. Influence of Allogeneic Blood Transfusion on Clinical Outcome during Radiotherapy for Cancer of the Uterine Cervix. Gynecologic And Obstetric Investigation 2003, 56: 28-34. PMID: 12867765, DOI: 10.1159/000072328.
- Kass R, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. Restoration of Tumor-Specific HLA Class I Restricted Cytotoxicity in Tumor Infiltrating Lymphocytes of Advanced Breast Cancer Patients by in vitro Stimulation with Tumor Antigen-Pulsed Autologous Dendritic Cells. Breast Cancer Research And Treatment 2003, 80: 275-285. PMID: 14503800, DOI: 10.1023/a:1024938215782.
- Kass R, Agha J, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells11Supported in part by grants from the Arkansas Breast Cancer Research Program, the Arkansas Special Population Network (A-SPAN), and the Camillo Golgi Foundation, Brescia, Italy (to A.S.). Journal Of Surgical Research 2003, 112: 189-197. PMID: 12888337, DOI: 10.1016/s0022-4804(03)00147-1.
- Santin AD, Bellone S, Palmieri M, Bossini B, Roman JJ, Cannon MJ, Bignotti E, Canè S, Pecorelli S. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecologic Oncology 2003, 89: 271-280. PMID: 12713991, DOI: 10.1016/s0090-8258(03)00083-0.
- Santin AD. HER2/neu overexpression: has the Achilles’ heel of uterine serous papillary carcinoma been exposed? Gynecologic Oncology 2003, 88: 263-265. PMID: 12648572, DOI: 10.1016/s0090-8258(02)00094-x.
- Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman JJ, Pecorelli S, Cannon M, Parham GP. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10. International Journal Of Radiation Oncology • Biology • Physics 2002, 54: 1345-1355. PMID: 12459356, DOI: 10.1016/s0360-3016(02)03757-4.
- Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. Vaccination with HPV-18 E7–Pulsed Dendritic Cells in a Patient with Metastatic Cervical Cancer. New England Journal Of Medicine 2002, 346: 1752-1753. PMID: 12037163, DOI: 10.1056/nejm200205303462219.
- Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clinical Cancer Research 2002, 8: 1271-9. PMID: 12006548.
- Santin AD, Bellone S, Underwood LJ, O'Brien TJ, Ravaggi A, Pecorelli S, Cannon MJ. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. Minerva Obstetrics And Gynecology 2002, 54: 133-44. PMID: 12032451.
- Cannon MJ, O’Brien T, Underwood LJ, Crew MD, Bondurant KL, Santin AD. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Review Of Anticancer Therapy 2002, 2: 97-105. PMID: 12113075, DOI: 10.1586/14737140.2.1.97.
- Santin AD, Bellone S, Ravaggi A, Roman JJ, Pecorelli S, Parham GP, Cannon MJ. Induction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. British Journal Of Cancer 2002, 86: 151-157. PMID: 11857027, PMCID: PMC2746546, DOI: 10.1038/sj.bjc.6600026.
- O’Brien T, Beard J, Underwood L, Dennis R, Santin A, York L. The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences. Tumor Biology 2001, 22: 348-366. PMID: 11786729, DOI: 10.1159/000050638.
- Santin A, Bellone S, Ravaggi A, Roman J, Smith C, Pecorelli S, Cannon M, Parham G. Increased levels of interleukin-10 and transforming growth factor-β in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG An International Journal Of Obstetrics & Gynaecology 2001, 108: 804-808. DOI: 10.1016/s0306-5456(00)00206-0.
- Santin A, Bellone S, Ravaggi A, Roman J, Smith C, Pecorelli S, Cannon M, Parham G. Increased levels of interleukin‐10 and transforming growth factor‐β in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG An International Journal Of Obstetrics & Gynaecology 2001, 108: 804-808. PMID: 11510703, DOI: 10.1111/j.1471-0528.2001.00206.x.
- Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Smith CV, Pecorelli S, Radominska-Pandya A, Cannon MJ, Parham GP. Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer. Gynecologic And Obstetric Investigation 2001, 51: 254-261. PMID: 11408737, DOI: 10.1159/000058060.
- Santin A, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham G, Hermonat P. Tumor-Infiltrating Lymphocytes Contain Higher Numbers of Type 1 Cytokine Expressors and DR+ T Cells Compared with Lymphocytes from Tumor Draining Lymph Nodes and Peripheral Blood in Patients with Cancer of the Uterine Cervix. Gynecologic Oncology 2001, 81: 424-432. PMID: 11371133, DOI: 10.1006/gyno.2001.6200.
- Clemons-Miller AR, Chatta GS, Hutchins L, Angtuaco EJ, Ravaggi A, Santin AD, Cannon MJ. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma. Clinical Cancer Research 2001, 7: 917s-924s. PMID: 11300492.
- Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Jayaprabhu S, Pecorelli S, Parham GP, Cannon MJ. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clinical Cancer Research 2001, 7: 804s-810s. PMID: 11300476.
- Santin A, Hermonat P, Ravaggi A, Bellone S, Roman J, Pecorelli S, Cannon M, Parham G. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 997-1006. PMID: 11072156, DOI: 10.1016/s0360-3016(00)00769-0.
- SANTIN A, BELLONE S, RAVAGGI A, PECORELLI S, CANNON M, PARHAM G. Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells. Obstetrics And Gynecology 2000, 96: 422-430. DOI: 10.1097/00006250-200009000-00019.
- Santin A, Hermonat P, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham G. In vitro induction of tumor-specific human lymphocyte antigen class I–restricted CD8+ cytotoxic T lymphocytes by ovarian tumor antigen–pulsed autologous dendritic cells from patients with advanced ovarian cancer. American Journal Of Obstetrics And Gynecology 2000, 183: 601-609. PMID: 10992180, DOI: 10.1067/mob.2000.107097.
- Santin A, Bellone S, Ravaggi A, Pecorelli S, Cannon M, Parham G. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstetrics And Gynecology 2000, 96: 422-30. PMID: 10960637, DOI: 10.1016/s0029-7844(00)00916-9.
- Santin A, Hermonat P, Ravaggi A, Bellone S, Pecorelli S, Roman J, Parham G, Cannon M. Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes. Journal Of Virology 2000, 74: 4729-4737. PMID: 10775611, PMCID: PMC111995, DOI: 10.1128/jvi.74.10.4729-4737.2000.
- Santin AD, Hermonat PL, Ravaggi A, Bellone S, Cowan C, Coke C, Pecorelli S, Cannon MJ, Parham GP. Development and Therapeutic Effect of Adoptively Transferred T Cells Primed by Tumor Lysate-Pulsed Autologous Dendritic Cells in a Patient with Metastatic Endometrial Cancer. Gynecologic And Obstetric Investigation 2000, 49: 194-203. PMID: 10729762, DOI: 10.1159/000010246.
- Santin AD, Hermonat PL, Ravaggi A, Bellone S, Cowan C, Korourian S, Pecorelli S, Cannon MJ, Parham GP. Development, characterization and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18 E7--pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix. European Journal Of Gynaecological Oncology 2000, 21: 17-23. PMID: 10726612.
- Hermonat PL, Santin AD, Zhan D. Binding of the human papillomavirus type 16 E7 oncoprotein and the adeno-associated virus Rep78 major regulatory protein in vitro and in yeast and the potential for downstream effects. Human Virology 2000, 3: 113-24. PMID: 10881991.
- Santin A. Lymph node metastases. Cancer 2000, 88: 175-179. PMID: 10618621, DOI: 10.1002/(sici)1097-0142(20000101)88:1<175::aid-cncr24>3.0.co;2-f.
- Liu Y, Santin AD, Mane M, Chiriva-Internati M, Parham GP, Ravaggi A, Hermonat PL. Transduction and Utility of the Granulocyte-Macrophage Colony-Stimulating Factor Gene into Monocytes and Dendritic Cells by Adeno-Associated Virus. Journal Of Interferon & Cytokine Research 2000, 20: 21-30. PMID: 10670649, DOI: 10.1089/107999000312702.
- Zhan D, Santin A, Liu Y, Parham G, Li C, Meyers C, Hermonat P. Binding of the Human Papillomavirus Type 16 p97 Promoter by the Adeno-associated Virus Rep78 Major Regulatory Protein Correlates with Inhibition*. Journal Of Biological Chemistry 1999, 274: 31619-31624. PMID: 10531369, DOI: 10.1074/jbc.274.44.31619.
- Santin A, Hermonat P, Ravaggi A, Pecorelli S, Cannon M, Parham G. Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstetrics And Gynecology 1999, 94: 78-82. PMID: 10389722, DOI: 10.1016/s0029-7844(99)00282-3.
- SANTIN A, HERMONAT P, RAVAGGI A, PECORELLI S, CANNON M, PARHAM G. Secretion of Vascular Endothelial Growth Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. Obstetrics And Gynecology 1999, 94: 78-82. DOI: 10.1097/00006250-199907000-00015.
- Santin A, Hermonat P, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham G, Cannon M. Induction of Human Papillomavirus-Specific CD4+ and CD8+ Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer. Journal Of Virology 1999, 73: 5402-5410. PMID: 10364287, PMCID: PMC112596, DOI: 10.1128/jvi.73.7.5402-5410.1999.
- Santin A, Hermonat P, Ravaggi M, Chiriva-Internat M, Cannon M, Hiserodt J, Pecorell S, Parham G. Expression of Surface Antigens During the Differentiation of Human Dendritic Cells vs Macrophages from Blood Monocytes in vitro. Immunobiology 1999, 200: 187-204. PMID: 10416127, DOI: 10.1016/s0171-2985(99)80069-2.
- Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. European Journal Of Gynaecological Oncology 1999, 20: 177-81. PMID: 10410879.
- Hermonat PL, Santin AD, De Greve J, De Rijcke M, Bishop BM, Han L, Mane M, Kokorina N. Chromosomal latency and expression at map unit 96 of a wild-type plus adeno-associated virus (AAV)/Neo vector and identification of p81, a new AAV transcriptional promoter. Human Virology 1999, 2: 359-68. PMID: 10774553.
- Santin A, Hermonat P, Ravaggi A, Chiriva‐Internati M, Pecorelli S, Parham G. Radiation‐enhanced expression of E6/E7 transforming oncogenes of human papillomavirus‐16 in human cervical carcinoma. Cancer 1998, 83: 2346-2352. PMID: 9840534, DOI: 10.1002/(sici)1097-0142(19981201)83:11<2346::aid-cncr14>3.0.co;2-g.
- Santin A, Hermonat P, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham G. Retinoic acid up-regulates the expression of major histocompatibility complex molecules and adhesion/costimulation molecules (specifically, intercellular adhesion molecule ICAM-1) in human cervical cancer. American Journal Of Obstetrics And Gynecology 1998, 179: 1020-1025. PMID: 9790391, DOI: 10.1016/s0002-9378(98)70209-1.
- Santin A, Hermonat P, Ravaggi A, Chiriva-Internati M, Hiserodt J, Pecorelli S, Parham G. Effects of Retinoic Acid Combined with Irradiation on the Expression of Major Histocompatibility Complex Molecules and Adhesion/Costimulation Molecules ICAM-1 in Human Cervical Cancer. Gynecologic Oncology 1998, 70: 195-201. PMID: 9740690, DOI: 10.1006/gyno.1998.5060.
- Hermonat P, Meyers C, Parham G, Santin A. Inhibition/Stimulation of Bovine Papillomavirus by Adeno-Associated Virus Is Time as Well as Multiplicity Dependent. Virology 1998, 247: 240-250. PMID: 9705917, DOI: 10.1006/viro.1998.9256.
- Hermonat P, Santin A, Batchu R, Zhan D. The Adeno-Associated Virus Rep78 Major Regulatory Protein Binds the Cellular TATA-Binding Proteinin Vitroandin Vivo. Virology 1998, 245: 120-127. PMID: 9614873, DOI: 10.1006/viro.1998.9144.
- Santin A, Hermonat P, Ravaggi A, Chiriva‐Internati M, Hiserodt J, Tian E, Carter C, Pecorelli S, Parham G. Effects of retinoic acid combined with interferon‐gamma on the expression of major‐histocompatibility‐complex molecules and intercellular adhesion molecule‐1 in human cervical cancer. International Journal Of Cancer 1998, 75: 254-258. PMID: 9462716, DOI: 10.1002/(sici)1097-0215(19980119)75:2<254::aid-ijc14>3.0.co;2-d.
- Involvement of protein-DNA interaction in adeno-associated virus Rep78-mediated inhibition of HIV-1.Kokorina NA, Santin AD, Li C, Hermonat PL. Involvement of protein-DNA interaction in adeno-associated virus Rep78-mediated inhibition of HIV-1. Human Virology 1998, 1: 441-50. PMID: 10195265.
- Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham GP. Effects of retinoic acid on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer. European Journal Of Gynaecological Oncology 1998, 19: 229-33. PMID: 9641219.
- Santin A, Parham G. Routine Lymph Node Dissection in the Treatment of Early Stage Cancer:Are We Doing the Right Thing? Gynecologic Oncology 1998, 68: 1-3. PMID: 9454650, DOI: 10.1006/gyno.1997.4900.
- Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Hiserodt JC, Batchu RB, Pecorelli S, Parham GP. The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer. International Journal Of Radiation Biology 1998, 73: 699-704. PMID: 9690688, DOI: 10.1080/095530098141951.
- Santin A, Hermonat P, Hiserodt J, Chiriva-Internati M, Woodliff J, Theus J, Barclay D, Pecorelli S, Parham G. Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. International Journal Of Radiation Oncology • Biology • Physics 1997, 39: 737-742. PMID: 9336157, DOI: 10.1016/s0360-3016(97)00372-6.
- Hermonat P, Carter C, Parham G, Quirk J, Santin A. Multiple cellular proteins are recognized by the adeno‐associated virus Rep78 major regulatory protein and the amino‐half of Rep78 is required for many of these interactions. IUBMB Life 1997, 43: 409-420. PMID: 9350349, DOI: 10.1080/15216549700204201.
- Hermonat PL, Plott RT, Santin AD, Parham GP, Flick JT. Adeno-Associated Virus Rep78 Inhibits Oncogenic Transformation of Primary Human Keratinocytes by a Human Papillomavirus Type 16-rasChimeric. Gynecologic Oncology 1997, 66: 487-494. PMID: 9299265, DOI: 10.1006/gyno.1997.4789.
- SANTIN A, HERMONAT P, HISERODT J, CHIRIVA‐INTERNATI M, RAVAGGI A, WOODLIFF J, BARCLAY D, PECORELLI S, PARHAM G. Expression and cytokine mediated modulation of adhesion/costimulation molecules ICAM‐1(CD54) and LFA‐3(CD58) in human ovarian cancer. International Journal Of Gynecological Cancer 1997, 7: 273-278. DOI: 10.1046/j.1525-1438.1997.00453.x.
- Santin A, Hermonat P, Hiserodt J, Fruehauf J, Schranz V, Barclay D, Pecorelli S, Parham G. Differential Transforming Growth Factor-β Secretion in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. Gynecologic Oncology 1997, 64: 477-480. PMID: 9062154, DOI: 10.1006/gyno.1996.4579.
- Hermonat PL, Santin AD, Batchu RB. The adeno-associated virus Rep78 major regulatory/transformation suppressor protein binds cellular Sp1 in vitro and evidence of a biological effect. Cancer Research 1996, 56: 5299-304. PMID: 8912872.
- Bishop BM, Santin AD, Quirk JG, Hermonat PL. Role of the terminal repeat GAGC trimer, the major Rep78 binding site, in adeno‐associated virus DNA replication. FEBS Letters 1996, 397: 97-100. PMID: 8941722, DOI: 10.1016/s0014-5793(96)01149-0.
- Government. T, Rose, Tocco, Granger, DiSaia, Hamilton, Santin, Hiserodt. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. American Journal Of Obstetrics And Gynecology 1996, 175: 593-599. PMID: 8828419, DOI: 10.1053/ob.1996.v175.a73595.
- Santin A, Hiserodt J, DiSaia P, Pecorelli S, Granger G. Differential Effects of High-Dose Gamma Irradiation on the Production of Transforming Growth Factor-Beta in Fresh and Established Human Ovarian Cancer. Gynecologic Oncology 1996, 61: 403-408. PMID: 8641623, DOI: 10.1006/gyno.1996.0164.
- Santin A, Hiserodt J, Fruehauf J, DiSaia P, Pecorelli S, Granger G. Effects of Irradiation on the Expression of Surface Antigens in Human Ovarian Cancer. Gynecologic Oncology 1996, 60: 468-474. PMID: 8774659, DOI: 10.1006/gyno.1996.0075.
- Santin A, Rose G, Hiserodt J, Fruehauf J, Eck L, Garcia R, Schranz V, Disaia P, Pecorelli S, Granger G. Effects of cytokines combined with high‐dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule‐1 in human ovarian cancers. International Journal Of Cancer 1996, 65: 688-694. PMID: 8598323, DOI: 10.1002/(sici)1097-0215(19960301)65:5<688::aid-ijc21>3.0.co;2-2.
- Santin A, Ioli G, Hiserodt J, Manetta A, Pecorelli S, DiSaia P, Granger G. Development and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules. American Journal Of Obstetrics And Gynecology 1996, 174: 633-640. PMID: 8623798, DOI: 10.1016/s0002-9378(96)70441-6.
- Santin AD, Ioli GR, Hiserodt JC, Rose GS, Graf MR, Lander JK, Disaia PJ, Pecorelli S, Granger GA. Development and in vitro characterization of a GM‐CSF secreting human ovarian carcinoma tumor vaccine. International Journal Of Gynecological Cancer 1995, 5: 401-410. PMID: 11578512, DOI: 10.1046/j.1525-1438.1995.05060401.x.
- Santin A, Ioli G, Hiserodt J, Rose G, Graf M, Tocco L, Lander J, Eck L, Burger R, DiSaia P, Pecorelli S, Granger G. Development and Characterization of an IL-4-Secreting Human Ovarian Carcinoma Cell Line. Gynecologic Oncology 1995, 58: 230-239. PMID: 7622110, DOI: 10.1006/gyno.1995.1216.
- Pecorelli S, Sartori E, Santin A. Follow-up after Primary Therapy: Management of the Symptomatic Patient—Surgery. Gynecologic Oncology 1994, 55: s138-s142. PMID: 7835798, DOI: 10.1006/gyno.1994.1353.
Departments and Programs
Locations
Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, Suite B
New Haven, CT 06511
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, Suite BNew Haven, CT 06511
Biography
Alessandro D. Santin, MD, is an oncologist who cares for patients with endometrial and other gynecologic cancers. He is experienced with intraperitoneal chemotherapy, which is given through the abdomen to treat ovarian cancer. Dr. Santin also treats patients from Connecticut and beyond who have been diagnosed with uterine serous carcinoma (USC), a highly aggressive and chemotherapy-resistant cancer.
Dr. Santin says his research, which explores cancers of the ovary, endometrium and cervix, as well as tumor immunology and immunotherapy, is driven by a desire to find better treatments for his patients.
“When you see a patient in the office, in the hospital after surgery or after they receive chemotherapy, you really understand that we need to do more,” Dr. Santin says.
Therefore, keeping an honest and open dialogue with patients is key, he says. “I let them know how serious the disease is,” he says. “But if we are upfront about their prognosis, we can also take advantage of cutting-edge treatments that we have available at Yale. Right now, genetics help us better understand the biology of the disease and allow for some patients to use new treatments that can make a difference.”
A professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine, Dr. Santin has been recognized as a "top doctor" in the state by a regional ranking service.
Titles
- Professor of Obstetrics, Gynecology, and Reproductive Sciences
- Co-Chief, Section of Gynecologic Oncology
- Clinical Research Team Leader, Gynecologic Oncology, Yale Cancer Center
Education & Training
- FellowUniversity of Arkansas for Medical Sciences (2000)
- FellowUniversity of California - Irvine Medical Center (1995)
- ResidentUniversity of Brescia School of Medicine (1993)
- MDUniversity of Brescia School of Medicine (1989)
Languages Spoken
- English
- Italiano (Italian)
Additional Information
Honors & Recognitions
- Genetics Institute Young Investigator Award.: American Association of Cancer Research (AACR) (1999)
Board Certifications
- Italian Board of Obstetrics & Gynecology, Obstetrics & Gynecology (1993)
Professional Service
- Society of Gynecologic Oncologists (2011 - Present): Scientific SGO Program Committee Member, 42nd Annual Meeting on Women's Cancer, March 6-9, 2011, Orlando, FL
- Board Member (2008 - Present): 2008-present, Member, Board of Permanent Officer, Yale University. 2009-present, Member, Protocol Review Committee, Smilow Yale Cancer Center. 2009-present, Director Elective/Subinternship in Gynecol/Oncol Yale University. 2010-present , Member of the Senior Appointments and Promotions Committee Yale University. 2012-present: Leader Disease Aligned Research Team in Gyn Oncology, Smilow Cancer Center.
Publications
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.
- McNamara B, Greenman M, Demirkiran C, Mutlu L, Hartwich T, Bellone S, Manavella D, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Santin A. Pre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer. Gynecologic Oncology 2024, 190: s36. DOI: 10.1016/j.ygyno.2024.07.058.
- Banerjee S, Van Nieuwenhuysen E, Santin A, Ring K, Colombo N, Thaker P, Prendergast E, Clamp A, Ray-Coquard I, Chon H, Moore K, Salinas E, Rose P, O'Malley D, Oaknin A, Monk B, Holloway R, Newman G, Moroney J, Van Gorp T, Kalbacher E, Gennigens C, Wojtynek N, Lustgarten S, Grisham R. Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Part A. Gynecologic Oncology 2024, 190: s55-s56. DOI: 10.1016/j.ygyno.2024.07.084.
- Mcnamara B, Greenman M, Bellone S, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. EV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma. 2024, a91.2-a91. DOI: 10.1136/ijgc-2024-igcs.135.
- Banerjee S, Aghajanian C, Nieuwenhuysen E, Santin A, Ring K, Colombo N, Thaker P, Prendergast E, Moore K, Chon H, Clamp A, O’malley D, Monk B, Cortés-Salgado A, Fabbro M, Kalbacher E, Gorp T, Lustgarten S, Youssoufian H, Grisham R. LB007/#1548 Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. 2024, a13-a13. DOI: 10.1136/ijgc-2024-igcs.13.
- Greenman M, Bellone S, Hartwich T, Buza N, Santin A. Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas. Gynecologic Oncology Reports 2024, 56: 101524. PMID: 39435258, PMCID: PMC11492078, DOI: 10.1016/j.gore.2024.101524.
- Greenman M, Chang Y, McNamara B, Mutlu L, Santin A. Unmet needs in cervical cancer – can biological therapies plug the gap? Expert Opinion On Biological Therapy 2024, 24: 995-1003. PMID: 39311611, DOI: 10.1080/14712598.2024.2408754.
- Hartwich T, Mansolf M, Demirkiran C, Greenman M, Bellone S, McNamara B, Nandi S, Alexandrov L, Yang‐Hartwich Y, Coma S, Pachter J, Santin A. Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer. Cancer Medicine 2024, 13: e70210. PMID: 39240189, PMCID: PMC11378359, DOI: 10.1002/cam4.70210.
- Danska-Bidzinska A, Makker V, Salutari V, Ayhan A, Romero I, Levy T, McCormack M, Baurain J, Mach P, Cadoo K, Mackay H, Friedlander M, Santin A, Slomovitz B, Miller D, McKenzie J, Yao L, Khemka V, Nogueira-Rodrigues A, Marth C. 737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study. Annals Of Oncology 2024, 35: s561. DOI: 10.1016/j.annonc.2024.08.799.
- Corr B, Dumbrava E, Spira A, Willmott L, Butrynski J, Tse K, Patel J, Mekan S, Mocci S, Wu T, Santin A. 733P Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03. Annals Of Oncology 2024, 35: s558. DOI: 10.1016/j.annonc.2024.08.795.
- Santin A, Corr B, Spira A, Willmott L, Butrynski J, Tse K, Patel J, Mekan S, Wu T, Lin K, Kuo P, Dumbrava E. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. Journal Of Clinical Oncology 2024, 42: 3421-3429. PMID: 39083724, PMCID: PMC11458108, DOI: 10.1200/jco.23.02767.
- Greenman M, Bellone S, Demirkiran C, Hartwich T, Santin A. Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer. Gynecologic Oncology Reports 2024, 54: 101459. PMID: 39108617, PMCID: PMC11300917, DOI: 10.1016/j.gore.2024.101459.
- McNamara B, Greenman M, Bellone S, Santin L, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecologic Oncology 2024, 189: 16-23. PMID: 38981151, DOI: 10.1016/j.ygyno.2024.07.002.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.
- Manrai P, McHenry A, Sun T, Santin A, Ratner E, Lin D, Elvin J, Hui P, Buza N. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations. International Journal Of Gynecological Pathology 2024 PMID: 38914011, DOI: 10.1097/pgp.0000000000001050.
- Danziger M, Noble H, Roque D, Xu F, Rao G, Santin A. Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy. Advances In Experimental Medicine And Biology 2024, 1452: 1-19. PMID: 38805122, DOI: 10.1007/978-3-031-58311-7_1.
- Erickson B, Enserro D, Lankes H, Dockery L, ghamande S, Oliver M, Gressel G, Castellano T, Ratner E, Deery A, Bishop E, Bradford L, Thomes Pepin J, Burton E, Blank S, Santin A, Havrilesky L, Aghajanian C, Nickles Fader A, Powell M. Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026). Journal Of Clinical Oncology 2024, 42: tps5641-tps5641. DOI: 10.1200/jco.2024.42.16_suppl.tps5641.
- Greenman M, McNamara B, Mutlu L, Santin A. Entering the golden age for antibody-drug conjugates in gynecologic cancer. Oncoscience 2024, 11: 51-52. PMID: 38770444, PMCID: PMC11104406, DOI: 10.18632/oncoscience.604.
- Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich T, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas. Gynecologic Oncology 2024, 187: 12-20. PMID: 38703673, DOI: 10.1016/j.ygyno.2024.04.010.
- Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.
- Garcia Y, Gorp T, Konecny G, Leary A, Santin A, Crusz S, Mantia-Smaldone G, Lorusso D, Colombo N, Thomes-Pepin J, Roszak A, Ottevanger P, Beiner M, Cibula D, Leath C, Li L, Method M, Moore K. 360 Health-related quality of life in patients with FRα positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator’s choice chemotherapy: analysis from the phase 3 MIRASOL trial. 2024, a34-a35. DOI: 10.1136/ijgc-2024-esgo.43.
- Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.
- Greenman M, McNamara B, Mutlu L, Santin A. Targeting cervical cancer with anti-PD-1 antibodies: what is new? Expert Opinion On Biological Therapy 2024, 24: 111-114. PMID: 38391293, DOI: 10.1080/14712598.2024.2323596.
- Bellone S, Siegel E, Scheim D, Santin A. Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID. Gynecologic Oncology Reports 2024, 51: 101324. PMID: 38273933, PMCID: PMC10809113, DOI: 10.1016/j.gore.2024.101324.
- Scheim D, Vottero P, Santin A, Hirsh A. Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19. International Journal Of Molecular Sciences 2023, 24: 17039. PMID: 38069362, PMCID: PMC10871123, DOI: 10.3390/ijms242317039.
- Grisham R, Aghajanian C, Nieuwenhuysen E, Rodrigues M, Ring K, Santin A, Colombo N, Prendergast E, Thaker P, Moore K, Salinas E, Ray-Coquard I, Chon H, Rose P, Oaknin A, Clamp A, Gandhi M, Monk B, Holloway R, Gorp T, Fabbro M, Gennigens C, Wojtynek N, Lustgarten S, Banerjee S. PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy. 2023, a3-a4. DOI: 10.1136/ijgc-2023-igcs.4.
- McNamara B, Greenman M, Pebley N, Mutlu L, Santin A. Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules 2023, 28: 7389. PMID: 37959808, PMCID: PMC10650896, DOI: 10.3390/molecules28217389.
- Bellone S, Siegel E, Santin A. Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID. Gynecologic Oncology Reports 2023, 50: 101301. PMID: 38029227, PMCID: PMC10654147, DOI: 10.1016/j.gore.2023.101301.
- AlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.
- Ledermann J, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Provencher D, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Kobie J, Nebozhyn M, Edmondson M, Sun Y, Cristescu R, Jelinic P, Keefe S, Matulonis U. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100. Gynecologic Oncology 2023, 178: 119-129. PMID: 37862791, DOI: 10.1016/j.ygyno.2023.09.012.
- Banerjee S, Ring K, Niewenhuysen E, Fabbro M, Aghajanian C, Oaknin A, Colombo N, Santin A, Clamp A, Moore K, Rose P, David M O, Chon H, Salinas E, Prendergast E, Lustgarten S, Rodrigues M, Gennigens C, Monk B, Grisham R. #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). 2023, a20-a21. DOI: 10.1136/ijgc-2023-esgo.29.
- Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.
- Characterization of tumor response with lenvatinib plus pembrolizumab in study 309/KEYNOTE-775 (177)Makker V, Lorusso D, Moore R, Miller D, Mackay H, Santin A, Ushijima K, Kim Y, Sanli U, Yonemori K, Xie R, Barresi G, McKenzie J, Colombo N. Characterization of tumor response with lenvatinib plus pembrolizumab in study 309/KEYNOTE-775 (177). Gynecologic Oncology 2023, 176: s68-s69. DOI: 10.1016/j.ygyno.2023.06.563.
- McNamara B, Mutlu L, Greenman M, Harold J, Santin A. HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma. Cancers 2023, 15: 4085. PMID: 37627113, PMCID: PMC10452357, DOI: 10.3390/cancers15164085.
- McNamara B, Chang Y, Goreshnik A, Santin A. Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals. International Journal Of Women's Health 2023, 15: 1353-1365. PMID: 37663226, PMCID: PMC10474218, DOI: 10.2147/ijwh.s400537.
- Vottero P, Tavernini S, Santin A, Scheim D, Tuszynski J, Aminpour M. Computational Prediction of the Interaction of Ivermectin with Fibrinogen. International Journal Of Molecular Sciences 2023, 24: 11449. PMID: 37511206, PMCID: PMC10380762, DOI: 10.3390/ijms241411449.
- Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.
- McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy. Gynecologic Oncology Reports 2023, 48: 101219. PMID: 37325293, PMCID: PMC10265462, DOI: 10.1016/j.gore.2023.101219.
- McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy. Gynecologic Oncology Reports 2023, 48: 101218. PMID: 37325296, PMCID: PMC10265468, DOI: 10.1016/j.gore.2023.101218.
- Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.
- Banerjee S, Ring K, Van Nieuwenhuysen E, Fabbro M, Aghajanian C, Oaknin A, Colombo N, Santin A, Clamp A, Moore K, Rose P, O'Malley D, Chon H, Salinas E, Prendergast E, Lustgarten S, Rodrigues M, Gennigens C, Monk B, Grisham R. Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). Journal Of Clinical Oncology 2023, 41: 5515-5515. DOI: 10.1200/jco.2023.41.16_suppl.5515.
- Santin A, Corr B, Spira A, Willmott L, Butrynski J, Tse K, Patel J, Mekan S, Wu T, Dumbrava E. TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC). Journal Of Clinical Oncology 2023, 41: 5610-5610. DOI: 10.1200/jco.2023.41.16_suppl.5610.
- Bellone S, McNamara B, Mutlu L, Demirkiran C, Hartwich T, Harold J, Yang-Hartwich Y, Siegel E, Santin A. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. International Journal Of Molecular Sciences 2023, 24: 8873. PMID: 37240216, PMCID: PMC10219151, DOI: 10.3390/ijms24108873.
- Makker V, Colombo N, Herráez A, Monk B, Mackay H, Santin A, Miller D, Moore R, Baron-Hay S, Ray-Coquard I, Ushijima K, Yonemori K, Kim Y, Alia E, Sanli U, Bird S, Orlowski R, McKenzie J, Okpara C, Barresi G, Lorusso D. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. Journal Of Clinical Oncology 2023, 41: 2904-2910. PMID: 37058687, PMCID: PMC10414727, DOI: 10.1200/jco.22.02152.
- Lorusso D, Colombo N, Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kim Y, McCormack M, Massaad R, Nguyen A, Zhao Q, McKenzie J, Prabhu V, Makker V. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice. European Journal Of Cancer 2023, 186: 172-184. PMID: 37086595, PMCID: PMC11003310, DOI: 10.1016/j.ejca.2023.03.015.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
- Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
- McNamara B, Chang Y, Mutlu L, Harold J, Santin A. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Expert Opinion On Biological Therapy 2023, 23: 227-233. PMID: 36800548, DOI: 10.1080/14712598.2023.2182679.
- Hill B, Graf R, Shah K, Danziger N, Lin D, Quintanilha J, Li G, Haberberger J, Ross J, Santin A, Slomovitz B, Elvin J, Eskander R. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. International Journal Of Gynecological Cancer 2023, 33: 504-513. PMID: 36750267, PMCID: PMC10086481, DOI: 10.1136/ijgc-2022-004026.
- Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
- Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
- Huang G, Tymon-Rosario J, Santin A. What role does adjuvant therapy play in the management of endometrial cancer? Expert Opinion On Pharmacotherapy 2023, 24: 7-10. PMID: 36594708, DOI: 10.1080/14656566.2022.2157207.
- Tymon-Rosario J, Chui M, Santin A. Chapter 3 Ovarian carcinosarcoma. 2023, 41-54. DOI: 10.1016/b978-0-323-82938-0.00003-3.
- Santin A, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland L, Monk B, Coleman R, Herzog T, Siegel J, Kasten L, Schlicker A, Schulz A, Köchert K, Walter A, Childs B, Elbi C, Bulat I. Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. International Journal Of Gynecological Cancer 2022, 33: ijgc-2022-003927. PMID: 36564099, PMCID: PMC10086500, DOI: 10.1136/ijgc-2022-003927.
- Manavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
- Tymon-Rosario J, Gorman M, Richardson D, Washington C, Santin A. Advances in antibody-drug conjugates for gynecologic malignancies. Current Opinion In Obstetrics & Gynecology 2022, 35: 6-14. PMID: 36484278, DOI: 10.1097/gco.0000000000000838.
- Mutlu L, Manavella D, Bellone S, Santin A. EP015/#546 In vitro and in vivo efficacy of trastuzumab deruxtecan (T-DXd) in epithelial ovarian cancer with HER2/NEU overexpression. 2022, a54.2-a54. DOI: 10.1136/ijgc-2022-igcs.106.
- Makker V, Colombo N, Herráez A, Monk B, Mackay H, Santin A, Miller D, Moore R, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Yonemori K, Kim Y, Alia E, Sanli U, Xie R, Zale M, Mckenzie J, Barresi G, Lorusso D. O018/#482 Updated safety of lenvatinib + pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775. 2022, a11-a11. DOI: 10.1136/ijgc-2022-igcs.20.
- Tymon-Rosario J, Gorman M, Santin A. Targeted Therapies in the Treatment of Uterine Serous Carcinoma. Current Treatment Options In Oncology 2022, 23: 1804-1817. PMID: 36447064, DOI: 10.1007/s11864-022-01030-7.
- Harold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
- Oaknin A, Kristeleit R, Mahdi H, Lim M, de Vivo R, Salinas E, Wilson M, Liontos M, Santin A, Provencher D, Demirkiran F, Willmott L, Chudecka-Głaz A, Herzog T, Beiner M, Copeland L, McNeish I, Lin K, Monk B. 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246). 2022, a472.1-a472. DOI: 10.1136/ijgc-2022-esgo.1018.
- Chow RD, Michaels T, Bellone S, Hartwich T, Bonazzoli E, Iwasaki A, Song E, Santin AD. Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma. Cancer Discovery 2022, 13: 312-331. PMID: 36301137, PMCID: PMC9905265, DOI: 10.1158/2159-8290.cd-22-0686.
- Doria D, Santin A, Tuszynski J, Scheim D, Aminpour M. Omicron SARS-CoV-2 Spike-1 Protein’s Decreased Binding Affinity to α7nAChr: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis. BioMedInformatics 2022, 2: 553-564. DOI: 10.3390/biomedinformatics2040035.
- Mutlu L, Manavella D, Gullo G, McNamara B, Santin A, Patrizio P. Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes. Cancers 2022, 14: 5187. PMID: 36358604, PMCID: PMC9656291, DOI: 10.3390/cancers14215187.
- Lorusso D, Makker V, Herraez A, Monk B, Mackay H, Santin A, Miller D, Moore R, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Yonemori K, Kim Y, Guerra Alia E, Sanli U, Huang J, McKenzie J, Barresi G, Colombo N. 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. 2022, a102.1-a102. DOI: 10.1136/ijgc-2022-esgo.223.
- Makker V, Colombo N, Herraez A, Monk B, Mackay H, Santin A, Miller D, Moore R, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Yonemori K, Kim Y, Alia E, Sanli U, Huang J, McKenzie J, Barresi G, Lorusso D. 525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775. Annals Of Oncology 2022, 33: s785-s786. DOI: 10.1016/j.annonc.2022.07.653.
- Makker V, Colombo N, Santin A, Miller D, Fujiwara K, Pignata S, Ray-Coquard I, Kim Y, Guerra E, Huang J, Barresi G, McKenzie J, Lorusso D. Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775. Journal Of Clinical Oncology 2022, 40: 5587-5587. DOI: 10.1200/jco.2022.40.16_suppl.5587.
- Santin A, Graf R, Shah K, Kelly A, Danziger N, Lin D, Oxnard G, Elvin J. Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study. Journal Of Clinical Oncology 2022, 40: 5596-5596. DOI: 10.1200/jco.2022.40.16_suppl.5596.
- Lorusso D, Colombo N, Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kim Y, McCormack M, Massaad R, Nguyen A, Zhao Q, McKenzie J, Prabhu V, Makker V. 20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC). Annals Of Oncology 2022, 33: s391-s392. DOI: 10.1016/j.annonc.2022.04.038.
- Yadav G, Roque DM, Bellone S, Manavella DD, Hartwich TMP, Zipponi M, Harold J, Tymon-Rosario J, Mutlu L, Altwerger G, Menderes G, Ratner E, Buza N, Hui P, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecologic Oncology 2022, 166: 351-357. PMID: 35641325, DOI: 10.1016/j.ygyno.2022.05.021.
- Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. Gynecologic Oncology 2022, 166: 117-125. PMID: 35599167, DOI: 10.1016/j.ygyno.2022.05.005.
- Makker V, Colombo N, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim Y, Guerra E, Sanli U, McCormack M, Smith A, Keefe S, Bird S, Dutta L, Orlowski R, Lorusso D. Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer. Obstetrical & Gynecological Survey 2022, 77: 275-276. DOI: 10.1097/ogx.0000000000001032.
- Aminpour M, Cannariato M, Preto J, Safaeeardebili M, Moracchiato A, Doria D, Donato F, Zizzi E, Deriu M, Scheim D, Santin A, Tuszynski J. In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds. Computation 2022, 10: 51. DOI: 10.3390/computation10040051.
- Mutlu L, Harold J, Tymon-Rosario J, Santin AD. Immune checkpoint inhibitors for recurrent endometrial cancer. Expert Review Of Anticancer Therapy 2022, 22: 249-258. PMID: 35176955, DOI: 10.1080/14737140.2022.2044311.
- Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.
- Reader JC, Fan C, Ory EC, Ju J, Lee R, Vitolo MI, Smith P, Wu S, Ching MMN, Asiedu EB, Jewell CM, Rao GG, Fulton A, Webb TJ, Yang P, Santin AD, Huang HC, Martin SS, Roque DM. Microtentacle Formation in Ovarian Carcinoma. Cancers 2022, 14: 800. PMID: 35159067, PMCID: PMC8834106, DOI: 10.3390/cancers14030800.
- Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.
- Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. New England Journal Of Medicine 2022, 386: 437-448. PMID: 35045221, DOI: 10.1056/nejmoa2108330.
- Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, Copeland LJ, Secord AA, Mutch DG, Santin A, Warshal DP, Spirtos NM, DiSilvestro PA, Ioffe OB, Miller DS. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. Journal Of Clinical Oncology 2022, 40: 968-977. PMID: 35007153, PMCID: PMC8937015, DOI: 10.1200/jco.21.02050.
- Tymon-Rosario J, Adjei NN, Roque DM, Santin AD. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment. Cancers 2021, 13: 6239. PMID: 34944858, PMCID: PMC8699494, DOI: 10.3390/cancers13246239.
- Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.
- Santin AD. VITT after ChAdOx1 nCoV-19 Vaccination. New England Journal Of Medicine 2021, 385: 2202-2205. PMID: 34731555, DOI: 10.1056/nejmc2111026.
- Makker V, Colombo N, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira R, Ushijima K, Sakata J, Yonemori K, Kim Y, Guerra E, Sanli U, Mccormack M, Huang J, Smith A. O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775. International Journal Of Gynecological Cancer 2021, 31: a4-a5. DOI: 10.1136/ijgc-2021-igcs.8.
- Makker V, Colombo N, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Banerjee S, Monk B, Ushijima K, Penson R, Kristeleit R, Fabbro M, Orlando M, Mackay H, Ren M, Orlowski R, Dutta L, Lorusso D. O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors. International Journal Of Gynecological Cancer 2021, 31: a1-a2. DOI: 10.1136/ijgc-2021-igcs.2.
- Zeybek B, Webster E, Pogosian N, Tymon-Rosario J, Balch A, Altwerger G, Clark M, Menderes G, Huang G, Azodi M, Ratner ES, Schwartz PE, Santin AD, Andikyan V. Financial toxicity in patients with gynecologic malignancies: a cross sectional study. Journal Of Gynecologic Oncology 2021, 32: e87. PMID: 34431257, PMCID: PMC8550931, DOI: 10.3802/jgo.2021.32.e87.
- Colombo N, Lorusso D, Santin A, Kim Y, Herráez A, Yonemori K, Fujiwara K, Colomba E, Miller D, Pignata S, Monk B, Guerra E, Kristeleit R, Orlando M, Sanli U, Dutta L, Orlowski R, Ren M, Makker V. 145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775). International Journal Of Gynecological Cancer 2021, 31: a78-a78. DOI: 10.1136/ijgc-2021-esgo.120.
- Liu F, Wu H, Peng B, Zhang S, Ma J, Deng G, Zou P, Liu J, Chen AT, Li D, Bellone S, Santin AD, Moliterno J, Zhou J. Vessel-Targeting Nanoclovers Enable Noninvasive Delivery of Magnetic Hyperthermia–Chemotherapy Combination for Brain Cancer Treatment. Nano Letters 2021, 21: 8111-8118. PMID: 34597054, DOI: 10.1021/acs.nanolett.1c02459.
- Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.
- Assem H, Rottmann D, Finkelstein A, Wang M, Ratner E, Santin AD, Buza N, Hui P. Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. Human Pathology 2021, 118: 1-8. PMID: 34508766, DOI: 10.1016/j.humpath.2021.09.001.
- Colombo N, Lorusso D, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Floquet A, Monk B, Banerjee S, Penson R, Kristeleit R, Fabbro M, Orlando M, Mackay H, Jensen E, Dutta L, Orlowski R, Makker V. 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775). Annals Of Oncology 2021, 32: s729-s730. DOI: 10.1016/j.annonc.2021.08.1169.
- Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.
- Tymon-Rosario J, Siegel ER, Bellone S, Harold J, Adjei N, Zeybek B, Mauricio D, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Azodi M, Schwartz PE, Fader AN, Santin AD. Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. Gynecologic Oncology 2021, 163: 93-99. PMID: 34372971, PMCID: PMC8721852, DOI: 10.1016/j.ygyno.2021.07.033.
- Santin A, Scheim D, McCullough P, Yagisawa M, Borody T. Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19. New Microbes And New Infections 2021, 43: 100924. PMID: 34466270, PMCID: PMC8383101, DOI: 10.1016/j.nmni.2021.100924.
- Makker V, Colombo N, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim Y, Guerra E, Sanli U, McCormack M, Huang J, Smith A, Keefe S, Dutta L, Orlowski R, Lorusso D. A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer. Gynecologic Oncology 2021, 162: s4. DOI: 10.1016/s0090-8258(21)00657-0.
- Levi G, Rocchetti C, Magri R, Uccelli S, Bottone D, Quadri F, Novali M, Santin AD, Bezzi M. Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. Monaldi Archives For Chest Disease 2021, 91 PMID: 34121379, DOI: 10.4081/monaldi.2021.1867.
- Roque D, Bellone S, Siegel E, Buza N, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Schwartz P, Ratner E, Alexandrov L, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin A. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Journal Of Clinical Oncology 2021, 39: 5523-5523. DOI: 10.1200/jco.2021.39.15_suppl.5523.
- Lorusso D, Colombo N, Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kim Y, McCormack M, Bird S, Prabhu V, Nguyen A, Zhao Q, Dutta L, Makker V. Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC). Journal Of Clinical Oncology 2021, 39: 5570-5570. DOI: 10.1200/jco.2021.39.15_suppl.5570.
- Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology 2021, 32: 1045-1046. PMID: 33932502, PMCID: PMC9465821, DOI: 10.1016/j.annonc.2021.04.013.
- Mauricio D, Zeybek B, Tymon-Rosario J, Harold J, Santin AD. Immunotherapy in Cervical Cancer. Current Oncology Reports 2021, 23: 61. PMID: 33852056, DOI: 10.1007/s11912-021-01052-8.
- Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2025182118. PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.
- McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, Leung S, Bellone S, Wong A, Brucker SY, Lee CH, Clarke BA, Huntsman DG, Bernardini MQ, Ngeow J, Santin AD, Goodfellow P, Levine DA, Köbel M, Kommoss S, Bosse T, Gilks CB, Talhouk A. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis. Cancer 2021, 127: 2409-2422. PMID: 33793971, DOI: 10.1002/cncr.33516.
- Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal Of The National Cancer Institute 2021, 113: 1369-1378. PMID: 33729494, PMCID: PMC8486331, DOI: 10.1093/jnci/djab034.
- Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Annals Of Oncology 2021, 32: 746-756. PMID: 33741442, DOI: 10.1016/j.annonc.2021.03.005.
- Mauricio D, Harold J, Tymon-Rosario JR, Zeybek B, Santin AD. Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer. Expert Opinion On Biological Therapy 2021, 21: 1087-1096. PMID: 33356644, DOI: 10.1080/14712598.2021.1869210.
- Santin A, Vergote I, Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland L, Monk B, Coleman R, Herzog T, Siegel J, Walter A, Childs B, Elbi C, Bulat I. 372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. International Journal Of Gynecological Cancer 2020, 30: a154-a154. DOI: 10.1136/ijgc-2020-igcs.322.
- Lee EK, Fader AN, Santin AD, Liu JF. Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies. Gynecologic Oncology 2020, 160: 322-332. PMID: 33160694, DOI: 10.1016/j.ygyno.2020.10.017.
- Webster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Arkfeld CK, Andikyan V, Menderes G, Huang G, Azodi M, Silasi DA, Santin AD, Schwartz PE, Ratner ES, Altwerger G. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports 2020, 34: 100667. PMID: 33204797, PMCID: PMC7653050, DOI: 10.1016/j.gore.2020.100667.
- Najjar O, Erickson B, Klein M, Dolan M, Shahi M, Grandelis A, Buza N, Tymon-Rosario J, Santin A, Ferriss J, Fader A. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort. Gynecologic Oncology 2020, 159: e13. DOI: 10.1016/j.ygyno.2020.07.048.
- Fader A, Roque D, Siegel E, Buza N, Hui P, Havrilesky L, Secord A, O'Malley D, Backes F, Nevadunsky N, Chambers S, Edraki B, Celano P, Bellone S, Azodi M, Ratner E, Litkouhi B, Silasi D, Schwartz P, Santin A. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis. Gynecologic Oncology 2020, 159: 7-8. DOI: 10.1016/j.ygyno.2020.06.014.
- Ledermann J, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Provencher D, Sehouli J, Colombo N, Martín A, Oaknin A, Saadatpour A, Kobie J, Jelinic P, Stein K, Matulonis U. Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100. Annals Of Oncology 2020, 31: s631-s632. DOI: 10.1016/j.annonc.2020.08.982.
- Romani C, Zizioli V, Silvestri M, Ardighieri L, Bugatti M, Corsini M, Todeschini P, Marchini S, D'Incalci M, Zanotti L, Ravaggi A, Facchetti F, Gambino A, Odicino F, Sartori E, Santin AD, Mitola S, Bignotti E, Calza S. Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients. Frontiers In Oncology 2020, 10: 1287. PMID: 32850397, PMCID: PMC7417514, DOI: 10.3389/fonc.2020.01287.
- Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research 2020, 26: 3928-3935. PMID: 32601075, PMCID: PMC8792803, DOI: 10.1158/1078-0432.ccr-20-0953.
- Oaknin A, Friedman CF, Roman LD, D’Souza A, Brana I, Bidard F, Goldman J, Alvarez EA, Boni V, ElNaggar AC, Passalacqua R, T.M. K, Santin AD, Keyvanjah K, Xu F, Eli LD, Lalani AS, Bryce RP, Hyman DM, Meric-Bernstam F, Solit DB, Monk BJ. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic Oncology 2020, 159: 150-156. PMID: 32723675, PMCID: PMC8336424, DOI: 10.1016/j.ygyno.2020.07.025.
- Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology 2020, 159: 17-22. PMID: 32709539, PMCID: PMC7541557, DOI: 10.1016/j.ygyno.2020.07.016.
- Li JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. Stage III uterine serous carcinoma: modern trends in multimodality treatment. Journal Of Gynecologic Oncology 2020, 31: e53. PMID: 32266802, PMCID: PMC7286763, DOI: 10.3802/jgo.2020.31.e53.
- Tymon-Rosario J, Zeybek B, Santin AD. Novel antibody-drug conjugates: current and future roles in gynecologic oncology. Current Opinion In Obstetrics & Gynecology 2020, 33: 26-33. PMID: 32618744, PMCID: PMC8253558, DOI: 10.1097/gco.0000000000000642.
- Bonazzoli E, Bellone S, Zammataro L, Gnutti B, Guglielmi A, Pelligra S, Nagarkatti N, Manara P, Tymon-Rosario J, Zeybek B, Altwerger G, Menderes G, Han C, Ratner E, Silasi DA, Huang GS, Andikyan V, Azodi M, Schwartz PE, Santin AD. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecologic Oncology 2020, 158: 769-775. PMID: 32600791, PMCID: PMC8253557, DOI: 10.1016/j.ygyno.2020.06.484.
- Webster EM, Zeybek B, Tymon-Rosario J, Santin AD. Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer. Oncoscience 2020, 7: 68-69. PMID: 33195736, PMCID: PMC7640901, DOI: 10.18632/oncoscience.514.
- Santin AD, Filiaci V, Bellone S, O'Cearbhaill R, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Birrer MJ. Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]. Gynecologic Oncology Reports 2020, 33: 100590. PMID: 32885014, PMCID: PMC7452617, DOI: 10.1016/j.gore.2020.100590.
- Matulonis U, Shapira R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Wu H, Keefe S, Stein K, Ledermann J. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. Journal Of Clinical Oncology 2020, 38: 6005-6005. DOI: 10.1200/jco.2020.38.15_suppl.6005.
- Santin A, Komiya T, Goldenberg D, Sharkey R, Hong Q, Wegener W, Goswami T, Bardia A. Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study. Journal Of Clinical Oncology 2020, 38: 6081-6081. DOI: 10.1200/jco.2020.38.15_suppl.6081.
- Erickson B, Najjar O, Klein M, Shahi M, Dolan M, Cimino-Mathews A, Grandelis A, Buza N, Delaney P, Tymon-Rosario J, Santin A, Ferriss J, Stone R, Nickles Fader A. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort. Journal Of Clinical Oncology 2020, 38: 6084-6084. DOI: 10.1200/jco.2020.38.15_suppl.6084.
- Saxena A, Michel L, Hong Q, Hilsinger K, Kanwal C, Pichardo C, Goswami T, Santin A. TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors. Journal Of Clinical Oncology 2020, 38: tps3648-tps3648. DOI: 10.1200/jco.2020.38.15_suppl.tps3648.
- Kim K, Hu W, Audenet F, Almassi N, Hanrahan AJ, Murray K, Bagrodia A, Wong N, Clinton TN, Dason S, Mohan V, Jebiwott S, Nagar K, Gao J, Penson A, Hughes C, Gordon B, Chen Z, Dong Y, Watson PA, Alvim R, Elzein A, Gao SP, Cocco E, Santin AD, Ostrovnaya I, Hsieh JJ, Sagi I, Pietzak EJ, Hakimi AA, Rosenberg JE, Iyer G, Vargas HA, Scaltriti M, Al-Ahmadie H, Solit DB, Coleman JA. Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications 2020, 11: 1975. PMID: 32332851, PMCID: PMC7181640, DOI: 10.1038/s41467-020-15885-7.
- Hassan R, Blumenschein GR, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, Seward SM, Thomas A, Kim SK, Rajagopalan P, Walter AO, Laurent D, Childs BH, Sarapa N, Elbi C, Bendell JC. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. Journal Of Clinical Oncology 2020, 38: 1824-1835. PMID: 32213105, PMCID: PMC7255978, DOI: 10.1200/jco.19.02085.
- Pelligra S, Buza N, Hui P, Bellone S, Zeybek B, Ratner E, Schwartz PE, Scambia G, Santin AD. Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. Gynecologic Oncology Reports 2020, 32: 100554. PMID: 32140533, PMCID: PMC7049633, DOI: 10.1016/j.gore.2020.100554.
- Perrone E, Lopez S, Zeybek B, Bellone S, Bonazzoli E, Pelligra S, Zammataro L, Manzano A, Manara P, Bianchi A, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Frontiers In Oncology 2020, 10: 118. PMID: 32117765, PMCID: PMC7028697, DOI: 10.3389/fonc.2020.00118.
- Lopez S, Perrone E, Bellone S, Bonazzoli E, Zeybek B, Han C, Tymon-Rosario J, Altwerger G, Menderes G, Bianchi A, Zammataro L, Manzano A, Manara P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Raspagliesi F, Angioli R, Buza N, Hui P, Bond HM, Santin AD. Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget 2020, 11: 560-570. PMID: 32082489, PMCID: PMC7007291, DOI: 10.18632/oncotarget.27342.
- Erickson BK, Zeybek B, Santin AD, Fader AN. Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. Current Opinion In Obstetrics & Gynecology 2020, 32: 57-64. PMID: 31833974, PMCID: PMC7307693, DOI: 10.1097/gco.0000000000000599.
- Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports 2020, 10: 973. PMID: 31969666, PMCID: PMC6976591, DOI: 10.1038/s41598-020-58009-3.
- Perrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon‐Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi D, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Molecular Oncology 2020, 14: 645-656. PMID: 31891442, PMCID: PMC7053235, DOI: 10.1002/1878-0261.12627.
- Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecologic Oncology 2020, 157: 161-166. PMID: 31924334, PMCID: PMC7127981, DOI: 10.1016/j.ygyno.2019.12.034.
- Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecologic Oncology Reports 2020, 31: 100532. PMID: 31934607, PMCID: PMC6951478, DOI: 10.1016/j.gore.2019.100532.
- Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, Bianchi A, Zammataro L, Manzano A, Bonazzoli E, Manara P, Buza N, Hui P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Lopez S, Santin AD. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecologic Oncology 2019, 156: 430-438. PMID: 31839338, DOI: 10.1016/j.ygyno.2019.11.018.
- Tymon-Rosario J, Zeybek B, Han C, Santin AD. Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. Annals Of Translational Medicine 2019, 0: s308. PMID: 32016027, PMCID: PMC6976388, DOI: 10.21037/atm.2019.10.28.
- Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22730-22736. PMID: 31624127, PMCID: PMC6842590, DOI: 10.1073/pnas.1911385116.
- Lopez S, Perrone E, Zeybek B, Bellone S, Manzano A, Zammataro L, Han C, Altwerger G, Angioli R, Santin A. 93 Sacituzumab govitecan in uterine and ovarian carcinosarcomas. International Journal Of Gynecological Cancer 2019, 29: a48. DOI: 10.1136/ijgc-2019-igcs.93.
- Perrone E, Lopez S, Zeibek B, Bellone S, Zammataro L, Manzano A, Bonazzoli E, Manara P, Scambia G, Santin A. 51 In vitro and in vivo activity of sacituzumab govitecan, in ovarian cancer. International Journal Of Gynecological Cancer 2019, 29: a29. DOI: 10.1136/ijgc-2019-igcs.51.
- Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Modern Pathology 2019, 33: 118-127. PMID: 31477811, DOI: 10.1038/s41379-019-0358-x.
- Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology 2019, 155: 144-150. PMID: 31434613, PMCID: PMC6788971, DOI: 10.1016/j.ygyno.2019.08.010.
- Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Annals Of Oncology 2019, 30: 1080-1087. PMID: 31046082, DOI: 10.1093/annonc/mdz135.
- Gay L, Schink J, Wright J, Lele S, Mayor P, Odunsi K, Hemmerich A, Ngo N, Secord A, Hou J, Konecny G, Santin A, Elvin J. Targeting ERBB family genomic alterations in gynecological malignancies. Gynecologic Oncology 2019, 154: 89. DOI: 10.1016/j.ygyno.2019.04.210.
- Yadav G, Lopez S, Han C, Altwerger G, Menderes G, Bellone S, Bianchi A, Ratner E, Schwartz P, Santin A. The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in uterine serous carcinoma overexpressing HER2. Gynecologic Oncology 2019, 154: 34. DOI: 10.1016/j.ygyno.2019.04.082.
- Lopez S, Han C, Altwerger G, Menderes G, Zammataro L, Bellone S, Bianchi A, Zeybek B, Ratner E, Schwartz P, Santin A. Whole exome sequencing (WES) reveals novel therapeutic targets in cervical cancer. Gynecologic Oncology 2019, 154: 61-62. DOI: 10.1016/j.ygyno.2019.04.146.
- Zeybek B, Bonazzoli E, Lopez S, Han C, Altwerger G, Menderes G, Bellone S, Bianchi A, Ratner E, Schwartz P, Santin A. Whole exome sequencing (WES) of primary, metastatic and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Gynecologic Oncology 2019, 154: 62-63. DOI: 10.1016/j.ygyno.2019.04.148.
- Powell M, Filiaci V, Hensley M, Huang H, Moore K, Tewari K, Copeland L, Secord A, Mutch D, Santin A, Richards W, Warshal D, Spirtos N, Disilverstro P, Ioffe O, Miller D. A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial. Journal Of Clinical Oncology 2019, 37: 5500-5500. DOI: 10.1200/jco.2019.37.15_suppl.5500.
- Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Buza N, Lopez S, Perrone E, Manara P, Bellone S, Zammataro L, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Journal Of Clinical Oncology 2019, 37: e17028-e17028. DOI: 10.1200/jco.2019.37.15_suppl.e17028.
- Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.
- Cocco E, Lopez S, Santin AD, Scaltriti M. Prevalence and role of HER2 mutations in cancer. Pharmacology & Therapeutics 2019, 199: 188-196. PMID: 30951733, PMCID: PMC6571037, DOI: 10.1016/j.pharmthera.2019.03.010.
- Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology 2019, 153: 335-342. PMID: 30827726, PMCID: PMC6486855, DOI: 10.1016/j.ygyno.2019.02.028.
- Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal Of Medicine 2019, 380: 741-751. PMID: 30786188, DOI: 10.1056/nejmoa1814213.
- Boettcher AN, Kiupel M, Adur MK, Cocco E, Santin AD, Bellone S, Charley SE, Blanco-Fernandez B, Risinger JI, Ross JW, Tuggle CK, Shapiro EM. Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs. Frontiers In Oncology 2019, 9: 9. PMID: 30723704, PMCID: PMC6349777, DOI: 10.3389/fonc.2019.00009.
- Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Gynecologic Oncology 2019, 153: 158-164. PMID: 30630630, PMCID: PMC6430698, DOI: 10.1016/j.ygyno.2019.01.002.
- Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.
- Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 116: 619-624. PMID: 30584090, PMCID: PMC6329978, DOI: 10.1073/pnas.1814027116.
- Lopez S, Zeybek B, Santin AD. Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management. Oncotarget 2018, 9: 36652-36653. PMID: 30613348, PMCID: PMC6291176, DOI: 10.18632/oncotarget.26413.
- Tewari K, Vergote I, Oaknin A, Alvarez E, Gaillard S, Lheureux S, Rischin D, Santin A, Feng M, Mathias M, Fury M, Lowy I, Monk B. 280TiP GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. Annals Of Oncology 2018, 29: ix86. DOI: 10.1093/annonc/mdy436.027.
- Blakaj A, Jairam V, Buza N, Schwartz P, Santin A, Damast S. HER2/neu Overexpression and Recurrence Risk in Early Stage Uterine Serous Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s218-s219. DOI: 10.1016/j.ijrobp.2018.07.139.
- Zeybek B, Lopez S, Santin AD. BET inhibitors: Betting on improved outcomes in uterine serous carcinoma. Oncotarget 2018, 9: 35470-35471. PMID: 30464799, PMCID: PMC6231456, DOI: 10.18632/oncotarget.26245.
- Ledermann J, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Provencher D, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Cristescu R, Kobie J, Ruman J, Matulonis U. LBA36 Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. Annals Of Oncology 2018, 29: viii728. DOI: 10.1093/annonc/mdy424.043.
- Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research 2018, 24: 4845-4853. PMID: 29941483, PMCID: PMC6168417, DOI: 10.1158/1078-0432.ccr-18-0864.
- Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerAltwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2449-2456. PMID: 30255380, DOI: 10.1007/s00432-018-2753-y.
- Menderes G, Lopez S, Han C, Altwerger G, Gysler S, Varughese J, Schwartz PE, Santin AD. Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it. Discovery Medicine 2018, 26: 39-50. PMID: 30265854.
- Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, Rimm DL, Liu Y, Ratner E, Schwartz PE, Santin AD. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clinical Cancer Research 2018, 24: 3282-3291. PMID: 29351920, PMCID: PMC6050068, DOI: 10.1158/1078-0432.ccr-17-1805.
- Feinberg J, Elvin J, Bellone S, Santin A. Identification of ovarian cancer patients for immunotherapy by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA). Gynecologic Oncology 2018, 149: 36. DOI: 10.1016/j.ygyno.2018.04.081.
- Santin A, Fader A. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002). Gynecologic Oncology 2018, 149: 12. DOI: 10.1016/j.ygyno.2018.04.033.
- Han C, Altwerger G, Menderes G, Haines K, Feinberg J, Lopez S, Manzano A, Varughese J, Santin AD. Novel targeted therapies in ovarian and uterine carcinosarcomas. Discovery Medicine 2018, 25: 309-319. PMID: 30021104.
- Han C, Bellone S, Zammataro L, Schwartz PE, Santin AD. Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment. Gynecologic Oncology Reports 2018, 25: 41-44. PMID: 29946554, PMCID: PMC6014583, DOI: 10.1016/j.gore.2018.05.011.
- Han C, Bellone S, Schwartz PE, Govindan SV, Sharkey RM, Goldenberg DM, Santin AD. Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. Gynecologic Oncology Reports 2018, 25: 37-40. PMID: 29977989, PMCID: PMC6030029, DOI: 10.1016/j.gore.2018.05.009.
- Matulonis U, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Provencher D, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Katchar K, Wang Z, Ruman J, Ledermann J. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. Journal Of Clinical Oncology 2018, 36: 5511-5511. DOI: 10.1200/jco.2018.36.15_suppl.5511.
- Bulat I, Moore K, Haceatrean A, Chung J, Rajagopalan P, Xia C, Laurent D, Childs B, Santin A. Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Journal Of Clinical Oncology 2018, 36: 5571-5571. DOI: 10.1200/jco.2018.36.15_suppl.5571.
- Tewari K, Vergote I, Oaknin A, Alvarez E, Chase D, Gaillard S, Lheureux S, Rischin D, Santin A, Feng M, Mathias M, Fury M, Lowy I, Monk B. GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer. Journal Of Clinical Oncology 2018, 36: tps5600-tps5600. DOI: 10.1200/jco.2018.36.15_suppl.tps5600.
- Santin A, Deng W, Frumovitz M, Huh W, Khleif S, Lankes H, Ratner E, O'Cearbhaill R, Jazaeri A, Birrer M. A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer. Journal Of Clinical Oncology 2018, 36: 5536-5536. DOI: 10.1200/jco.2018.36.15_suppl.5536.
- Grechukhina O, Gressel GM, Munday W, Wong S, Santin A, Vash-Margita A. Endometrial Carcinoma in a 26‐Year‐Old Patient with Bardet‐Biedl Syndrome. Case Reports In Obstetrics And Gynecology 2018, 2018: 1952351. PMID: 29854508, PMCID: PMC5960523, DOI: 10.1155/2018/1952351.
- Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.
- Corsini M, Ravaggi A, Odicino F, Santin AD, Ravelli C, Presta M, Romani C, Mitola S. Claudin3 is localized outside the tight junctions in human carcinomas. Oncotarget 2018, 9: 18446-18453. PMID: 29719617, PMCID: PMC5915084, DOI: 10.18632/oncotarget.24858.
- Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal Of Clinical Oncology 2018, 36: 2044-2051. PMID: 29584549, DOI: 10.1200/jco.2017.76.5966.
- Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.
- Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human Pathology 2018, 76: 133-140. PMID: 29518404, DOI: 10.1016/j.humpath.2018.02.019.
- Albright BB, Black JD, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Buza N, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. Gynecologic Oncology Reports 2018, 23: 28-33. PMID: 29387776, PMCID: PMC5771964, DOI: 10.1016/j.gore.2018.01.003.
- Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clinical Cancer Research 2017, 23: 5836-5845. PMID: 28679774, PMCID: PMC5626613, DOI: 10.1158/1078-0432.ccr-16-2862.
- MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget 2017, 5: 84579-84594. PMID: 29137450, PMCID: PMC5663622, DOI: 10.18632/oncotarget.19961.
- Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology 2017, 147: 145-152. PMID: 28705408, PMCID: PMC5605415, DOI: 10.1016/j.ygyno.2017.07.009.
- Menderes G, Bonazzoli E, Bellone S, Black J, Pettinella F, Masserdotti A, Zammataro L, Lopez S, Litkouhi B, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A. Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2017, 145: 112. DOI: 10.1016/j.ygyno.2017.03.263.
- Altwerger G, Gressel G, Menderes G, Black J, Nelson W, Litkouhi B, Santin A, Schwartz P, Ratner E. Carboplatin hypersensitivity correlates with mutations in the DNA repair enzyme BRCA. Gynecologic Oncology 2017, 145: 113. DOI: 10.1016/j.ygyno.2017.03.265.
- Altwerger G, Gressel G, English D, Nelson W, Menderes G, Black J, Santin A, Schwartz P, Ratner E. A single institution’s experience with a fast, effective carboplatin desensitization protocol and identification of risk factors for high-grade hypersensitivity reactions. Gynecologic Oncology 2017, 145: 123. DOI: 10.1016/j.ygyno.2017.03.288.
- Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Pettinella F, Masserdotti A, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression. Journal Of Clinical Oncology 2017, 35: e14009-e14009. DOI: 10.1200/jco.2017.35.15_suppl.e14009.
- Huang GS, Santin AD. Genetic landscape of clear cell endometrial cancer and the era of precision medicine. Cancer 2017, 123: 3216-3218. PMID: 28485840, PMCID: PMC5907932, DOI: 10.1002/cncr.30743.
- Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D’Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Journal Of Experimental & Clinical Cancer Research 2017, 36: 63. PMID: 28482906, PMCID: PMC5422964, DOI: 10.1186/s13046-017-0536-y.
- Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology 2017, 146: 179-186. PMID: 28473206, PMCID: PMC5533304, DOI: 10.1016/j.ygyno.2017.04.023.
- Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Medical Oncology 2017, 34: 91. PMID: 28397106, PMCID: PMC5896014, DOI: 10.1007/s12032-017-0956-8.
- Carvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Gynecologic Oncology 2017, 145: 154-158. PMID: 28196634, PMCID: PMC5941302, DOI: 10.1016/j.ygyno.2017.02.002.
- Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics 2017, 16: 323-333. PMID: 27956521, PMCID: PMC5292071, DOI: 10.1158/1535-7163.mct-16-0501.
- Santin AD, Bellone S, Buza N, Schwartz PE. Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1). Gynecologic Oncology Reports 2016, 19: 10-12. PMID: 28018954, PMCID: PMC5175991, DOI: 10.1016/j.gore.2016.12.003.
- Roque DM, Santin AD. Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade. Expert Review Of Clinical Immunology 2016, 13: 175-180. PMID: 27905822, PMCID: PMC5537620, DOI: 10.1080/1744666x.2017.1266938.
- Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, Lifton RP. Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clinical Cancer Research 2016, 22: 5682-5687. PMID: 27486176, PMCID: PMC5135588, DOI: 10.1158/1078-0432.ccr-16-1031.
- Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.
- Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecologic Oncology 2016, 144: 77-82. PMID: 27789084, DOI: 10.1016/j.ygyno.2016.09.027.
- Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. Journal Of Clinical Investigation 2016, 126: 4157-4173. PMID: 27721235, PMCID: PMC5096908, DOI: 10.1172/jci87252.
- Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 12238-12243. PMID: 27791010, PMCID: PMC5087050, DOI: 10.1073/pnas.1614120113.
- Gunderson C, Santin A, delPriore G, Elvin J, Ramkissoon S, Ali S, McMahon C, Fabrizio D, Chalmers Z, Frampton G, Chmielecki J, Vergilio J, Suhn J, Gay L, Miller V, Stephens P, Ross J, Moore K. Comprehensive Genomic Profiling of Uterine Leiomyosarcomas Identifies Frequent Clinically Relevant Genomic Alterations and Opportunities for Personalized Therapies. Gynecologic Oncology 2016, 143: 208-209. DOI: 10.1016/j.ygyno.2016.08.276.
- Deng Y, Yang F, Cocco E, Song E, Zhang J, Cui J, Mohideen M, Bellone S, Santin AD, Saltzman WM. Improved i.p. drug delivery with bioadhesive nanoparticles. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 11453-11458. PMID: 27663731, PMCID: PMC5068292, DOI: 10.1073/pnas.1523141113.
- Hoque SM, Huang Y, Cocco E, Maritim S, Santin AD, Shapiro EM, Coman D, Hyder F. Improved specific loss power on cancer cells by hyperthermia and MRI contrast of hydrophilic FexCo1‐xFe2O4 nanoensembles. Contrast Media & Molecular Imaging 2016, 11: 514-526. PMID: 27659164, DOI: 10.1002/cmmi.1713.
- Bandiera E, Todeschini P, Romani C, Zanotti L, Erba E, Colmegna B, Bignotti E, Santin AD, Sartori E, Odicino FE, Pecorelli S, Tassi RA, Ravaggi A. The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines. Oncology Letters 2016, 12: 2493-2500. PMID: 27698818, PMCID: PMC5038480, DOI: 10.3892/ol.2016.5008.
- Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Molecular Cancer Therapeutics 2016, 15: 1900-1909. PMID: 27256376, DOI: 10.1158/1535-7163.mct-16-0163.
- Muralikrishnan S, Hatzis C, Katz A, Santin A, Schwartz PE, Abu-Khalaf MM. Chemotherapy for Elderly Ovarian Cancer Patients. Gynecology & Obstetrics 2016, 69: 1-5. PMID: 27695647, PMCID: PMC5042145, DOI: 10.4172/2161-0932.1000397.
- Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal Of Cancer 2016, 115: 303-311. PMID: 27351214, PMCID: PMC4973158, DOI: 10.1038/bjc.2016.198.
- English DP, Menderes G, Black J, Schwab CL, Santin AD. Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer. Expert Review Of Molecular Diagnostics 2016, 16: 769-782. PMID: 27169329, DOI: 10.1080/14737159.2016.1188692.
- Blumenschein G, Hassan R, Moore K, Santin A, Kindler H, Nemunaitis J, Seward S, Rajagopalan P, Walter A, Sarapa N, Bendell J. Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). Journal Of Clinical Oncology 2016, 34: 2509-2509. DOI: 10.1200/jco.2016.34.15_suppl.2509.
- Santin A, Moore K, Gunderson C, Gowen K, Fabrizio D, Frampton G, Vergilio J, Suh J, Gay L, Ramkissoon S, Ali S, Miller V, Stephens P, Ross J, Sun J, Elvin J. Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA). Journal Of Clinical Oncology 2016, 34: 5591-5591. DOI: 10.1200/jco.2016.34.15_suppl.5591.
- Menderes G, Zhao S, Schwab C, Lopez S, Black J, Bellone S, Silasi D, Ratner E, Azodi M, Litkouhi B, Schwartz P, Schlessinger J, Lifton R, Santin A. Mutational landscape of uterine and ovarian carcinosarcomas. Journal Of Clinical Oncology 2016, 34: 5589-5589. DOI: 10.1200/jco.2016.34.15_suppl.5589.
- Roque DM, Santin AD. Oncofertility in gynecologic oncology: an oxymoron? Future Oncology 2016, 12: 1683-1686. PMID: 27173792, DOI: 10.2217/fon-2016-0167.
- Menderes G, Hicks C, Black JD, Schwab CL, Santin AD. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. Expert Opinion On Biological Therapy 2016, 16: 989-1004. PMID: 27070175, DOI: 10.1080/14712598.2016.1177018.
- Menderes G, Clark M, Santin AD. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discovery Medicine 2016, 21: 293-303. PMID: 27232515.
- Dioguardi C, Uslu B, Haynes M, Kurus M, Gul M, Miao DQ, De Santis L, Ferrari M, Bellone S, Santin A, Giulivi C, Hoffman G, Usdin K, Johnson J. Granulosa cell and oocyte mitochondrial abnormalities in a mouse model of fragile X primary ovarian insufficiency. Molecular Human Reproduction 2016, 22: 384-396. PMID: 26965313, PMCID: PMC4884918, DOI: 10.1093/molehr/gaw023.
- Menderes G, Schwab CL, Black J, Santin AD. The Role of the Immune System in Ovarian Cancer and Implications on Therapy. Expert Review Of Clinical Immunology 2016, 12: 681-695. PMID: 26821930, DOI: 10.1586/1744666x.2016.1147957.
- Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. European Journal Of Gynaecological Oncology 2016, 37: 199-203. PMID: 27172745.
- de Haydu C, Black JD, Schwab CL, English DP, Santin AD. An update on the current pharmacotherapy for endometrial cancer. Expert Opinion On Pharmacotherapy 2015, 17: 489-499. PMID: 26629895, DOI: 10.1517/14656566.2016.1127351.
- Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Review Of Anticancer Therapy 2015, 16: 83-98. PMID: 26568261, DOI: 10.1586/14737140.2016.1121108.
- Black J, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab C, English D, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. Gynecologic Oncology 2015, 139: 596. DOI: 10.1016/j.ygyno.2015.09.058.
- Schwab C, English D, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology 2015, 139: 597. DOI: 10.1016/j.ygyno.2015.09.061.
- Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Erratum: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. British Journal Of Cancer 2015, 113: 1641-1641. PMID: 26625219, PMCID: PMC4705897, DOI: 10.1038/bjc.2015.388.
- Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. Molecular Cancer Therapeutics 2015, 14: 2519-2526. PMID: 26333383, PMCID: PMC4636465, DOI: 10.1158/1535-7163.mct-15-0383.
- Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Menderes G, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal Of Experimental & Clinical Cancer Research 2015, 34: 123. PMID: 26474755, PMCID: PMC4609066, DOI: 10.1186/s13046-015-0241-7.
- Romani C, Cocco E, Bignotti E, Moratto D, Bugatti A, Todeschini P, Bandiera E, Tassi R, Zanotti L, Pecorelli S, Sartori E, Odicino FE, de Marco A, Santin AD, Ravaggi A, Mitola S. Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery. Oncotarget 2015, 6: 34617-34628. PMID: 26416446, PMCID: PMC4741477, DOI: 10.18632/oncotarget.5315.
- Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. British Journal Of Cancer 2015, 113: 1020-1026. PMID: 26325104, PMCID: PMC4651122, DOI: 10.1038/bjc.2015.306.
- Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer. International Journal Of Cancer 2015, 137: 2618-2629. PMID: 26060989, PMCID: PMC4573336, DOI: 10.1002/ijc.29632.
- Santin AD, Roque DM. Reply. American Journal Of Obstetrics And Gynecology 2015, 213: 881. PMID: 26292047, DOI: 10.1016/j.ajog.2015.08.029.
- Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. American Journal Of Obstetrics And Gynecology 2015, 214: 99.e1-99.e8. PMID: 26272866, PMCID: PMC4698047, DOI: 10.1016/j.ajog.2015.08.011.
- Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology 2015, 139: 112-117. PMID: 26260909, PMCID: PMC4587290, DOI: 10.1016/j.ygyno.2015.08.002.
- Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics. Gynecologic And Obstetric Investigation 2015, 81: 169-173. PMID: 26067608, DOI: 10.1159/000431219.
- Black J, Lopez S, Cocco E, Bellone S, Bonazzoli E, Schwab C, English D, Goedings P, Beusker P, van der Lee M, Timmers M, Dokter W, Schwartz P, Santin A. SYD985, a novel HER2-targeting antibody-drug conjugate in preclinical models for USC, both in vitro and in vivo. Journal Of Clinical Oncology 2015, 33: e16527-e16527. DOI: 10.1200/jco.2015.33.15_suppl.e16527.
- Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, Silasi DA, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecologic Oncology 2015, 138: 11-17. PMID: 25931171, PMCID: PMC4469551, DOI: 10.1016/j.ygyno.2015.04.027.
- Black JD, Lopez S, Cocco E, Schwab CL, English DP, Santin AD. Clostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (c-CPE) for the Detection and Treatment of Gynecologic Cancers. Toxins 2015, 7: 1116-1125. PMID: 25835384, PMCID: PMC4417958, DOI: 10.3390/toxins7041116.
- Schwab C, English D, Black J, Lopez S, Bellone S, Roque D, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology 2015, 137: 61. DOI: 10.1016/j.ygyno.2015.01.142.
- Black J, Lopez S, Bellone S, Schwab C, English D, Roque D, Silasi D, Ratner E, Azodi M, Rutherford T, Schwartz P, Santin A. Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma. Gynecologic Oncology 2015, 137: 161-162. DOI: 10.1016/j.ygyno.2015.01.404.
- Roque D, Schwab C, Goloubeva O, English D, Black J, Silasi D, Azodi M, Rutherford T, Santin A, Schwartz P, Ratner E. Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and interval debulking. Gynecologic Oncology 2015, 137: 106-107. DOI: 10.1016/j.ygyno.2015.01.265.
- Pasternak M, Jorgensen E, Azodi M, Ratner E, Rutherford T, Santin A, Schwartz P, Silasi D. Cervical adenocarcinoma in situ: An institutional retrospective review of surgical management and outcome. Gynecologic Oncology 2015, 137: 76. DOI: 10.1016/j.ygyno.2015.01.184.
- Lopez S, Bellone S, Black J, Schwab C, English D, Terranova C, Schwartz P, Rutherford T, Angioli R, Santin A. Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations. Gynecologic Oncology 2015, 137: 144. DOI: 10.1016/j.ygyno.2015.01.359.
- Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecologic Oncology 2015, 137: 392-400. PMID: 25792179, DOI: 10.1016/j.ygyno.2015.03.008.
- Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. Tumor Biology 2015, 36: 5505-5513. PMID: 25669172, PMCID: PMC5573583, DOI: 10.1007/s13277-015-3218-4.
- English D, Bellone S, Schwab C, Roque D, Chatterjee S, Ratner E, Schwartz P, Rutherford T, Santin A. Solitomab, an EpCAM/CD3 bispecific antibody (BITE), is highly active against primary chemotherapy resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Gynecologic Oncology 2015, 136: 401. DOI: 10.1016/j.ygyno.2014.11.041.
- Schwab C, Roque D, English D, Bellone S, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi D, Azodi M, Schwartz P, Rutherford T, Santin A. Afatinib, an irreversible ErbB family blocker, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro and in vivo. Gynecologic Oncology 2015, 136: 397-398. DOI: 10.1016/j.ygyno.2014.11.032.
- Damast S, Higgins SA, Ratner E, De Leon MC, Mani S, Silasi DA, Azodi M, Santin A, Rutherford T, Schwartz PE. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal Of Contemporary Brachytherapy 2015, 7: 35-40. PMID: 25829935, PMCID: PMC4371058, DOI: 10.5114/jcb.2015.48539.
- Santin AD, Bellone S, Centritto F, Schlessinger J, Lifton R. Improved survival of patients with hypermutation in uterine serous carcinoma. Gynecologic Oncology Reports 2015, 12: 3-4. PMID: 26076146, PMCID: PMC4442647, DOI: 10.1016/j.gore.2015.01.005.
- Schwab CL, Santin AD. Targeted therapy in the treatment of uterine serous carcinoma. Pharmacogenomics 2015, 16: 97-99. PMID: 25616096, DOI: 10.2217/pgs.14.176.
- Miller DT, Roque DM, Santin AD. Use of Monsel solution to treat obstetrical hemorrhage: a review and comparison to other topical hemostatic agents. American Journal Of Obstetrics And Gynecology 2015, 212: 725-735. PMID: 25577672, PMCID: PMC4457701, DOI: 10.1016/j.ajog.2014.12.029.
- English D, Roque D, Buza N, Santin A. HER2 as Biomarker for Endometrial Cancer. Biomarkers In Disease: Methods, Discoveries And Applications 2015, 507-526. DOI: 10.1007/978-94-007-7681-4_26.
- Black J, Roque D, Gold L, Santin A. Future Directions and New Targets in Endometrial Cancer. Current Clinical Oncology 2015, 259-271. DOI: 10.1007/7631_2015_1.
- Schwab CL, English DP, Roque DM, Pasternak M, Santin AD. Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy 2014, 6: 1279-1293. PMID: 25524384, PMCID: PMC4312614, DOI: 10.2217/imt.14.90.
- Romani C, Calza S, Todeschini P, Tassi RA, Zanotti L, Bandiera E, Sartori E, Pecorelli S, Ravaggi A, Santin AD, Bignotti E. Identification of Optimal Reference Genes for Gene Expression Normalization in a Wide Cohort of Endometrioid Endometrial Carcinoma Tissues. PLOS ONE 2014, 9: e113781. PMID: 25473950, PMCID: PMC4256201, DOI: 10.1371/journal.pone.0113781.
- Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical & Experimental Metastasis 2014, 32: 29-38. PMID: 25398397, PMCID: PMC4310789, DOI: 10.1007/s10585-014-9688-8.
- English D, Santin A. FIGO 2008 staging for endometrial cancer. 2014, 82-96. DOI: 10.2217/fmeb2013.13.115.
- Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. British Journal Of Cancer 2014, 111: 1750-1756. PMID: 25268372, PMCID: PMC4453741, DOI: 10.1038/bjc.2014.519.
- English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer 2014, 121: 403-412. PMID: 25251053, PMCID: PMC4304922, DOI: 10.1002/cncr.29062.
- Lopez S, Schwab CL, Cocco E, Bellone S, Bonazzoli E, English DP, Schwartz PE, Rutherford T, Angioli R, Santin AD. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecologic Oncology 2014, 135: 312-317. PMID: 25172762, PMCID: PMC4270135, DOI: 10.1016/j.ygyno.2014.08.024.
- Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecologic Oncology 2014, 135: 142-148. PMID: 25124161, DOI: 10.1016/j.ygyno.2014.08.006.
- Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, Yang Y, Liu N, Zhao X, Santin AD, Taylor H, Huang Y. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene 2014, 34: 3076-3084. PMID: 25088204, DOI: 10.1038/onc.2014.236.
- Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA. Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging. International Journal Of Gynecological Cancer 2014, 24: 1118-1125. PMID: 24927247, DOI: 10.1097/igc.0000000000000156.
- English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Medicine 2014, 3: 1256-1265. PMID: 24890382, PMCID: PMC4302675, DOI: 10.1002/cam4.274.
- Roque D, Schwab C, English D, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: An institutional experience. Gynecologic Oncology 2014, 133: 69. DOI: 10.1016/j.ygyno.2014.03.187.
- Schwab CL, English DP, Roque DM, Santin AD. Taxanes. Anti-Cancer Drugs 2014, 25: 522-535. PMID: 24300913, PMCID: PMC3980024, DOI: 10.1097/cad.0000000000000057.
- English D, Schwab C, Roque D, Bellone S, Ratner E, Silasi D, Azodi M, Schwartz P, Rutherford T, Santin A. Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Gynecologic Oncology 2014, 133: 98. DOI: 10.1016/j.ygyno.2014.03.261.
- English D, Pasternak M, Warmington J, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A, Rutherford T. Evaluation of the diagnostic accuracy of cervical biopsy and determination of associated risk factors for positive margin status in recurrent cervical dysplasia after leep or conization. Journal Of Clinical Oncology 2014, 32: 5609-5609. DOI: 10.1200/jco.2014.32.15_suppl.5609.
- Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM. Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer. International Journal Of Gynecological Cancer 2014, 24: 528-533. PMID: 24557436, DOI: 10.1097/igc.0000000000000085.
- Buza N, Roque DM, Santin AD. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Archives Of Pathology & Laboratory Medicine 2014, 138: 343-50. PMID: 24576030, DOI: 10.5858/arpa.2012-0416-ra.
- Black JD, English DP, Roque DM, Santin AD. Targeted Therapy in Uterine Serous Carcinoma: An Aggressive Variant of Endometrial Cancer. Women's Health 2014, 10: 45-57. PMID: 24328598, PMCID: PMC3984476, DOI: 10.2217/whe.13.72.
- English D, Roque D, Buza N, Santin A. HER2 as Biomarker for Endometrial Cancer. 2014, 1-16. DOI: 10.1007/978-94-007-7744-6_26-1.
- Damast S, Higgins S, Ratner E, de Leon M, Mani S, Silasi D, Azodi M, Santin A, Rutherford T, Schwartz P. 7 Gy x 2 – An Effective Brachytherapy Regimen for Stage I-II Uterine Papillary Serous Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s420-s421. DOI: 10.1016/j.ijrobp.2013.06.1106.
- Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clinical & Experimental Metastasis 2013, 31: 101-110. PMID: 24005572, PMCID: PMC3947146, DOI: 10.1007/s10585-013-9614-5.
- English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecologic Oncology 2013, 131: 753-758. PMID: 24012800, DOI: 10.1016/j.ygyno.2013.08.033.
- English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). American Journal Of Obstetrics And Gynecology 2013, 209: 465.e1-465.e9. PMID: 23891627, DOI: 10.1016/j.ajog.2013.07.020.
- Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, Roque DM, Santin AD. Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. Journal Of Translational Medicine 2013, 11: 162. PMID: 23819652, PMCID: PMC3706350, DOI: 10.1186/1479-5876-11-162.
- Ahmad A, Varughese J, Hui P, Santin A, Azodi M, Silasi D, Schwartz P, Rutherford T, Ratner E. Institutional review of primary lymphoma of the female genital tract: A 32-year experience. Gynecologic Oncology 2013, 130: e152-e153. DOI: 10.1016/j.ygyno.2013.04.428.
- Ahmad A, Ahmad S, Weidhaas J, Hui P, Santin A, Azodi M, Silasi D, Schwartz P, Rutherford T, Ratner E. Ovarian versus uterine serous carcinomas: Clinicopathologic and miRNA analysis. Gynecologic Oncology 2013, 130: e92. DOI: 10.1016/j.ygyno.2013.04.274.
- Roque D, Buza N, Glasgow M, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Gynecologic Oncology 2013, 130: e124-e125. DOI: 10.1016/j.ygyno.2013.04.358.
- Joo W, Silasi D, Ratner E, Santin A, Azodi M, Rutherford T, Schwartz P. Risk factors for omental metastasis in clinical stage I endometrial cancer: A meta-analysis. Gynecologic Oncology 2013, 130: e67. DOI: 10.1016/j.ygyno.2013.04.220.
- Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighieri L, Falchetti M, Donzelli C, Siegel ER, Azodi M, Silasi DA, Ratner E, Schwartz PE, Rutherford TJ, Santin AD. Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. British Journal Of Cancer 2013, 109: 462-471. PMID: 23807163, PMCID: PMC3721400, DOI: 10.1038/bjc.2013.315.
- Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology 2013, 26: 1605-1612. PMID: 23765245, DOI: 10.1038/modpathol.2013.113.
- English DP, Santin AD. Claudins Overexpression in Ovarian Cancer: Potential Targets for Clostridium Perfringens Enterotoxin (CPE) Based Diagnosis and Therapy. International Journal Of Molecular Sciences 2013, 14: 10412-10437. PMID: 23685873, PMCID: PMC3676847, DOI: 10.3390/ijms140510412.
- Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi D, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013, 119: 2582-2592. PMID: 23585021, PMCID: PMC3700638, DOI: 10.1002/cncr.28017.
- Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. American Journal Of Obstetrics And Gynecology 2013, 209: 62.e1-62.e9. PMID: 23583215, DOI: 10.1016/j.ajog.2013.04.017.
- English DP, Roque DM, Santin AD. HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies. Molecular Diagnosis & Therapy 2013, 17: 85-99. PMID: 23529353, PMCID: PMC3660991, DOI: 10.1007/s40291-013-0024-9.
- Roque DM, Santin AD. Updates in therapy for uterine serous carcinoma. Current Opinion In Obstetrics & Gynecology 2013, 25: 29-37. PMID: 23138439, DOI: 10.1097/gco.0b013e32835af98d.
- Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 2916-2921. PMID: 23359684, PMCID: PMC3581983, DOI: 10.1073/pnas.1222577110.
- Fader AN, Santin AD, Gehrig PA. Early stage uterine serous carcinoma: Management updates and genomic advances. Gynecologic Oncology 2013, 129: 244-250. PMID: 23321062, DOI: 10.1016/j.ygyno.2013.01.004.
- English DP, Roque DM, Santin AD. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? Expert Review Of Anticancer Therapy 2013, 13: 63-74. PMID: 23259428, DOI: 10.1586/era.12.158.
- Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, Romani C, Todeschini P, Bandiera E, Tassi RA, Facchetti F, Sartori E, Pecorelli S, Roque DM, Santin AD. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clinical Pathology 2012, 12: 22. PMID: 23151048, PMCID: PMC3534488, DOI: 10.1186/1472-6890-12-22.
- Lal-Nag M, Battis M, Santin AD, Morin PJ. Claudin-6: a novel receptor for CPE-mediated cytotoxicity in ovarian cancer. Oncogenesis 2012, 1: e33-e33. PMID: 23552466, PMCID: PMC3511677, DOI: 10.1038/oncsis.2012.32.
- Roque D, Schwartz P, Santin A. Targeted therapy for high-risk endometrial carcinoma. Journal Of Clinical Practice 2012, 9: 539-554. DOI: 10.2217/cpr.12.44.
- Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A. Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer. International Scholarly Research Notices 2012, 2012: 245756. PMID: 22792477, PMCID: PMC3390037, DOI: 10.5402/2012/245756.
- ElSahwi K, Barber E, Illuzzi J, Buza N, Ratner E, Silasi D, Santin A, Azodi M, Schwartz P, Hui P, Rutherford T. Corrigendum to “The Significance of Perineural Invasion in Early-stage Cervical Cancer” [Gynecologic Oncology 123 (2011) 561–564]. Gynecologic Oncology 2012, 125: 770. DOI: 10.1016/j.ygyno.2012.02.026.
- Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi D, Santin AD, Schwartz PE. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal Of Surgical Oncology 2012, 107: 195-200. PMID: 22648987, DOI: 10.1002/jso.23171.
- Santin A, Varughese J, Chan J, McClure C, Lea J. In vitro chemosensitivity assay for patients with gynecologic sarcoma. Journal Of Clinical Oncology 2012, 30: e13078-e13078. DOI: 10.1200/jco.2012.30.15_suppl.e13078.
- deLeon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC). Journal Of Clinical Oncology 2012, 30: 5099-5099. DOI: 10.1200/jco.2012.30.15_suppl.5099.
- de Leon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Demographics of uterine serous cancer (USC) patients: A single institutional experience. Journal Of Clinical Oncology 2012, 30: e15581-e15581. DOI: 10.1200/jco.2012.30.15_suppl.e15581.
- Roque D, Ratner E, Silasi D, Azodi M, Schwartz P, Rutherford T, Santin A. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer. Journal Of Clinical Oncology 2012, 30: e15526-e15526. DOI: 10.1200/jco.2012.30.15_suppl.e15526.
- Guzzo F, Bellone S, Buza N, Hui P, Carrara L, Varughese J, Cocco E, Betti M, Todeschini P, Gasparrini S, Schwartz PE, Rutherford TJ, Angioli R, Pecorelli S, Santin AD. HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas. International Journal Of Gynecological Pathology 2012, 31: 211-221. PMID: 22498937, PMCID: PMC3366047, DOI: 10.1097/pgp.0b013e31823bb24d.
- Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. British Journal Of Cancer 2012, 106: 1543-1550. PMID: 22531721, PMCID: PMC3341945, DOI: 10.1038/bjc.2012.132.
- Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ. EGFR/HER-targeted therapeutics in ovarian cancer. Future Medicinal Chemistry 2012, 4: 447-469. PMID: 22416774, PMCID: PMC4620931, DOI: 10.4155/fmc.12.11.
- Roque D, Santin A. Antigen-specific immunotherapy for ovarian cancer. 2012, 136-154. DOI: 10.2217/ebo.11.180.
- Roque D, Carrara L, Cocco E, Guzzo F, Sartori E, Bellone S, Pecorelli S, Schwartz P, Rutherford T, Santin A. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcomas cell lines is linked to tubulin-beta-III expression. Gynecologic Oncology 2012, 125: s81. DOI: 10.1016/j.ygyno.2011.12.195.
- Roque D, Bellone S, Betti M, Silasi D, Ratner E, Azodi M, Schwartz P, Rutherford T, Pecorelli S, Santin A. Mammaglobin B (SCGB2A1)-specific CD8+ cytotoxic T lymphocytes (CTL) are highly effective in killing autologous chemotherapy resistant ovarian cancer cells: Implications for SCGB2A1 dendritic cell-based therapeutic vaccines. Gynecologic Oncology 2012, 125: s34. DOI: 10.1016/j.ygyno.2011.12.078.
- El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Review Of Anticancer Therapy 2012, 12: 41-49. PMID: 22149431, PMCID: PMC3287395, DOI: 10.1586/era.11.192.
- Carrara L, Guzzo F, Roque DM, Bellone S, Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Gynecologic Oncology 2011, 125: 231-236. PMID: 22209775, PMCID: PMC3303974, DOI: 10.1016/j.ygyno.2011.12.446.
- Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31: 4559-4566. PMID: 22139083, PMCID: PMC3342446, DOI: 10.1038/onc.2011.539.
- Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A. Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 2496-2506. PMID: 22028406, PMCID: PMC3237732, DOI: 10.1158/1055-9965.epi-11-0635.
- Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi DA, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. Journal Of Experimental & Clinical Cancer Research 2011, 30: 106. PMID: 22075385, PMCID: PMC3224774, DOI: 10.1186/1756-9966-30-106.
- Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD, DiMaio D. Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology 2011, 422: 114-124. PMID: 22056390, PMCID: PMC3229657, DOI: 10.1016/j.virol.2011.10.012.
- Bignotti E, Ravaggi A, Romani C, Falchetti M, Lonardi S, Facchetti F, Pecorelli S, Varughese J, Cocco E, Bellone S, Schwartz PE, Rutherford TJ, Santin AD. Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma. International Journal Of Gynecological Cancer 2011, 21: 1613-1621. PMID: 21892093, PMCID: PMC3233648, DOI: 10.1097/igc.0b013e318228f6da.
- ElSahwi KS, Hooper C, De Leon MC, Gallo TN, Ratner E, Silasi DA, Santin AD, Schwartz PE, Rutherford TJ, Azodi M. Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecologic Oncology 2011, 124: 260-264. PMID: 22036203, DOI: 10.1016/j.ygyno.2011.09.038.
- El-Sahwi KS, Illuzzi J, Varughese J, Carusillo N, Ratner ES, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study. Gynecologic Oncology 2011, 124: 471-473. PMID: 22014628, DOI: 10.1016/j.ygyno.2011.09.029.
- ElSahwi KS, Barber E, Illuzzi J, Buza N, Ratner E, Silasi DA, Santin AD, Azodi M, Schwartz PE, Rutherford TJ. The significance of perineural invasion in early-stage cervical cancer. Gynecologic Oncology 2011, 123: 561-564. PMID: 21968340, DOI: 10.1016/j.ygyno.2011.08.028.
- Todeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. British Journal Of Cancer 2011, 105: 1176-1182. PMID: 21915118, PMCID: PMC3208497, DOI: 10.1038/bjc.2011.369.
- Santin AD, Sill MW, McMeekin DS, Leitao MM, Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecologic Oncology 2011, 122: 495-500. PMID: 21684583, PMCID: PMC3152667, DOI: 10.1016/j.ygyno.2011.05.040.
- Richter C, Buza N, Hui P, Silasi D, Azodi M, Santin A, Rutherford T, Schwartz P. Urinary hCG Screening in the Gynecologic Oncology Population. Journal Of Gynecologic Surgery 2011, 27: 143-146. DOI: 10.1089/gyn.2010.0048.
- ElSahwi KS, Santin AD. erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. Obstetrics And Gynecology International 2011, 2011: 128295. PMID: 21876697, PMCID: PMC3159302, DOI: 10.1155/2011/128295.
- Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. American Journal Of Obstetrics And Gynecology 2011, 205: 567.e1-567.e7. PMID: 21889762, PMCID: PMC3224189, DOI: 10.1016/j.ajog.2011.06.093.
- Cocco E, Varughese J, Buza N, Bellone S, Lin KY, Bellone M, Todeschini P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Carrara L, Tassi R, Pecorelli S, Lockwood CJ, Santin AD. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. Clinical & Experimental Metastasis 2011, 28: 689-700. PMID: 21725665, PMCID: PMC3697933, DOI: 10.1007/s10585-011-9401-0.
- Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. Retraction to “A 3′ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer” [Gynecol. Oncol. 120 (2011) S3]. Gynecologic Oncology 2011, 122: 205. PMID: 21770066, DOI: 10.1016/j.ygyno.2011.03.028.
- Cocco E, Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, Todeschini P, Carrara L, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Lockwood CJ, Santin AD. Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor. BMC Cancer 2011, 11: 263. PMID: 21693061, PMCID: PMC3141777, DOI: 10.1186/1471-2407-11-263.
- Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin‐Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin. Cancer 2011, 117: 5519-5528. PMID: 21692061, PMCID: PMC3701957, DOI: 10.1002/cncr.26215.
- Santin A, Varughese J, Lea J. In vitro chemosensitivity assay for patients with gynecologic sarcoma. Journal Of Clinical Oncology 2011, 29: e20513-e20513. DOI: 10.1200/jco.2011.29.15_suppl.e20513.
- Varughese J, Casagrande F, Cocco E, Bellone S, Richter C, Bellone M, Todeschini P, Carrara L, Guzzo F, Siegel E, Silasi D, Azodi M, Rutherford T, Pecorelli S, Schwartz P, Santin A. The effect of intraperitoneal administration of clostridium perfringens enterotoxin on chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice. Journal Of Clinical Oncology 2011, 29: e13077-e13077. DOI: 10.1200/jco.2011.29.15_suppl.e13077.
- Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecologic Oncology 2011, 122: 171-177. PMID: 21453957, PMCID: PMC3104081, DOI: 10.1016/j.ygyno.2011.03.002.
- Bellone M, Cocco E, Varughese J, Bellone S, Todeschini P, El-Sahwi K, Carrara L, Guzzo F, Schwartz PE, Rutherford TJ, Pecorelli S, Marshall DJ, Santin AD. Expression of αV-Integrins in Uterine Serous Papillary Carcinomas; Implications for Targeted Therapy With Intetumumab (CNTO 95), a Fully Human Antagonist Anti-αV-Integrin Antibody. International Journal Of Gynecological Cancer 2011, 21: 1084. PMID: 21633302, PMCID: PMC3690508, DOI: 10.1097/igc.0b013e3182187324.
- Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. RETRACTED: A 3’ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer. Gynecologic Oncology 2011, 120: s3. DOI: 10.1016/j.ygyno.2010.12.010.
- Santin A, Bellone S, Varughese J, Cocco E, Ratner E, Silasi D, Rutherford T, Schwartz P, Azodi M, Pecorelli S. Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Gynecologic Oncology 2011, 120: s6-s7. DOI: 10.1016/j.ygyno.2010.12.018.
- Abu-Khalaf M, Santin A, Ratner E, Silasi D, ElSahwi K, Baker L, Luther M, Azodi M, Rutherford T, Schwartz P. A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer. Gynecologic Oncology 2011, 120: s97-s98. DOI: 10.1016/j.ygyno.2010.12.232.
- Santin A, Patricia G, Sill M, McMeekin D, Leitao M, Brown J, Sutton G, Van Le L, Boardman C. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecologic Oncology 2011, 120: s18. DOI: 10.1016/j.ygyno.2010.12.047.
- Varughese J, Cocco E, Bellone S, de Leon M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Uterine serous papillary carcinomas overexpress human trophoblast‐cell‐surface marker (trop‐2) and are highly sensitive to immunotherapy with hRS7, a humanized anti‐trop‐2 monoclonal antibody. Cancer 2011, 117: 3163-3172. PMID: 21246534, PMCID: PMC3128671, DOI: 10.1002/cncr.25891.
- Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Primary Cervical Carcinoma Cell Lines Overexpress Epithelial Cell Adhesion Molecule (EpCAM) and Are Highly Sensitive to Immunotherapy With MT201, a Fully Human Monoclonal Anti-EpCAM Antibody. International Journal Of Gynecological Cancer 2010, 20: 1440-1447. PMID: 21370592, PMCID: PMC3701951, DOI: 10.1111/igc.0b013e3181fb18a1.
- Elsahwi K, Hooper C, Rutherford T, Silasi D, Santin A, Schwartz P, Azodi M. Comparison between 150 Cases of Robotic vs. 150 Cases of Open Surgical Staging for Endometrial Cancer. Journal Of Minimally Invasive Gynecology 2010, 17: s45. DOI: 10.1016/j.jmig.2010.08.234.
- Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. American Journal Of Obstetrics And Gynecology 2010, 203: 582.e1-582.e7. PMID: 20870202, PMCID: PMC2993821, DOI: 10.1016/j.ajog.2010.07.041.
- Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.
- Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. British Journal Of Cancer 2010, 103: 812-819. PMID: 20700124, PMCID: PMC2966612, DOI: 10.1038/sj.bjc.6605760.
- Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, Siegel EE, Richter CE, Schwartz PE, Rutherford TJ, Santin AD. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecologic Oncology 2010, 119: 140-145. PMID: 20673976, PMCID: PMC2939197, DOI: 10.1016/j.ygyno.2010.06.024.
- Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer 2010, 10: 349. PMID: 20598131, PMCID: PMC2908101, DOI: 10.1186/1471-2407-10-349.
- Wang H, Lin K, Merl M, Higgins S, Silasi D, Santin A, Azodi M, Rutherford T, Schwartz P, Abu-Khalaf M. Cisplastin (C) and ifosfamide (I) chemotherapy with vaginal cuff brachytherapy (VCBT) for treatment of uterine carcinosarcoma. Journal Of Clinical Oncology 2010, 28: 5123-5123. DOI: 10.1200/jco.2010.28.15_suppl.5123.
- Schwartz P, Glasgow M, Yu H, Rutherford T, Azodi M, Silasi D, Santin A. Neoadjuvant carboplatin and paclitaxel (CP) chemotherapy (NACT) in patients (pts) with advancedstage (AS) epithelial ovarian cancer (EOC) compared with upfront surgical cytoreduction (USC) followed by CP. Journal Of Clinical Oncology 2010, 28: e15511-e15511. DOI: 10.1200/jco.2010.28.15_suppl.e15511.
- Richter C, Cocco E, Bellone S, Casagrande F, Bellone M, Silasi D, Azodi M, Schwartz P, Rutherford T, Santin A. EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201) in chemotherapy-resistant ovarian cancer cell lines. Journal Of Clinical Oncology 2010, 28: e15524-e15524. DOI: 10.1200/jco.2010.28.15_suppl.e15524.
- Katz A, Yu H, Elsahwi K, Ratner E, Silasi D, Santin A, Azodi M, Rutherford T, Schwartz P, Abu-Khalaf M. Retrospective analysis of elderly patients (pts) with primary epithelial ovarian cancer (EOC) age 70 or older. Journal Of Clinical Oncology 2010, 28: e15518-e15518. DOI: 10.1200/jco.2010.28.15_suppl.e15518.
- Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, Siegel ER, Schwartz PE, Rutherford TJ, Santin AD. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. American Journal Of Obstetrics And Gynecology 2010, 203: 162.e1-162.e8. PMID: 20417484, PMCID: PMC2918912, DOI: 10.1016/j.ajog.2010.02.056.
- Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal Of Clinical Pathology 2010, 63: 544. PMID: 20418225, DOI: 10.1136/jcp.2010.077446.
- Santin AD. Letter to the Editor referring to the manuscript entitled: “Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study” recently reported by Fleming et al., (Gynecol Oncol., 116;15–20;2010). Gynecologic Oncology 2010, 118: 95-96. PMID: 20172595, DOI: 10.1016/j.ygyno.2010.01.043.
- Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. European Journal Of Cancer 2010, 46: 944-953. PMID: 20060709, DOI: 10.1016/j.ejca.2009.12.019.
- El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201). Molecular Cancer Therapeutics 2010, 9: 57-66. PMID: 20053761, PMCID: PMC2806489, DOI: 10.1158/1535-7163.mct-09-0675.
- Cocco E, Bellone S, El‐Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A. Cancer 2009, 116: 843-851. PMID: 20041483, PMCID: PMC2819580, DOI: 10.1002/cncr.24838.
- Xu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P. HER‐2/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology 2009, 56: 269-273. PMID: 20102407, DOI: 10.1111/j.1365-2559.2009.03464.x.
- El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. British Journal Of Cancer 2009, 102: 134-143. PMID: 19920829, PMCID: PMC2813756, DOI: 10.1038/sj.bjc.6605448.
- Tassi R, Siegel E, Bignotti E, Ravaggi A, Todeschini P, Zanotti L, Bandiera E, Romani C, Santin A, Pecorelli S. 8016 Gene expression profile as a diagnostic tool for synchronous ovarian/endometrial cancer. European Journal Of Cancer Supplements 2009, 7: 454. DOI: 10.1016/s1359-6349(09)71538-1.
- Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, Romani C, Bandiera E, Zanotti L, Pecorelli S, Santin AD. Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer 2009, 9: 253. PMID: 19635143, PMCID: PMC2724548, DOI: 10.1186/1471-2407-9-253.
- Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, Tognon G, Ragnoli M, Santin AD, Gion M, Pecorelli S, Ravaggi A. Human Kallikrein 5. International Journal Of Gynecological Cancer 2009, 19: 1015-1021. PMID: 19820362, DOI: 10.1111/igc.0b013e3181ab597f.
- Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy. International Journal Of Gynecological Cancer 2009, 19: 860-866. PMID: 19574774, DOI: 10.1111/igc.0b013e3181a8331f.
- Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. British Journal Of Cancer 2009, 101: 335-341. PMID: 19536090, PMCID: PMC2720219, DOI: 10.1038/sj.bjc.6605129.
- Santin A, Bellone S, El-Sahwi K, Buza N, Tavassoli F, Silasi D, Azodi M, Schwartz P, Rutherford T, Pecorelli S. Potential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma. Journal Of Clinical Oncology 2009, 27: e16502-e16502. DOI: 10.1200/jco.2009.27.15_suppl.e16502.
- Romani C, Comper F, Bandiera E, Ravaggi A, Bignotti E, Tassi RA, Pecorelli S, Santin AD. Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. American Journal Of Obstetrics And Gynecology 2009, 201: 70.e1-70.e9. PMID: 19426958, PMCID: PMC3701950, DOI: 10.1016/j.ajog.2009.02.010.
- Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines. Journal Of Virology 2009, 83: 6779-6789. PMID: 19386711, PMCID: PMC2698533, DOI: 10.1128/jvi.02443-08.
- Santin A. Prospective identification and characterization of ovarian cancer stem cells: Implications for the treatment of chemotherapy resistant/recurrent ovarian disease. Cell Cycle 2009, 8: 3-5. DOI: 10.4161/cc.8.1.7670.
- Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Induction of human tumor‐associated differentially expressed gene‐12 (TADG‐12/TMPRSS3)‐specific cytotoxic T lymphocytes in human lymphocyte antigen‐A2.1–positive healthy donors and patients with advanced ovarian cancer. Cancer 2008, 115: 800-811. PMID: 19117353, DOI: 10.1002/cncr.24048.
- Ravindranath M, Muthugounder S, Presser N, Selvan S, Santin A, Bellone S, Saravanan T, Morton D. Corrigendum to “Immunogenic gangliosides in human ovarian carcinoma” [Biochem. Biophys. Res. Commun. 353 (2007) 251–258]. Biochemical And Biophysical Research Communications 2008, 377: 1331. DOI: 10.1016/j.bbrc.2008.09.103.
- Wang X, Santin A, Bellone S, Gupta S, Nakagawa M. A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. Cancer Immunology, Immunotherapy 2008, 58: 309-309. PMCID: PMC11030283, DOI: 10.1007/s00262-008-0617-z.
- Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. American Journal Of Obstetrics And Gynecology 2008, 200: 75.e1-75.e10. PMID: 18976739, DOI: 10.1016/j.ajog.2008.08.014.
- TASSI RA, BIGNOTTI E, FALCHETTI M, RAVANINI M, CALZA S, RAVAGGI A, BANDIERA E, FACCHETTI F, PECORELLI S, SANTIN AD. Claudin‐7 expression in human epithelial ovarian cancer. International Journal Of Gynecological Cancer 2008, 18: 1262-1271. PMID: 18298564, DOI: 10.1111/j.1525-1438.2008.01194.x.
- Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, Romani C, Bandiera E, Odicino FE, Pecorelli S, Santin AD. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. British Journal Of Cancer 2008, 99: 768-773. PMID: 18682706, PMCID: PMC2528153, DOI: 10.1038/sj.bjc.6604546.
- TASSI RA, BIGNOTTI E, FALCHETTI M, CALZA S, RAVAGGI A, ROSSI E, MARTINELLI F, BANDIERA E, PECORELLI S, SANTIN AD. Mammaglobin B expression in human endometrial cancer. International Journal Of Gynecological Cancer 2008, 18: 1090-1096. PMID: 18021217, DOI: 10.1111/j.1525-1438.2007.01137.x.
- Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. International Journal Of Gynecology & Obstetrics 2008, 102: 128-131. PMID: 18555254, DOI: 10.1016/j.ijgo.2008.04.008.
- Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. American Journal Of Obstetrics And Gynecology 2008, 199: e7-e10. PMID: 18550023, DOI: 10.1016/j.ajog.2008.04.012.
- Wang X, Santin AD, Bellone S, Gupta S, Nakagawa M. A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. Cancer Immunology, Immunotherapy 2008, 58: 301-308. PMID: 18446336, PMCID: PMC2782377, DOI: 10.1007/s00262-008-0525-2.
- Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ. Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial. Journal Of Virology 2007, 82: 1968-1979. PMID: 18057249, PMCID: PMC2258728, DOI: 10.1128/jvi.02343-07.
- Santin A. Reply. American Journal Of Obstetrics And Gynecology 2007, 197: 555-556. DOI: 10.1016/j.ajog.2007.08.029.
- Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic cell-based therapeutic vaccines for cervical cancer. Expert Review Of Anticancer Therapy 2007, 7: 1473-1486. PMID: 17944571, DOI: 10.1586/14737140.7.10.1473.
- Boerma M, Wang J, Burnett AF, Santin AD, Roman JJ, Hauer-Jensen M. Local Administration of Interleukin-11 Ameliorates Intestinal Radiation Injury in Rats. Cancer Research 2007, 67: 9501-9506. PMID: 17909060, DOI: 10.1158/0008-5472.can-07-0810.
- Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor. Obstetrics And Gynecology 2007, 110: 518-520. PMID: 17666649, DOI: 10.1097/01.aog.0000267533.56546.c2.
- Facchetti F, Lonardi S, Gentili F, Bercich L, Falchetti M, Tardanico R, Baronchelli C, Lucini L, Santin A, Murer B. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Archiv 2007, 451: 669-680. PMID: 17609977, DOI: 10.1007/s00428-007-0448-x.
- Santin AD, Bellone S, Siegel ER, McKenney JK, Thomas M, Roman JJ, Burnett A, Tognon G, Bandiera E, Pecorelli S. Overexpression of Clostridium perfringens Enterotoxin Receptors Claudin-3 and Claudin-4 in Uterine Carcinosarcomas. Clinical Cancer Research 2007, 13: 3339-3346. PMID: 17545541, DOI: 10.1158/1078-0432.ccr-06-3037.
- Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S, Santin AD. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecologic Oncology 2007, 106: 513-520. PMID: 17540437, DOI: 10.1016/j.ygyno.2007.04.028.
- Winfield HL, De Las Casas LE, Greenfield WW, Santin AD, McKenney JK. Low-grade Fibromyxoid Sarcoma Presenting Clinically as a Primary Ovarian Neoplasm. International Journal Of Gynecological Pathology 2007, 26: 173-176. PMID: 17413985, DOI: 10.1097/01.pgp.0000228145.36807.43.
- Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD. Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecologic Oncology 2007, 105: 578-585. PMID: 17343903, DOI: 10.1016/j.ygyno.2007.01.043.
- Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, Santin AD. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. American Journal Of Obstetrics And Gynecology 2007, 196: 245.e1-245.e11. PMID: 17346539, DOI: 10.1016/j.ajog.2006.10.874.
- Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S. Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma. Cancer 2007, 109: 1312-1322. PMID: 17326053, DOI: 10.1002/cncr.22536.
- Ravindranath MH, Muthugounder S, Presser N, Selvan SR, Santin AD, Bellone S, Saravanan TS, Morton DL. Immunogenic gangliosides in human ovarian carcinoma. Biochemical And Biophysical Research Communications 2006, 353: 251-258. PMID: 17188646, DOI: 10.1016/j.bbrc.2006.12.001.
- Santin A, Bandiera E, Comper F, Bellone M, Marizzoni S, Zanolini A, Palmieri M, Siegel E, Mckinney J, Thomas M, Hennings L, Roman J, Burnett A, Cannon M, Pecorelli S. 0047: Claudin-3 and Claudin-4 Receptor Overexpression: Novel Targets for a Type Specific Therapy Against Uterine Serous Papillary Carcinomas Using Clostridium Perfringens Enterotoxin. International Journal Of Gynecological Cancer 2006, 16: 612.2-612. DOI: 10.1136/ijgc-00009577-200610001-00047.
- Santin A, Bellone S, Palmieri M, Ravaggi A, Zanolini A, Roman J, Burnett A, Cannon M, Pecorelli S. 0348: Phase I Dose Escalation Trial of Hpv16/18 E7-Pulsed Dendritic Cell Vaccination in Stage Ib-Iia Cervical Cancer Patients. International Journal Of Gynecological Cancer 2006, 16: 699.3-699. DOI: 10.1136/ijgc-00009577-200610001-00348.
- Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immunology Research 2006, 6: 9. PMID: 16808432.
- Ravaggi A, Romani C, Pasinetti B, Tassi RA, Bignotti E, Bandiera E, Odicino FE, Ragnoli M, Donzelli C, Falchetti M, Calza S, Santin AD, Pecorelli S. Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. Archives Of Virology 2006, 151: 1899-1916. PMID: 16732494, DOI: 10.1007/s00705-006-0787-y.
- Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecologic Oncology 2006, 103: 405-416. PMID: 16725184, DOI: 10.1016/j.ygyno.2006.03.056.
- Santin AD, Diamandis EP, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A, Pecorelli S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. American Journal Of Obstetrics And Gynecology 2006, 194: 1296-1302. PMID: 16647913, DOI: 10.1016/j.ajog.2005.10.794.
- Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecologic Oncology 2005, 100: 469-478. PMID: 16249018, DOI: 10.1016/j.ygyno.2005.09.040.
- Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S. Amplification of c‐erbB2 oncogene. Cancer 2005, 104: 1391-1397. PMID: 16116605, DOI: 10.1002/cncr.21308.
- Bignotti E, Tassi R, Calza S, Ravaggi A, Romani C, Rossi E, Donzelli C, Falchetti M, Pasinetti B, Odicino F, Pecorelli S, Santin A. 00086 ANALYSIS OF GENE EXPRESSION PATTERNS THAT DEFINES SEROUS PAPILLARY OVARIAN CARCINOMAS. International Journal Of Gynecological Cancer 2005, 15: 75.2-75. DOI: 10.1136/ijgc-00009577-200509001-00086.
- Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecologic Oncology 2005, 98: 92-98. PMID: 15904949, DOI: 10.1016/j.ygyno.2005.03.016.
- Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecologic Oncology 2005, 98: 24-30. PMID: 15894362, DOI: 10.1016/j.ygyno.2005.03.041.
- Santin AD, Cané S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin. Cancer Research 2005, 65: 4334-4342. PMID: 15899825, DOI: 10.1158/0008-5472.can-04-3472.
- Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ. Definition of an Immunogenic Region Within the Ovarian Tumor Antigen Stratum Corneum Chymotryptic Enzyme. Clinical Cancer Research 2005, 11: 3446-3454. PMID: 15867247, DOI: 10.1158/1078-0432.ccr-04-2043.
- Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S. Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer. Clinical Cancer Research 2005, 11: 3320-3325. PMID: 15867230, DOI: 10.1158/1078-0432.ccr-04-2528.
- Santin AD, Zhan F, Cane' S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal Of Cancer 2005, 92: 1561-1573. PMID: 15785748, PMCID: PMC2362016, DOI: 10.1038/sj.bjc.6602480.
- Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer. American Journal Of Obstetrics And Gynecology 2005, 192: 813-818. PMID: 15746676, DOI: 10.1016/j.ajog.2004.10.605.
- Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Current Pharmaceutical Design 2005, 11: 3485-500. PMID: 16248803, DOI: 10.2174/138161205774414565.
- Santin AD, Zhan F, Bignotti E, Siegel ER, Cané S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005, 331: 269-291. PMID: 15629771, DOI: 10.1016/j.virol.2004.09.045.
- Santin A. 3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer. Handbook Of Immunohistochemistry And In Situ Hybridization Of Human Carcinomas 2005, 4: 333-338. DOI: 10.1016/s1874-5784(05)80089-3.
- Santin A, Bellone S, Cane' S, Palmieri M, Bignotti E, Anfossi S, Thomas M, Roman J, Kay H, Burnett A, O'Brien T, Cannon M, John S, Zhan F, Tian E, Pecorelli S. GENE EXPRESSION FINGERPRINT OF UTERINE SEROUS PAPILLARY CARCINOMA: IDENTIFICATION OF NOVEL MOLECULAR MARKERS FOR UTERINE SEROUS CANCER DIAGNOSIS AND THERAPY. International Journal Of Gynecological Cancer 2004, 14: 2.3-2. DOI: 10.1136/ijgc-00009577-200409001-00006.
- Santin AD, Cane' S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Roman JJ, Anfossi S, O'Brien T, Pecorelli S. The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. Gynecologic Oncology 2004, 94: 283-288. PMID: 15297163, DOI: 10.1016/j.ygyno.2004.05.023.
- Santin AD, Bellone S, O’Brien T, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Review Of Anticancer Therapy 2004, 4: 679-689. PMID: 15270671, DOI: 10.1586/14737140.4.4.679.
- Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. International Journal Of Cancer 2004, 112: 14-25. PMID: 15305371, DOI: 10.1002/ijc.20408.
- Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. British Journal Of Cancer 2004, 90: 1814-1824. PMID: 15208622, PMCID: PMC2409747, DOI: 10.1038/sj.bjc.6601791.
- Santin AD, Ravindranath MH, Bellone S, Muthugounder S, Palmieri M, O'Brien TJ, Roman J, Cannon MJ, Pecorelli S. Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG An International Journal Of Obstetrics & Gynaecology 2004, 111: 613-618. PMID: 15198791, DOI: 10.1111/j.1471-0528.2004.00142.x.
- Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Current Opinion In Obstetrics & Gynecology 2004, 16: 87-92. PMID: 15128013, DOI: 10.1097/00001703-200402000-00015.
- Cane' S, Bignotti E, Bellone S, Palmieri M, De Las Casas L, Roman JJ, Pecorelli S, Cannon MJ, O'Brien T, Santin AD. The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer. American Journal Of Obstetrics And Gynecology 2004, 190: 60-66. PMID: 14749636, DOI: 10.1016/j.ajog.2003.07.020.
- Santin A, Bellone S, Palmieri M, Bossini B, Cane' S, Bignotti E, Roman J, Cannon M, Pecorelli S. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. International Journal Of Gynecological Cancer 2004, 14: 64-75. DOI: 10.1136/ijgc-00009577-200401000-00008.
- Santin A. Response to letter to the editor by Lu et al. Gynecologic Oncology 2004, 92: 387. DOI: 10.1016/j.ygyno.2003.10.014.
- Santin AD, Bellone S, Palmieri M, Bossini B, Cane' S, Bignotti E, Roman JJ, Cannon MJ, Pecorelli S. Restoration of tumor specific human leukocyte antigens class I‐restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. International Journal Of Gynecological Cancer 2004, 14: 64-75. PMID: 14764031, DOI: 10.1111/j.1048-891x.2004.014175.x.
- Santin AD, Cane' S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Anfossi S, Roman JJ, O'Brien T, Pecorelli S. The novel serine protease tumor‐associated differentially expressed gene–15 (matriptase/MT‐SP1) is highly overexpressed in cervical carcinoma. Cancer 2003, 98: 1898-1904. PMID: 14584072, DOI: 10.1002/cncr.11753.
- Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecologic Oncology 2003, 91: 231-240. PMID: 14529687, DOI: 10.1016/s0090-8258(03)00460-8.
- Santin AD, Bellone S, Parrish RS, Coke C, Dunn D, Roman J, Theus JW, Cannon MJ, Parham GP, Pecorelli S. Influence of Allogeneic Blood Transfusion on Clinical Outcome during Radiotherapy for Cancer of the Uterine Cervix. Gynecologic And Obstetric Investigation 2003, 56: 28-34. PMID: 12867765, DOI: 10.1159/000072328.
- Kass R, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. Restoration of Tumor-Specific HLA Class I Restricted Cytotoxicity in Tumor Infiltrating Lymphocytes of Advanced Breast Cancer Patients by in vitro Stimulation with Tumor Antigen-Pulsed Autologous Dendritic Cells. Breast Cancer Research And Treatment 2003, 80: 275-285. PMID: 14503800, DOI: 10.1023/a:1024938215782.
- Kass R, Agha J, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells11Supported in part by grants from the Arkansas Breast Cancer Research Program, the Arkansas Special Population Network (A-SPAN), and the Camillo Golgi Foundation, Brescia, Italy (to A.S.). Journal Of Surgical Research 2003, 112: 189-197. PMID: 12888337, DOI: 10.1016/s0022-4804(03)00147-1.
- Santin AD, Bellone S, Palmieri M, Bossini B, Roman JJ, Cannon MJ, Bignotti E, Canè S, Pecorelli S. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecologic Oncology 2003, 89: 271-280. PMID: 12713991, DOI: 10.1016/s0090-8258(03)00083-0.
- Santin AD. HER2/neu overexpression: has the Achilles’ heel of uterine serous papillary carcinoma been exposed? Gynecologic Oncology 2003, 88: 263-265. PMID: 12648572, DOI: 10.1016/s0090-8258(02)00094-x.
- Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman JJ, Pecorelli S, Cannon M, Parham GP. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10. International Journal Of Radiation Oncology • Biology • Physics 2002, 54: 1345-1355. PMID: 12459356, DOI: 10.1016/s0360-3016(02)03757-4.
- Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. Vaccination with HPV-18 E7–Pulsed Dendritic Cells in a Patient with Metastatic Cervical Cancer. New England Journal Of Medicine 2002, 346: 1752-1753. PMID: 12037163, DOI: 10.1056/nejm200205303462219.
- Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clinical Cancer Research 2002, 8: 1271-9. PMID: 12006548.
- Santin AD, Bellone S, Underwood LJ, O'Brien TJ, Ravaggi A, Pecorelli S, Cannon MJ. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. Minerva Obstetrics And Gynecology 2002, 54: 133-44. PMID: 12032451.
- Cannon MJ, O’Brien T, Underwood LJ, Crew MD, Bondurant KL, Santin AD. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Review Of Anticancer Therapy 2002, 2: 97-105. PMID: 12113075, DOI: 10.1586/14737140.2.1.97.
- Santin AD, Bellone S, Ravaggi A, Roman JJ, Pecorelli S, Parham GP, Cannon MJ. Induction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. British Journal Of Cancer 2002, 86: 151-157. PMID: 11857027, PMCID: PMC2746546, DOI: 10.1038/sj.bjc.6600026.
- O’Brien T, Beard J, Underwood L, Dennis R, Santin A, York L. The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences. Tumor Biology 2001, 22: 348-366. PMID: 11786729, DOI: 10.1159/000050638.
- Santin A, Bellone S, Ravaggi A, Roman J, Smith C, Pecorelli S, Cannon M, Parham G. Increased levels of interleukin-10 and transforming growth factor-β in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG An International Journal Of Obstetrics & Gynaecology 2001, 108: 804-808. DOI: 10.1016/s0306-5456(00)00206-0.
- Santin A, Bellone S, Ravaggi A, Roman J, Smith C, Pecorelli S, Cannon M, Parham G. Increased levels of interleukin‐10 and transforming growth factor‐β in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG An International Journal Of Obstetrics & Gynaecology 2001, 108: 804-808. PMID: 11510703, DOI: 10.1111/j.1471-0528.2001.00206.x.
- Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Smith CV, Pecorelli S, Radominska-Pandya A, Cannon MJ, Parham GP. Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer. Gynecologic And Obstetric Investigation 2001, 51: 254-261. PMID: 11408737, DOI: 10.1159/000058060.
- Santin A, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham G, Hermonat P. Tumor-Infiltrating Lymphocytes Contain Higher Numbers of Type 1 Cytokine Expressors and DR+ T Cells Compared with Lymphocytes from Tumor Draining Lymph Nodes and Peripheral Blood in Patients with Cancer of the Uterine Cervix. Gynecologic Oncology 2001, 81: 424-432. PMID: 11371133, DOI: 10.1006/gyno.2001.6200.
- Clemons-Miller AR, Chatta GS, Hutchins L, Angtuaco EJ, Ravaggi A, Santin AD, Cannon MJ. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma. Clinical Cancer Research 2001, 7: 917s-924s. PMID: 11300492.
- Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Jayaprabhu S, Pecorelli S, Parham GP, Cannon MJ. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clinical Cancer Research 2001, 7: 804s-810s. PMID: 11300476.
- Santin A, Hermonat P, Ravaggi A, Bellone S, Roman J, Pecorelli S, Cannon M, Parham G. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 997-1006. PMID: 11072156, DOI: 10.1016/s0360-3016(00)00769-0.
- SANTIN A, BELLONE S, RAVAGGI A, PECORELLI S, CANNON M, PARHAM G. Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells. Obstetrics And Gynecology 2000, 96: 422-430. DOI: 10.1097/00006250-200009000-00019.
- Santin A, Hermonat P, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham G. In vitro induction of tumor-specific human lymphocyte antigen class I–restricted CD8+ cytotoxic T lymphocytes by ovarian tumor antigen–pulsed autologous dendritic cells from patients with advanced ovarian cancer. American Journal Of Obstetrics And Gynecology 2000, 183: 601-609. PMID: 10992180, DOI: 10.1067/mob.2000.107097.
- Santin A, Bellone S, Ravaggi A, Pecorelli S, Cannon M, Parham G. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstetrics And Gynecology 2000, 96: 422-30. PMID: 10960637, DOI: 10.1016/s0029-7844(00)00916-9.
- Santin A, Hermonat P, Ravaggi A, Bellone S, Pecorelli S, Roman J, Parham G, Cannon M. Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes. Journal Of Virology 2000, 74: 4729-4737. PMID: 10775611, PMCID: PMC111995, DOI: 10.1128/jvi.74.10.4729-4737.2000.
- Santin AD, Hermonat PL, Ravaggi A, Bellone S, Cowan C, Coke C, Pecorelli S, Cannon MJ, Parham GP. Development and Therapeutic Effect of Adoptively Transferred T Cells Primed by Tumor Lysate-Pulsed Autologous Dendritic Cells in a Patient with Metastatic Endometrial Cancer. Gynecologic And Obstetric Investigation 2000, 49: 194-203. PMID: 10729762, DOI: 10.1159/000010246.
- Santin AD, Hermonat PL, Ravaggi A, Bellone S, Cowan C, Korourian S, Pecorelli S, Cannon MJ, Parham GP. Development, characterization and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18 E7--pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix. European Journal Of Gynaecological Oncology 2000, 21: 17-23. PMID: 10726612.
- Hermonat PL, Santin AD, Zhan D. Binding of the human papillomavirus type 16 E7 oncoprotein and the adeno-associated virus Rep78 major regulatory protein in vitro and in yeast and the potential for downstream effects. Human Virology 2000, 3: 113-24. PMID: 10881991.
- Santin A. Lymph node metastases. Cancer 2000, 88: 175-179. PMID: 10618621, DOI: 10.1002/(sici)1097-0142(20000101)88:1<175::aid-cncr24>3.0.co;2-f.
- Liu Y, Santin AD, Mane M, Chiriva-Internati M, Parham GP, Ravaggi A, Hermonat PL. Transduction and Utility of the Granulocyte-Macrophage Colony-Stimulating Factor Gene into Monocytes and Dendritic Cells by Adeno-Associated Virus. Journal Of Interferon & Cytokine Research 2000, 20: 21-30. PMID: 10670649, DOI: 10.1089/107999000312702.
- Zhan D, Santin A, Liu Y, Parham G, Li C, Meyers C, Hermonat P. Binding of the Human Papillomavirus Type 16 p97 Promoter by the Adeno-associated Virus Rep78 Major Regulatory Protein Correlates with Inhibition*. Journal Of Biological Chemistry 1999, 274: 31619-31624. PMID: 10531369, DOI: 10.1074/jbc.274.44.31619.
- Santin A, Hermonat P, Ravaggi A, Pecorelli S, Cannon M, Parham G. Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstetrics And Gynecology 1999, 94: 78-82. PMID: 10389722, DOI: 10.1016/s0029-7844(99)00282-3.
- SANTIN A, HERMONAT P, RAVAGGI A, PECORELLI S, CANNON M, PARHAM G. Secretion of Vascular Endothelial Growth Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. Obstetrics And Gynecology 1999, 94: 78-82. DOI: 10.1097/00006250-199907000-00015.
- Santin A, Hermonat P, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham G, Cannon M. Induction of Human Papillomavirus-Specific CD4+ and CD8+ Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer. Journal Of Virology 1999, 73: 5402-5410. PMID: 10364287, PMCID: PMC112596, DOI: 10.1128/jvi.73.7.5402-5410.1999.
- Santin A, Hermonat P, Ravaggi M, Chiriva-Internat M, Cannon M, Hiserodt J, Pecorell S, Parham G. Expression of Surface Antigens During the Differentiation of Human Dendritic Cells vs Macrophages from Blood Monocytes in vitro. Immunobiology 1999, 200: 187-204. PMID: 10416127, DOI: 10.1016/s0171-2985(99)80069-2.
- Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. European Journal Of Gynaecological Oncology 1999, 20: 177-81. PMID: 10410879.
- Hermonat PL, Santin AD, De Greve J, De Rijcke M, Bishop BM, Han L, Mane M, Kokorina N. Chromosomal latency and expression at map unit 96 of a wild-type plus adeno-associated virus (AAV)/Neo vector and identification of p81, a new AAV transcriptional promoter. Human Virology 1999, 2: 359-68. PMID: 10774553.
- Santin A, Hermonat P, Ravaggi A, Chiriva‐Internati M, Pecorelli S, Parham G. Radiation‐enhanced expression of E6/E7 transforming oncogenes of human papillomavirus‐16 in human cervical carcinoma. Cancer 1998, 83: 2346-2352. PMID: 9840534, DOI: 10.1002/(sici)1097-0142(19981201)83:11<2346::aid-cncr14>3.0.co;2-g.
- Santin A, Hermonat P, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham G. Retinoic acid up-regulates the expression of major histocompatibility complex molecules and adhesion/costimulation molecules (specifically, intercellular adhesion molecule ICAM-1) in human cervical cancer. American Journal Of Obstetrics And Gynecology 1998, 179: 1020-1025. PMID: 9790391, DOI: 10.1016/s0002-9378(98)70209-1.
- Santin A, Hermonat P, Ravaggi A, Chiriva-Internati M, Hiserodt J, Pecorelli S, Parham G. Effects of Retinoic Acid Combined with Irradiation on the Expression of Major Histocompatibility Complex Molecules and Adhesion/Costimulation Molecules ICAM-1 in Human Cervical Cancer. Gynecologic Oncology 1998, 70: 195-201. PMID: 9740690, DOI: 10.1006/gyno.1998.5060.
- Hermonat P, Meyers C, Parham G, Santin A. Inhibition/Stimulation of Bovine Papillomavirus by Adeno-Associated Virus Is Time as Well as Multiplicity Dependent. Virology 1998, 247: 240-250. PMID: 9705917, DOI: 10.1006/viro.1998.9256.
- Hermonat P, Santin A, Batchu R, Zhan D. The Adeno-Associated Virus Rep78 Major Regulatory Protein Binds the Cellular TATA-Binding Proteinin Vitroandin Vivo. Virology 1998, 245: 120-127. PMID: 9614873, DOI: 10.1006/viro.1998.9144.
- Santin A, Hermonat P, Ravaggi A, Chiriva‐Internati M, Hiserodt J, Tian E, Carter C, Pecorelli S, Parham G. Effects of retinoic acid combined with interferon‐gamma on the expression of major‐histocompatibility‐complex molecules and intercellular adhesion molecule‐1 in human cervical cancer. International Journal Of Cancer 1998, 75: 254-258. PMID: 9462716, DOI: 10.1002/(sici)1097-0215(19980119)75:2<254::aid-ijc14>3.0.co;2-d.
- Involvement of protein-DNA interaction in adeno-associated virus Rep78-mediated inhibition of HIV-1.Kokorina NA, Santin AD, Li C, Hermonat PL. Involvement of protein-DNA interaction in adeno-associated virus Rep78-mediated inhibition of HIV-1. Human Virology 1998, 1: 441-50. PMID: 10195265.
- Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham GP. Effects of retinoic acid on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer. European Journal Of Gynaecological Oncology 1998, 19: 229-33. PMID: 9641219.
- Santin A, Parham G. Routine Lymph Node Dissection in the Treatment of Early Stage Cancer:Are We Doing the Right Thing? Gynecologic Oncology 1998, 68: 1-3. PMID: 9454650, DOI: 10.1006/gyno.1997.4900.
- Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Hiserodt JC, Batchu RB, Pecorelli S, Parham GP. The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer. International Journal Of Radiation Biology 1998, 73: 699-704. PMID: 9690688, DOI: 10.1080/095530098141951.
- Santin A, Hermonat P, Hiserodt J, Chiriva-Internati M, Woodliff J, Theus J, Barclay D, Pecorelli S, Parham G. Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. International Journal Of Radiation Oncology • Biology • Physics 1997, 39: 737-742. PMID: 9336157, DOI: 10.1016/s0360-3016(97)00372-6.
- Hermonat P, Carter C, Parham G, Quirk J, Santin A. Multiple cellular proteins are recognized by the adeno‐associated virus Rep78 major regulatory protein and the amino‐half of Rep78 is required for many of these interactions. IUBMB Life 1997, 43: 409-420. PMID: 9350349, DOI: 10.1080/15216549700204201.
- Hermonat PL, Plott RT, Santin AD, Parham GP, Flick JT. Adeno-Associated Virus Rep78 Inhibits Oncogenic Transformation of Primary Human Keratinocytes by a Human Papillomavirus Type 16-rasChimeric. Gynecologic Oncology 1997, 66: 487-494. PMID: 9299265, DOI: 10.1006/gyno.1997.4789.
- SANTIN A, HERMONAT P, HISERODT J, CHIRIVA‐INTERNATI M, RAVAGGI A, WOODLIFF J, BARCLAY D, PECORELLI S, PARHAM G. Expression and cytokine mediated modulation of adhesion/costimulation molecules ICAM‐1(CD54) and LFA‐3(CD58) in human ovarian cancer. International Journal Of Gynecological Cancer 1997, 7: 273-278. DOI: 10.1046/j.1525-1438.1997.00453.x.
- Santin A, Hermonat P, Hiserodt J, Fruehauf J, Schranz V, Barclay D, Pecorelli S, Parham G. Differential Transforming Growth Factor-β Secretion in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. Gynecologic Oncology 1997, 64: 477-480. PMID: 9062154, DOI: 10.1006/gyno.1996.4579.
- Hermonat PL, Santin AD, Batchu RB. The adeno-associated virus Rep78 major regulatory/transformation suppressor protein binds cellular Sp1 in vitro and evidence of a biological effect. Cancer Research 1996, 56: 5299-304. PMID: 8912872.
- Bishop BM, Santin AD, Quirk JG, Hermonat PL. Role of the terminal repeat GAGC trimer, the major Rep78 binding site, in adeno‐associated virus DNA replication. FEBS Letters 1996, 397: 97-100. PMID: 8941722, DOI: 10.1016/s0014-5793(96)01149-0.
- Government. T, Rose, Tocco, Granger, DiSaia, Hamilton, Santin, Hiserodt. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. American Journal Of Obstetrics And Gynecology 1996, 175: 593-599. PMID: 8828419, DOI: 10.1053/ob.1996.v175.a73595.
- Santin A, Hiserodt J, DiSaia P, Pecorelli S, Granger G. Differential Effects of High-Dose Gamma Irradiation on the Production of Transforming Growth Factor-Beta in Fresh and Established Human Ovarian Cancer. Gynecologic Oncology 1996, 61: 403-408. PMID: 8641623, DOI: 10.1006/gyno.1996.0164.
- Santin A, Hiserodt J, Fruehauf J, DiSaia P, Pecorelli S, Granger G. Effects of Irradiation on the Expression of Surface Antigens in Human Ovarian Cancer. Gynecologic Oncology 1996, 60: 468-474. PMID: 8774659, DOI: 10.1006/gyno.1996.0075.
- Santin A, Rose G, Hiserodt J, Fruehauf J, Eck L, Garcia R, Schranz V, Disaia P, Pecorelli S, Granger G. Effects of cytokines combined with high‐dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule‐1 in human ovarian cancers. International Journal Of Cancer 1996, 65: 688-694. PMID: 8598323, DOI: 10.1002/(sici)1097-0215(19960301)65:5<688::aid-ijc21>3.0.co;2-2.
- Santin A, Ioli G, Hiserodt J, Manetta A, Pecorelli S, DiSaia P, Granger G. Development and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules. American Journal Of Obstetrics And Gynecology 1996, 174: 633-640. PMID: 8623798, DOI: 10.1016/s0002-9378(96)70441-6.
- Santin AD, Ioli GR, Hiserodt JC, Rose GS, Graf MR, Lander JK, Disaia PJ, Pecorelli S, Granger GA. Development and in vitro characterization of a GM‐CSF secreting human ovarian carcinoma tumor vaccine. International Journal Of Gynecological Cancer 1995, 5: 401-410. PMID: 11578512, DOI: 10.1046/j.1525-1438.1995.05060401.x.
- Santin A, Ioli G, Hiserodt J, Rose G, Graf M, Tocco L, Lander J, Eck L, Burger R, DiSaia P, Pecorelli S, Granger G. Development and Characterization of an IL-4-Secreting Human Ovarian Carcinoma Cell Line. Gynecologic Oncology 1995, 58: 230-239. PMID: 7622110, DOI: 10.1006/gyno.1995.1216.
- Pecorelli S, Sartori E, Santin A. Follow-up after Primary Therapy: Management of the Symptomatic Patient—Surgery. Gynecologic Oncology 1994, 55: s138-s142. PMID: 7835798, DOI: 10.1006/gyno.1994.1353.
Departments and Programs
Locations
Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, Suite B
New Haven, CT 06511
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, Suite BNew Haven, CT 06511
Yale Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Wing North Pavilion 1, Suite B
New Haven, CT 06511
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, Suite BNew Haven, CT 06511